The arrival of anti-amyloid therapies has revived the field of Alzheimer’s disease, but whether they truly qualify as disease-modifying remains an open and unresolved question.

This post is the summary of a discussion with my friend and mentor, Lon Schneider, whose work on Alzheimer’s trials has shaped my interpretation of AD clinical trial readouts.

To get a better understanding of the background of this post, I suggest you take a look at two past posts:

1. Where does amyloid fit in the pathogenesis of AD?

2. How do we interpret blood amyloid biomarkers?

In 2023, the U.S. Food and Drug Administration approved a new drug for early Alzheimer’s disease called lecanemab (sold as Leqembi). A second drug, donanemab (Kisunla), followed in 2024. Both are antibodies — proteins made in a lab and given by IV — designed to clear amyloid, the sticky protein that builds up in Alzheimer’s brains. Some regulators and drugmakers describe them as “disease-modifying.”

Their arrival is the first significant progress in Alzheimer’s drug development in decades. After many years of failed trials, these are the first treatments to clear amyloid from patients’ brains and to produce statistically significant benefits on composite, cognitive, and daily-living measures in large Phase 3 studies, and on core AD biomarkers. Those results justified FDA approval and are not in dispute.

Figure 1. Changes in plasma Alzheimer’s disease biomarkers with donanemab treatment.
Least-squares mean (±SE) change from baseline over 76 weeks in (A) plasma p-tau217, (B) GFAP, (C) neurofilament light chain (NfL), and (D) Aβ42/40 ratio in patients receiving donanemab versus placebo. Donanemab treatment is associated with sustained reductions in p-tau217 and GFAP, stabilization of NfL compared with placebo, and an increase in the Aβ42/40 ratio, consistent with amyloid clearance. Numbers at risk are shown below each panel.

The “disease-modifying” label, though, sets a higher bar than the trial evidence has yet met. By the European Medicines Agency’s standard, a disease-modifying drug has to do more than help while you’re taking it — it has to actually change the course of the illness. No anti-amyloid antibody has been shown to do that in a trial designed to test it. Most data so far support that these drugs may modestly reduce symptoms while patients receive them.

After 18 months, patients on lecanemab or donanemab decline a little less than placebo patients on tests of memory and daily function. The difference is real and statistically reliable — but statistical reliability isn’t the same as a noticeable change, and a measurable difference on a test isn’t the same as a meaningful change in the disease.

What “disease-modifying” actually means

A 2017 paper by my colleague Dr. Jeffrey Cummings offered a framework for evaluating disease-modifying therapies (DMT) in Alzheimer’s. It uses the “slope of decline” to separate drugs that truly slow the disease from those that only ease symptoms.

Figure 2 above (adapted from Cummings, J. (2017). JPAD) illustrates one framework for how a disease-modifying treatment (DMT) can change the trajectory of Alzheimer’s.

The Solid Line: The typical path of the disease, with memory and thinking declining steadily over time. The arrow marks DMT initiation — when a treatment that targets the biology of the disease begins.

The Dashed Line: The goal of treatment is to slow the rate of decline so a person keeps their independence and cognitive health longer.

The European Medicines Agency — Europe’s drug regulator — has since set out a clear working standard. A symptomatic drug helps you while you take it; stop it, and the benefit fades. A disease-modifying drug actually changes the disease, so that people who took it remain better off even after stopping. The disease has been put on a different track.

To prove this, regulators look for specific trial designs — typically ones in which some patients start on a placebo and are later switched to the active drug. If the late-starters never catch up, the early treatment must have changed something durable. If they do catch up, the drug was probably just helping with symptoms while it was being given.

This “slope separation” picture above is a useful starting point, but on its own it doesn’t meet the EMA’s bar. The agency expects a real slowing of clinical decline alongside a matching change in biological markers like amyloid or tau. It also asks that the slowing be meaningful in patients’ daily lives, not just on a graph — and that it reflect a true shift in the disease, not an ongoing symptomatic effect. That is why regulators favor “delayed-start” or “withdrawal” designs over simple slope comparisons.

An example of a delayed start is shown in Figure 3 below:

• Early Starters: Patients who start the active treatment on day one.

• Late Starters: Patients who start on a placebo and switch to active treatment after a set period.

• The Outcome: If late starters never catch up, the drug likely slows the disease itself rather than just masking symptoms.

In the TRAILBLAZER-ALZ 2 donanemab trial, the delayed-start and early-start groups appear to converge over time, Figure 4 (Modified from Mintun MA. Donanemab TRAILBLAZER-ALZ in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety from the Long-Term Extension. Presented at: 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD); March 28–April 1, 2023; Gothenburg, Sweden. Eli Lilly and Company, Indianapolis, IN. Available from Eli Lilly medical materials.

“Time Saved” Does Not Mean the Disease Is Changed

Another framing of the benefit is “time saved” (see figure 5 below). It describes a delay in reaching a given level of symptoms — not a fundamental change in the disease itself. “Time saved” only reflects true disease modification if the benefit persists after treatment stops, or if the trajectory is permanently changed. Current studies have shown neither. So while the phrase sounds meaningful, it may simply represent a temporary slowing of symptoms.

Adapted from Dickson SP, et al. Time saved as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. Journal of Prevention of Alzheimer’s Disease, 2023

What the drugs appear to do

Two things show up consistently in the trials.

First, the drugs clear amyloid from the brain. PET scans confirm that plaques drop, often back to normal levels, and other markers of brain damage — including the protein tau — also move in the expected direction.

Second, after 18 months, patients on the drug score slightly better than patients on placebo on standard tests of memory, thinking, and daily activities. The relative slowing of decline is roughly 25 to 30 percent. Supporters frame this as about seven to eight extra months in the milder stages of disease, with simulation models projecting up to two and a half years if the slowing keeps compounding. “Time saved” is one framing that patients and families may likely hear from a doctor.

Two cautions about that framing.

First, the absolute differences on the tests are small. On the cognitive test most often used (ADAS-Cog, 0–70), the average difference between groups was less than one point. On a common dementia severity scale (CDR-SB, 0–18), it was about a third of a point. Most clinicians say a patient or family wouldn’t notice anything smaller than 2–4 points on the cognitive test or 1–2 points on the dementia scale — the trial differences fall below those thresholds. A 2026 Cochrane review pooling 17 trials and more than 20,000 patients called the effect on memory and thinking “trivial.”

Second, the “time saved” calculation only really makes sense if the slowing is true disease modification. If a patient takes lecanemab for two years, comes out a bit ahead on cognitive testing, and then stops — does the gap hold, close, or grow? The answer determines whether “time saved” is a real bank balance or a temporary read on the meter. We don’t yet have one.

Why the disease-modifying claim outruns the data

Two further problems push the other way.

First, the trials weren’t set up to test it. After CLARITY AD ended, all participants were offered the active drug in an open-label extension. The manufacturer has used that follow-up to argue that the benefit accumulates over three years, and the placebo group never catches up. A 2026 commentary coming out soon in Alzheimer’s & Dementia points out that the statistical analysis needed to support this claim was never done; the argument relies on visual separation in figures rather than formal modeling.

Second, where the analysis has been done, it points the other way. In the 36-month donanemab data, the placebo-then-treated group catches up to the early-treated group — the pattern of a symptomatic drug. And in the DIAN-TU trial, in people with rare genetic forms of Alzheimer’s caused unambiguously by amyloid, treatment cleared amyloid but produced no clinical benefit over nearly five years.

A useful comparison: cholinesterase inhibitors

For more than two decades, an older class of Alzheimer’s drugs — cholinesterase inhibitors taken as daily pills (donepezil, rivastigmine, galantamine) — has been used to treat the disease. These have always been called “symptomatic”: they help while they’re taken but don’t change the underlying disease.

A recent analysis across more than 40 trials compared the older pills with the newer antibodies. On the same tests of memory and daily function, the two classes produce similar effects — on some measures, the older pills produce slightly larger differences.

A 2026 study in The Lancet Regional Health – Europe found that patients who stayed on cholinesterase inhibitors for four years were nearly two points ahead on a standard cognitive test (the MMSE) compared with patients who stopped. By the same reasoning used to argue lecanemab is disease-modifying, that sustained benefit would also count — yet no one calls cholinesterase inhibitors disease-modifying.

This isn’t to say the two classes are interchangeable. The biology differs. Cholinesterase inhibitors boost acetylcholine, a brain chemical that supports memory and thinking; they ease symptoms but don’t touch amyloid, tau, or the underlying pathology. The anti-amyloid antibodies clear amyloid from the brain and lower tau biomarkers in blood and spinal fluid. That biological effect is unprecedented in Alzheimer’s care, and it is the foundation for regulatory approval. The unsettled question — the one ongoing trials are designed to answer — is whether that biological change will translate into a durable, disease-modifying clinical benefit. On the scales that matter for patients and families today, the two classes still look similar in size of effect, even though the underlying biology is different.

What could resolve this

Two ongoing trials are worth watching.

The first is TRAILBLAZER-ALZ 3, testing donanemab in people who don’t yet have Alzheimer’s symptoms but whose brain scans show elevated amyloid. The endpoint is whether participants reach a clinical diagnosis over roughly three and a half years. Because the trial measures whether disease itself emerges, a positive result would be hard to explain as merely symptomatic — and the disease-modifying claim would become much stronger. A negative result would be a serious blow to the amyloid hypothesis as a basis for prevention.

AHEAD 3-45 is a similar prevention trial of lecanemab. It is important, but on its own, it cannot prove disease modification — even a statistically significant cognitive benefit could be explained as a temporary effect.

Trials combining anti-amyloid drugs with treatments targeting tau or brain inflammation are also underway. Larger and more durable effects from those combinations would strengthen the case for amyloid as part of a disease-modifying strategy.

Take-home messages

• FDA approval rests on Phase 3 trials showing statistically significant benefits on composite, cognitive, and daily-living measures at 18 months. After decades of failed Alzheimer’s trials, that is real progress.

• By Europe’s regulatory standard, however, no anti-amyloid antibody has yet been formally shown to be disease-modifying — that is, to change the underlying course of the illness. The 18-month evidence is consistent with a symptomatic effect; ongoing trials may shift that picture.

• The differences favoring treatment are real but small in absolute terms — below what many clinicians consider noticeable on standard scales.

• Advocates frame the benefit as “time saved” — months of additional independence. That framing only fully holds if the slowing is durable, which hasn’t yet been demonstrated.

• The antibodies differ biologically from older cholinesterase inhibitors: they clear amyloid and lower tau, while the older drugs don’t touch this pathology. Whether that biological difference translates into a durable disease-modifying clinical benefit is the central open question.

• Costs and risks are real: about 1 in 8 treated patients develops brain swelling or microbleeds, and treatment requires IV infusions, repeat MRIs, genetic testing, and around $26,000 a year.

• Even if current evidence does not yet meet strict definitions of disease modification, anti-amyloid antibodies represent progress: they show that targeting a biological feature associated with Alzheimer’s disease can translate into consistent, measurable slowing of clinical decline in large trials.

• The TRAILBLAZER-ALZ 3 prevention trial of donanemab could potentially settle the disease-modifying question over the next few years.

• Decisions about starting, continuing, or stopping treatment are personal, best made with a clinician who can weigh the evidence, costs, and individual circumstances. Nothing here, on its own, is a reason to stop a treatment that is working for someone.

Sources

• European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease (CPMP/EWP/553/95 Rev. 2). 2018.

• Cummings, J. (2017). “Defining Disease Modifying Therapy for Alzheimer’s Disease.” The Journal of Prevention of Alzheimer’s Disease, 4(2), 109–115. doi.org.

• Aisen P, Bateman RJ, Crowther D, et al. The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer’s disease based on clearcut biomarker evidence. Alzheimer’s & Dementia 2025;21:e14342.

• Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs 2023;83:569–576.

• Nonino F, Minozzi S, Sambati L, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews 2026, Issue 4: CD016297.

• Schneider LS, Kennedy RE, Cutter G. Caution in interpreting disease-modification claims with lecanemab: selective reporting and causal inference. Alzheimer’s & Dementia 2026 (Letter to the Editor).

• The Lancet Neurology. Stopping Alzheimer’s disease before symptoms start [Editorial]. Lancet Neurology 2026;25:213.

• Giacobini E, Schneider LS. Cholinesterase inhibitors and amyloid-targeting antibody treatments show similar clinical effect. Presented at ADPD, Copenhagen, March 2026.

• Lecerf S, Guinebretiere O, Bentegeac R, et al. The Lancet Regional Health – Europe 2026;62.

• Dickson SP, et al. Time saved as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. Journal of Prevention of Alzheimer’s Disease, JPAD 2023.

Today is Mother's Day — and for many of us, the fear of watching someone we love lose their memory is very real. Wishing all mothers a beautiful day.

A new study published in the Journal of Prevention of Alzheimer’s Disease made headlines with a finding that seems to defy common sense: people who took omega-3 supplements in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort showed faster cognitive decline than those who didn’t. If true, should millions of people stop taking their fish oil capsules?

Not so fast. While the findings deserve attention, understanding what this study can and cannot tell us is essential before drawing any conclusions.

What the Study Found

The researchers analyzed data from 819 older adults in the ADNI database, comparing 273 omega-3 users — primarily fish oil — to 546 matched non-users over a median of five years. Using statistical techniques designed to create comparable groups (propensity score matching), they found that omega-3 users showed faster declines on three standard cognitive tests: the MMSE, ADAS-Cog13, and CDR-SB.

Importantly, this accelerated decline appeared linked not to the classic hallmarks of Alzheimer’s disease — amyloid plaques or tau tangles — but to reduced glucose metabolism in key brain regions, a marker of synaptic dysfunction or damaged mitochondria where omega-3s may get oxidized. The authors proposed that commercially available fish oil, which is particularly vulnerable to oxidation, might be generating harmful byproducts that damage synaptic function. It’s a provocative hypothesis. But the study design makes it very difficult to draw that conclusion.

This figure is striking visually, but it illustrates the core limitation — an observational design cannot tell us whether omega-3s caused the faster metabolic decline, or whether people already heading toward faster decline were the ones who reached for supplements.

The Problem with Observational Studies

The ADNI analysis is an observational study — it watches what people do in real life and looks for patterns. This is a valuable starting point, but it comes with a fundamental limitation: people who take supplements are systematically different from those who don’t, and no amount of statistical adjustment can perfectly account for all those differences.

The authors used propensity score matching, a technique that pairs omega-3 users with non-users who look similar on measured characteristics like age, sex, APOE genetic status, and diagnosis. But “similar on paper” is not the same as “truly comparable.” People who reach for a fish oil bottle may do so because a physician flagged concerns about their cognition, because they are managing cardiovascular or inflammatory conditions, or because they’ve noticed early memory changes themselves. These hidden motivations — what researchers call unmeasured confounders — can create a spurious association between a supplement and a bad outcome, even when the supplement itself is entirely innocent.

There is also a well-known phenomenon in observational research called “healthy user bias,” where supplement takers tend to be healthier overall than non-takers. In this case, however, the study found the opposite — omega-3 users appeared to do worse. The authors acknowledge this paradox themselves, noting that it “presents a puzzle” since healthy user bias would typically favor detecting a protective effect. This unusual direction of effect makes unmeasured confounding an especially important concern.

Propensity Scoring Does Not Eliminate Reverse Causation

This brings us to one of the most critical points in interpreting this kind of research: propensity score matching reduces baseline imbalances on measured variables, but it cannot solve the problem of reverse causation. That is, people may begin taking omega-3 supplements because they are already experiencing subtle cognitive concerns — concerns that haven’t yet shown up on formal tests but are real enough to prompt self-medication.

The authors tried to address this by comparing cognitive trajectories during the pre-supplementation period, finding no significant differences. That’s a thoughtful step. But it is an incomplete test. Pre-clinical Alzheimer’s pathology — the kind that silently accumulates for years before symptoms emerge — can generate subtle functional concerns that motivate lifestyle changes long before they register on cognitive scales. No retrospective analysis of pre-treatment trajectories can fully rule out this possibility. The authors themselves noted that their analysis “may miss subtle trajectories that prompt individuals to start supplements.” That is not a minor caveat — it is the central interpretive challenge.

Putting It in Context: What the Rest of the Evidence Says

Perhaps the most important corrective to this study is the broader evidence base. In the UK Biobank — one of the largest prospective cohorts ever assembled, following hundreds of thousands of participants — omega-3 supplement use was associated with lower rates of dementia, not higher. If omega-3 supplements were genuinely accelerating neurodegeneration, we would expect to see that signal consistently across different populations and methodologies. We don’t.

Large randomized controlled trials, which are far less vulnerable to confounding, have consistently found something different and more mundane: omega-3 supplements produce no significant benefit in people with established Alzheimer’s disease or mild cognitive impairment, but they also cause no meaningful harm. Multiple meta-analyses have reached similar conclusions. “Ineffective” and “harmful” are very different verdicts, and the RCT evidence supports the former, not the latter.

The ADNI findings may also reflect a quirk of the supplement itself. Studies have found that a large proportion of commercially available fish oil products are already oxidized before they are consumed — meaning the capsule delivers not clean DHA and EPA, but a mixture that includes pro-inflammatory breakdown products. If the ADNI signal reflects anything real, it may tell us more about supplement quality than about omega-3 biology.

Why Omega-3 Supplements May Have Only a Limited Role

Even setting aside these methodological concerns, there are strong reasons to think that omega-3 supplements taken in isolation may simply not be potent enough to meaningfully alter Alzheimer’s trajectories in either direction. The biology is more complicated than the supplement industry suggests.

DHA — the primary omega-3 fatty acid in the brain — has genuine neuroprotective functions: maintaining membrane fluidity, supporting synaptic signaling, resolving inflammation, and facilitating amyloid clearance. But how effectively a supplement translates into actual brain DHA levels depends heavily on individual factors: APOE genetic status, age, existing brain pathology, baseline omega-3 levels, and the health of the gut microbiome. In people with already-established Alzheimer’s pathology — where glucose metabolism is disrupted, oxidative stress is high, and the blood-brain barrier is compromised — the situation becomes even more complex. Under these conditions, additional DHA may face a hostile metabolic environment, and any benefit is easily overwhelmed.

This is not a reason to conclude that omega-3s are harmful. It is a reason to conclude that supplements, delivered as isolated capsules outside the context of overall dietary patterns, are likely to have a modest — and possibly negligible — effect on cognitive aging.

There is also a little-known biological wrinkle: high-dose DHA supplementation can paradoxically suppress the body’s own DHA production. Research published by the Bazinet group demonstrates that dietary DHA inhibits a liver enzyme called ELOVL2, which elongates EPA along the DHA biosynthesis pathway. In plain terms, when you take a DHA supplement, you send a signal to your liver to stop making its own DHA from plant-based precursors found in foods like flaxseed and walnuts. The body is tuned for a steady dietary supply — not a daily bolus from a capsule — and flooding it with preformed DHA suppresses the more nuanced, on-demand synthesis the liver would otherwise perform. Long-term supplementation may therefore not simply add DHA on top of what the body makes; it may partly replace endogenous production with an external dependency.

Compounding this is the problem of oxidation. DHA and EPA are polyunsaturated fats — chemically fragile and prone to oxidative damage. When the metabolic environment is already compromised, as in an aging brain facing elevated oxidative stress, disrupted glucose metabolism, and mitochondrial dysfunction, supplemental omega-3s may not arrive at their destination intact. Rather than being incorporated into neuronal membranes to support synaptic function, they can be oxidized into pro-inflammatory byproducts. This is why the context in which omega-3s are consumed may matter as much as the omega-3s themselves. A healthy dietary and lifestyle pattern — regular physical activity, a diet rich in fiber and polyphenols, restorative sleep, metabolic health — creates the cellular conditions under which DHA can actually be used well. The same fatty acids delivered into a dysfunctional metabolic environment may have a very different fate.

Uncertainty and Future Directions

There is much we genuinely do not know. Whether omega-3 supplementation could prevent Alzheimer’s if started early enough — potentially decades before symptoms — in people who are genetically vulnerable and nutritionally deficient remains an open question. The PreventE4 trial — testing high-dose DHA in cognitively normal APOE4 carriers well before the onset of cognitive decline — is expected to publish its results within the next two months. If high-dose DHA shows meaningful benefit in this genetically at-risk, presymptomatic population, it would reframe the entire debate: not whether omega-3s work, but when and for whom the intervention needs to start. We also don’t understand well how the gut microbiome shapes the response to omega-3 supplementation, or whether certain genetic profiles (such as APOE4 carriers with low baseline omega-3 levels) might benefit more than others.

Supplement quality is also an underappreciated problem. If fish oil products are frequently oxidized by the time of consumption, then what we are testing in many observational studies is not omega-3s per se, but a degraded product. Rigorous studies with verified, high-quality formulations are needed.

Finally, the broader question remains unresolved: do omega-3s work better as part of a complex dietary pattern than as a standalone supplement? Emerging evidence consistently suggests yes. Whole omega-3 dietary patterns — both of which feature regular fatty fish consumption alongside fiber, polyphenols, and other anti-inflammatory nutrients — show more consistent associations with cognitive resilience than any single nutrient taken in isolation. The whole appears to be greater than the sum of its parts.

Take-Home Messages

The ADNI finding is thought-provoking but should not cause alarm. Observational studies cannot establish causation, and the pattern seen here — where omega-3 users appear sicker than non-users — is more consistent with reverse causation than with genuine neurotoxicity. The UK Biobank and randomized trial evidence do not support the conclusion that fish oil harms the brain.

Omega-3 supplements are unlikely to have a major effect in either direction for most people. The balance of evidence suggests that they don’t meaningfully slow Alzheimer’s disease in people who already have cognitive impairment or established pathology, but they also don’t accelerate it. The story is mostly one of modest-to-neutral impact.

A diet naturally rich in omega-3s is almost certainly more beneficial than any supplement. Eating fatty fish regularly, or omega-3s from plants, alongside a diet high in vegetables, fiber, and plant-based foods, delivers omega-3s in an unoxidized form, within a matrix of other nutrients, in a gut environment that supports beneficial metabolism. That package — not a capsule — is what the observational evidence consistently associates with better brain aging.

Don’t throw away your fish oil based on a single observational study. But do invest more in your overall diet. No supplement replaces the complexity of real food, and this study — whatever its ultimate interpretation — is a useful reminder of that.

References

1. Liao et al. “The association between omega-3 supplementation and cognitive decline in older adults.” Journal of Prevention of Alzheimer’s Disease, 2026.

2. Metherel AH et al. “Dietary docosahexaenoic acid (DHA) downregulates liver DHA synthesis by inhibiting eicosapentaenoic acid elongation.” Journal of Lipid Research, 65(6):100548, 2024.

3. Huang Y et al. "Associations of fish oil supplementation with incident dementia: Evidence from the UK Biobank cohort study." Frontiers in Neuroscience, 2022.

4. Kerman BE, Self WK, Yassine HN. “Can the gut microbiome inform the effects of omega-3 supplementation?” Current Opinion in Clinical Nutrition and Metabolic Care, 2023.

5. Ebright B, Duro MV, Chen J, Louie G, Yassine HN. “APOE4 effects on DHA brain metabolism across the Alzheimer’s disease spectrum.” Trends in Endocrinology & Metabolism, 2024.

Your brain is not a passive organ. Tucked between neurons, constantly on patrol, is a population of cells called microglia — the brain’s resident immune cells. Think of them as a hybrid between a security guard and a janitor. When something goes wrong — a dead cell, a misfolded protein, a threatening invader — microglia are the first responders. They sense the problem, move toward it, surround it, and break it down.

In Alzheimer’s disease, one of the earliest events is the accumulation of a sticky protein called amyloid, which clumps into plaques outside neurons. Microglia are supposed to recognize those plaques and clear them. For decades, most Alzheimer’s research focused almost exclusively on amyloid itself, as if the cleanup crew didn’t exist. That changed in 2013.

A Signal Hidden in the Genome

That year, two independent research teams published back-to-back papers in the New England Journal of Medicine, each arriving at the same unexpected finding. They had been scanning the entire genetic code of tens of thousands of people — comparing those with Alzheimer’s to those without — searching for places where the DNA spelling differed. This kind of large-scale comparison, called a genome-wide association study or GWAS, is like comparing two manuscripts letter by letter across three billion characters, looking for the discrepancies that explain why one reader ends up with dementia and another doesn’t.

Both teams kept landing on the same gene: TREM2. A specific variant — called R47H — increased the risk of developing Alzheimer’s by two to four times. TREM2 encodes a receptor that sits on the surface of microglia, acting as the sensor that tells them when to swing into action. When TREM2 detects amyloid, cellular debris, or the molecular fingerprints of a dying cell, it instructs the microglia to cluster around the threat and clear it. TREM2, in short, is the alarm system of the brain’s cleanup crew.

A Tempting Hypothesis — and Its Early Warning Signs

The R47H variant blunts that alarm. It is a loss-of-function mutation: the sensor becomes less sensitive. People carrying it have microglia that respond sluggishly to amyloid plaques. Their brains show less microglial clustering around plaques, more diffuse and toxic forms of amyloid, and worse damage to nerve cell branches. Less TREM2 activity. More disease.

The therapeutic idea writes itself: if a broken alarm means the janitors don’t show up, what if you make the alarm louder? Could boosting TREM2 activity help the brain clear amyloid and slow the disease?

The first warning signs were easy to miss. One study found that chronically activating TREM2 could actually worsen the spread of tau — the second major toxic protein in Alzheimer’s, which propagates between neurons and drives irreversible neurodegeneration. Another comprehensive analysis tested TREM2-activating antibodies across multiple mouse models and found neutral or even detrimental results. But the genetic rationale was compelling enough that a clinical-grade drug was built, and a major trial was launched.

Building AL002: The Drug and Its Preclinical Story

What the drug does

AL002, developed by Alector, is a monoclonal antibody — an engineered protein designed to bind to TREM2 and activate it. When it binds, the receptor gets pulled inside the cell and degraded, triggering a burst of downstream signaling. A fragment of TREM2 that normally floats in spinal fluid — called soluble TREM2, or sTREM2 — drops sharply after treatment. Counterintuitively, that drop means the drug is working: the receptor was activated, did its job, and was cleared.

Why the animal studies were misleading

In mice engineered to carry both human TREM2 and five familial Alzheimer’s mutations — the 5xFAD model — a related antibody caused microglia to multiply around plaques, reduced the most toxic forms of amyloid, and decreased nerve cell damage. The mice looked better.

But several important gaps were quietly baked into this evidence. The molecule tested in mice was not AL002 itself — it differed in the region of the antibody that interacts with the broader immune system. The actual human drug was never tested in animals. The 5xFAD mice also accumulate amyloid at extraordinary speed driven by five stacked mutations borrowed from rare inherited forms of disease — an engineered catastrophe that bears little resemblance to the decades-long, genetically complex disease unfolding in a 70-year-old patient. And the mice were treated early, before significant pathology had accumulated, while patients in the trial already had confirmed amyloid and measurable cognitive impairment. Testing a fire suppression system in a controlled drill, then expecting it to work the same way in a building already fully engulfed, is not a reliable methodology. Mouse microglia also differ from human microglia at the level of gene expression and activation states — a gap that further undermines the predictive value of these models.

A Phase 1 trial in healthy volunteers confirmed AL002 was safe and produced the expected spinal fluid signals. But healthy volunteers in their thirties tell you about safety, not whether a drug will slow neurodegeneration in elderly patients with established disease.

What the Trial Found: Active Drug, Passive Disease

The bottom line

Target engagement occurred — CSF sTREM2 fell and CSF osteopontin rose — but amyloid PET showed zero reduction, and nearly one in three treated patients developed amyloid-related imaging abnormalities (ARIA).

INVOKE-2 enrolled 381 people with early Alzheimer’s confirmed by amyloid biomarkers at 69 sites worldwide. Participants received AL002 at one of three doses or placebo by intravenous infusion every four weeks for up to two years.

The drug hit its pharmacological targets. sTREM2 fell in spinal fluid across all treated groups. Osteopontin — a protein linked to TREM2-driven microglial activation — rose. AL002 was reaching the brain and engaging TREM2. The biology was happening.

Figure 1: AL1002 engaged its target as shown with the drop in sTREM2, and raised Osteopontin, inflammatory markers. From Mummery et al, 2026

It just wasn’t helping. After 96 weeks, cognitive and functional decline was identical between treated and placebo groups across every measure tested — memory, orientation, daily function, composite scales. Blood and spinal fluid biomarkers of amyloid, tau, and neurodegeneration showed no difference. The disease progressed as if the drug were not there.

Fig 2: Clinical progression did not change after treatment, despite target engagement. From Mummery et al, 2026

What AL002 Actually Did to Microglia

Activated but not eating

The pharmacodynamic data tells a story, and it is not the story researchers hoped to tell. AL002 activated microglia — they moved toward plaques, enclosed nearby neurons, and protected them from the most acutely toxic fragments of amyloid. But critically, the drug did not activate the intracellular machinery that microglia need to actually engulf and digest an amyloid plaque. The downstream signaling cascade required — involving a pathway called PI3K and the physical restructuring of the cell’s internal skeleton — was not sufficiently engaged. The microglia arrived at the scene. They did not clean it up.

The result was what researchers now recognize as a Toxic Disease-Associated Microglia state — microglia that are biologically loud (secreting cytokines and inflammatory signals) but mechanically lazy (not phagocytosing the amyloid they were sent to clear). Sterile inflammation without productive action.

Osteopontin: a marker we misread

This reinterpretation fundamentally changes how we read one of the trial’s key biomarkers. CSF osteopontin (encoded by the SPP1 gene) was treated as a positive pharmacodynamic signal — evidence that TREM2 signaling had been activated and that microglia were responding. And in a narrow sense, it was. But osteopontin rising without a corresponding fall in amyloid is not a success marker. It is a failure marker.

High osteopontin drives microglia to activate the complement cascade — a set of immune proteins that tag structures for removal. The problem is that complement tags are not specific to amyloid. Microglia hypersensitized by complement activation mistake the molecular markers on healthy synapses — the connections between neurons — for debris, and prune them. The cleanup crew, activated but directionless, starts dismantling functional connections instead of toxic plaques. That pruning of healthy synapses is itself a driver of cognitive decline.

The lesson is subtle but important: moving toward a plaque is not the same as eating it. And eating the wrong thing is worse than not eating at all.

How the Drug Damaged Blood Vessels

The drug’s first encounter is not with microglia

AL002 is given by intravenous infusion — it enters the bloodstream. Before it ever reaches a microglial cell sitting next to an amyloid plaque deep in brain tissue, it must pass through the brain’s vasculature. Lining the outside of those blood vessels is a separate population of immune cells called perivascular macrophages (PVMs). PVMs also express high levels of TREM2, and AL002 binds them just as readily as it binds microglia.

When AL002 cross-links TREM2 receptors on a PVM, it triggers a pathway called Syk signaling — a molecular alarm that, in a PVM, is interpreted as a pathogen trying to breach the blood-brain barrier. The cell does not know it is responding to a drug. It responds as if an infection is trying to force its way into the brain. It begins preparing to demolish the vessel wall so that reinforcements — peripheral immune cells from the blood — can flood in.

In patients who also carry amyloid deposits within their blood vessel walls, a condition called cerebral amyloid angiopathy (CAA), the alarm is compounded. The PVM is simultaneously sensing the drug (interpreted as an invader) and vascular amyloid (interpreted as structural damage). The result is maximum alert: a large release of an enzyme called MMP-9 — molecular scissors that cut the structural collagen holding blood vessel walls together.

When the vessel wall fails

As MMP-9 dissolves the vessel wall, the blood-brain barrier fails. Fluid leaks from the bloodstream into surrounding brain tissue, causing swelling — this is ARIA-E (edema). Red blood cells also escape, releasing heme and toxic iron into brain tissue — this is ARIA-H (microhemorrhage). In APOE4 homozygotes, whose vessel walls are already structurally weakened and who carry the most CAA, the same mechanism produced the most severe outcomes: high rates of both ARIA types, and in some cases seizures, as heme disrupted the electrical signaling of neurons nearby.

This mechanism also explains why testing in standard APOE3 mouse models gave a false sense of safety. APOE3 blood vessels are structurally robust — the same MMP-9 release that ruptures weakened APOE4 vessels simply does not cause visible damage in a mouse with healthier vasculature. The risk was not detectable in the model used.

What This Means for the Next Generation of Microglial Drugs

New benchmarks — and a higher bar

AL002’s failure demands a reckoning with what we actually ask of drugs before they enter trials. Activation alone is no longer an acceptable endpoint. The field now needs to require three things that AL002 could not demonstrate: that a drug suppresses sterile inflammatory signaling rather than amplifying it; that it drives genuine amyloid phagocytosis — actual engulfment and lysosomal digestion — not just microglial recruitment; and that it is vascular-safe in APOE4-bearing models with pre-weakened vessel walls, not just in APOE3 mice whose stronger vessels will hide the damage.

A practical early-screening signal is emerging from this: before advancing any microglial drug, examine its transcriptomic fingerprint. If the SPP1 gene — which encodes osteopontin — dominates the signature without a parallel rise in amyloid-digestion and lysosomal genes, the drug is likely pushing microglia toward inflammatory noise rather than productive cleanup. That is the AL002 pattern. Catching it in the dish or the mouse, before a Phase 2 trial, could save years and patients.

Strategy 1: Refining TREM2 itself

Not everyone has abandoned TREM2 as a target — but the next wave of TREM2 drugs is being designed with AL002’s failures explicitly in mind. VHB937, currently in Phase 2 trials, takes a different approach: rather than activating and degrading the TREM2 receptor (as AL002 did), it stabilizes TREM2 at the cell surface, sustaining signaling without the receptor disappearing. Early data suggest it reduces pro-inflammatory biomarkers, which is the opposite of what AL002 accomplished. Whether stabilizing TREM2 drives more productive amyloid phagocytosis — rather than the inflammatory state AL002 induced — is the question the trial will answer.

A separate approach, VG-3927, recently acquired by Sanofi after positive Phase 1 data, takes a striking detour from the antibody format entirely. It is an oral small molecule TREM2 agonist. An oral drug distributes through the body differently from an intravenous antibody — potentially reaching microglia at lower, more sustained levels rather than flooding the system with a large pulse every four weeks. Whether that changes the vascular risk profile, and whether it drives phagocytosis or inflammation, are open questions for its upcoming Phase 2.

Strategy 2: Release the brakes instead of flooring the gas

Rather than forcing TREM2 to signal louder, a more physiological strategy is to remove the proteins that naturally suppress microglial phagocytosis. Three genetic targets identified in GWAS point this way.

SHIP1 (encoded by INPP5D) acts as a molecular brake downstream of TREM2 — it damps the PI3K signaling cascade that drives microglial engulfment of amyloid. Inhibiting SHIP1 removes that brake, enhancing amyloid uptake and lysosomal capacity in primary microglia without requiring TREM2 agonism. The catch, as described above, is that SHIP1 inhibition would also disinhibit perivascular macrophages, risking the same MMP-9-driven vascular damage seen with AL002. One proposed solution is combining SHIP1 inhibition with cPLA2 blockade — which would physically prevent PVMs from producing the enzyme that damages blood vessel walls, leaving microglia empowered to eat plaques while the vascular risk is contained.

PILRA is a second inhibitory receptor on microglia whose protective variant (G78R) is associated with reduced Alzheimer’s risk, particularly in APOE4 carriers. Recent work published in Science Translational Medicine showed that blocking PILRA with a high-affinity antibody rescued the metabolic and phagocytic deficits that APOE4 specifically causes in microglia — reducing amyloid pathology and restoring synaptic integrity in mouse models transplanted with human microglia. This makes PILRA especially interesting as a target in APOE4 carriers, potentially addressing a genotype that drove the most severe complications in INVOKE-2.

CD33 (Siglec-3) is a third inhibitory receptor whose loss-of-function variants are protective in Alzheimer’s GWAS. CD33 suppresses TREM2 signaling and blocks microglial phagocytosis partly through interaction with SHIP1. A CD33-blocking antibody (AL003) was discontinued in 2022, but the target remains biologically valid — and given what we now know about what AL002 lacked, a drug that disinhibits phagocytosis through CD33 blockade rather than activating inflammation through TREM2 agonism may deserve fresh attention.

Strategy 3: Dampen the inflammatory fire

A third approach asks a different question: rather than trying to redirect microglial activity toward phagocytosis, what if we simply reduce the inflammatory damage those microglia are causing? Two drugs in Phase 2 trials test this idea directly. XPro1595 is a selective TNFα inhibitor designed to block type 1 TNF receptors — the ones that drive neuroinflammation — while leaving type 2 receptors intact, which support myelin maintenance and protective immune functions. The goal is to cool the inflammatory microglial state without broadly suppressing the immune system. Canakinumab, an antibody against IL-1β, targets a specific inflammatory cytokine that activated microglia produce in abundance. Neither drug is designed to drive amyloid clearance directly — they aim to reduce the collateral damage that inflamed microglia cause while other mechanisms handle the plaques.

Strategy 4: Fix the digestive machinery

Even microglia that successfully engulf amyloid may fail to destroy it if the cellular machinery for digestion is impaired. This is an underappreciated dimension of the problem, and it points toward a fourth class of targets: the lysosomal system inside the cell that is supposed to break down ingested material. Progranulin, encoded by GRN, is a protein that supports lysosomal health in microglia. Loss-of-function mutations in GRN cause frontotemporal dementia, and progranulin deficiency impairs the microglial ability to clear amyloid even when phagocytosis is initiated. More broadly, activating TFEB — a master transcription factor that drives production of lysosomal enzymes — could theoretically turn phagocytically recruited microglia into effective digesters, completing the process that AL002 started but could not finish.

These are not fully formed clinical programs yet, but they represent the conceptual shift that INVOKE-2 has accelerated: from asking ‘did we activate microglia?’ to asking ‘did the microglia actually eat the right thing, and digest it?’

Take-Home Messages

Finding a risk gene is not a treatment roadmap. TREM2 is genetically validated and biologically important. But knowing that a gene matters is very different from knowing when, how, and in which patients to intervene on it.

Mouse models have limits that matter. The 5xFAD model produces aggressive, artificial disease in pre-symptomatic mice using a molecule that wasn’t AL002. This model is useful for certain readouts, but not sufficient. Preclinical AD testing remains a formidable task.

Engaging a target is not the same as helping a patient. AL002 hit TREM2, activated microglia, and reached the brain. None of that translated into clinical benefit. Amyloid clearance may prove to be a useful efficacy biomarker.

Microglia that move are not microglia that eat. AL002 drove recruitment without phagocytosis. The next generation of drugs must demonstrate actual amyloid digestion — not just inflammatory activation — before advancing to trials.

Rising osteopontin was not a success signal — it was a failure signal. High CSF osteopontin reflects inflammatory, synapse-pruning microglia, not productive amyloid clearance. Inflammation is a tough target and a complex readout.

The vascular damage had a specific mechanism. AL002 activated TREM2 on blood vessel-lining macrophages, not just neurons. Those cells released MMP-9, cut structural collagen, and damaged the blood-brain barrier — an effect invisible in standard mouse models but devastating in APOE4 patients.

Future microglial drugs need a vascular safety test. ARIA-like damage only appears in APOE4 models with pre-weakened vessels. Testing in APOE3 mice provides false reassurance. That benchmark must be built into preclinical programs.

The next drugs must prove they actually clean up, not just show up. The field is now pursuing four distinct strategies and fixing the cellular digestive machinery (lysosomal and progranulin approaches) is in the pipeline. We have reasons to be hopeful for a breakthrough.

Sources

Mummery CJ et al. The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial. Nature Medicine (2026). https://doi.org/10.1038/s41591-026-04273-1

Guerreiro R et al. TREM2 variants in Alzheimer’s disease. N Engl J Med 368, 117–127 (2013).

Jonsson T et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368, 107–116 (2013).

Jain N et al. Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading. J Exp Med 220, e20220654 (2023).

Etxeberria A et al. Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of Alzheimer’s disease and multiple sclerosis. J Neurosci 44, e2347232024 (2024).

Wang S et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med 217, e20200785 (2020).

Zhong L et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun 10, 1365 (2019).

Edwin TH et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer’s disease. Alzheimers Dement (Amst) 12, e12128 (2020).

Cummings J et al. Alzheimer’s disease drug development pipeline: 2025. Alzheimers Dement (N Y) (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12131090/

Loss of PILRA promotes microglial immunometabolism to reduce amyloid pathology in cell and mouse models of Alzheimer’s disease. Science Translational Medicine (2025). https://doi.org/10.1126/scitranslmed.adw7428

VHB937 Phase 2 trial in Alzheimer’s disease — NeurologyLive (2025). https://www.neurologylive.com/view/new-phase-2-trial-test-trem2-stabilizing-agent-vhb937-alzheimer-disease

Vigil Neuroscience VG-3927 Phase 1 data (2025). https://www.globenewswire.com/news-release/2025/1/23/3014135/0/en/Vigil-Neuroscience-Reports-Positive-Data-from-its-Phase-1-Clinical-Trial-Evaluating-VG-3927-for-the-Potential-Treatment-of-Alzheimer-s-Disease.html

Sanofi acquires Vigil Neuroscience (2025). https://www.sanofi.com/en/media-room/press-releases/2025/2025-05-21-23-15-31-3086232

Optimization of SHIP1 inhibitors for the treatment of Alzheimer’s disease. PMC (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC11713407/

But a large new study published in the American Journal of Preventive Medicine adds an interesting wrinkle to that story. It’s not just how long you sit, it suggests. It might be what you’re doing while you’re sitting.

The Study

Researchers followed over 20,000 Swedish adults for nearly 20 years, tracking who developed dementia along the way. What made this study different from previous research is that it distinguished between two types of sedentary behavior:

Mentally passive: TV watching, listening to music, sitting in a bath — activities where your brain is largely in low gear.

Mentally active: Office work, attending meetings, knitting or sewing — activities that require sustained attention, planning, or problem-solving, even if your body isn’t moving.

The question they asked was simple: does it matter which kind of sitting you do?

What They Found

The answer appears to be yes — at least when it comes to the mentally active kind.

People who spent more time in mentally active sedentary behaviors had a measurably lower risk of developing dementia (Table 2). Each additional hour per day of this type of sitting was associated with roughly a 4% reduction in risk, since HR=0.96 means a 4% lower hazard per 60 min/day increment. And when researchers modeled what would happen if people swapped one hour of passive sitting for one hour of mentally active sitting, they found about a 7% reduction in dementia risk with HR=0.93 (95% CI: 0.87–0.99).

That’s a modest effect, but it was statistically meaningful and held up even after accounting for age, education, smoking, diet, and other factors.

The protective effect was notably stronger among older participants (ages 50–64), which the researchers speculate may be because mentally active behaviors build up what’s called “cognitive reserve” — essentially a buffer of mental resilience that only becomes apparent later in life.

Think of cognitive reserve as a savings account for your brain. Decades of research show that people who accumulate more of it — through education, demanding work, intellectually stimulating leisure, and social engagement — can sustain significantly more physical brain damage before showing clinical symptoms of dementia. Their brains have, in a sense, built alternative routes. A 2024 meta-analysis found that higher cognitive reserve across the life course was consistently associated with reduced dementia risk, and that its benefits compound over time — meaning that what you do in your 40s and 50s may matter as much as, or more than, what you do in your 70s. The catch is that cognitive reserve isn’t something you can bank quickly. It’s built slowly, through years of habits, not months of effort.

What This Doesn’t Mean

Before you swap your gym membership for a puzzle subscription, a few important caveats.

This is observational research. The study can show an association, but it can’t prove that mentally active sitting causes lower dementia risk. It’s possible — and this is a real concern — that people who are already cognitively sharper simply tend to choose more engaging activities. In other words, the direction of causation could run the other way.

The exercise findings are puzzling. Strangely, the study found no significant protective effect from physical activity — even vigorous exercise. That contradicts a mountain of previous research showing PA is one of the strongest dementia protectors we know of. The authors suggest this may be a quirk of how they captured dementia cases (through specialist registers, which miss milder cases). But it’s a flag worth noting: if the model can’t detect a well-known effect, it invites some caution about what it does detect.

The measurement was basic. Sedentary behavior was assessed once, in 1997, using a questionnaire that lumped together very different activities. Knitting and a high-stakes work presentation both counted as “mentally active.” Listening to a podcast and zoning out in front of reality TV both counted as “mentally passive.” The real world is messier than these categories suggest.

19 years is a long time. People’s habits change. The study couldn’t account for how sedentary behavior evolved over two decades of follow-up.

The Elephant in the Room: Your Phone

There’s one glaring gap in this study that researchers and outside experts have been quick to point out: it was designed in 1997, when smartphones didn’t exist, social media hadn’t been invented, and short-form video was science fiction. The passive sedentary behaviors measured back then — TV, music, a long bath — look almost quaint by today’s standards.

Scientists studying dementia and cognitive decline have raised concerns that the kind of passive consumption most of us now do for hours each day — endless scrolling, short-form video, algorithmic feeds designed to hold attention without requiring it — may be doing something more insidious than old-fashioned TV watching. The worry isn’t just that it’s passive. It’s that it may actively train your brain away from the kind of sustained, focused attention that mentally active behaviors depend on.

The idea is that when you spend large amounts of time in a state of passive, low-effort reception — jumping from clip to clip without really concentrating — you may be degrading the very neural pathways you need for concentration, learning, and memory consolidation. The next time you sit down to do something genuinely demanding, your brain has gotten a little worse at it.

Whether this translates into measurable long-term dementia risk is still an open question. The research on “brain rot” and attention spans is early and contested. But the underlying biological logic — that the brain adapts to what it repeatedly does — is well-established. And the sheer volume of passive screen time that now fills daily life dwarfs anything studied in this or most other research.

It’s worth sitting with that for a moment. The study’s data ends in 2016. The TikTok era hadn’t even begun.

Not All Brain Activity Is the Same

Not all “mentally active” activities are equal, and the brain training industry has learned this the hard way. The FTC fined the makers of Lumosity for falsely claiming their games could stave off cognitive decline — because the evidence simply didn’t support it. The core problem is transfer: getting better at a brain-training app mostly makes you better at that app. The skills don’t generalize. What does appear to generalize are activities with genuine complexity, novelty, and depth — learning a new language, picking up a musical instrument, taking up knitting or woodworking. These demand the kind of sustained, layered attention that exercises multiple cognitive systems at once: memory, sequencing, spatial reasoning, problem-solving, and often social engagement too. A crossword is better than scrolling, but learning to play chess or speak conversational Spanish is probably better than a crossword.

The Takeaway

Here’s what the evidence, taken together, suggests:

• Type of sitting matters. Mentally active sedentary behavior — work that demands focus, creative hobbies, learning — is associated with lower dementia risk. Passive sitting is not.

• Cognitive reserve is built over decades. The habits you build in midlife compound quietly. There is no shortcut.

• Brain training apps don’t cut it. The benefit of games like Lumosity doesn’t transfer to real-world cognitive function. Genuine novelty and complexity are what count.

• Your phone may be working against you. Passive scrolling and short-form video may erode the very capacity for focused attention that protects the brain. This is speculative but biologically plausible — and the scale of modern screen time is unprecedented.

• This is one study with real limits. It can’t prove causation, it missed the smartphone era entirely, and it couldn’t even detect the well-established link between exercise and dementia. Hold the findings with appropriate humility.

• The simplest advice still holds. Sit less. Move more. And when you do sit, make it count.

References

1. Werneck et al., “Mentally Active Versus Passive Sedentary Behavior and Risk of Dementia: 19-Year Cohort Study,” American Journal of Preventive Medicine (2026). https://doi.org/10.1016/j.amepre.2026.108317

2. Livingston G et al., “Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission,” The Lancet (2024). https://doi.org/10.1016/S0140-6736(24)01296-0

3. Fracolli LA et al., “Cognitive reserve over the life course and risk of dementia: a systematic review and meta-analysis,” Frontiers in Aging Neuroscience (2024). https://doi.org/10.3389/fnagi.2024.1358992

4. “How Cognitive Reserve Could Protect from Dementia? An Analysis of Everyday Activities and Social Behaviors During Lifespan,” Brain Sciences (2025). https://www.mdpi.com/2076-3425/15/6/652

5. “Brain-training games remain unproven, but research shows what sorts of activities do benefit cognitive functioning,” The Conversation. https://theconversation.com/brain-training-games-remain-unproven-240499

6. “U.S. Cracking Down on ‘Brain Training’ Games,” Scientific American. https://www.scientificamerican.com/article/u-s-cracking-down-on-brain-training-games/

7. Xu C et al., “Associations between recreational screen time and brain health in middle-aged and older adults,” J Am Med Dir Assoc (2024). https://doi.org/10.1016/j.jamda.2024.03.010

8. Fehring D et al., “Changes in prefrontal hemodynamics and mood states during screen use,” Scientific Reports (2025). https://doi.org/10.1038/s41598-025-09360-w

This vascular dimension of Alzheimer’s has long been underappreciated and undertreated. We do not yet have a drug that directly targets the vascular inflammation driving it. Ambreen Kanwal and Bilal Kerman, leading this work at USC, set out to ask whether a specific enzyme — called cPLA2 — might be that target. Their perspective article, just published in Alzheimer’s & Dementia, argues that cPLA2 sits at the intersection of amyloid burden, APOE4-driven lipid dysregulation, and blood-brain barrier breakdown, and that it may be a key upstream driver of vascular injury in Alzheimer’s disease. This post walks through the biology behind that hypothesis, the evidence supporting it, and what would be needed to test it in patients.

Cerebral Amyloid Angiopathy (CAA): Amyloid in the Wrong Place

Most people understand that Alzheimer’s disease involves amyloid plaques building up between brain cells. What is less appreciated is that amyloid also accumulates in the walls of the brain’s blood vessels — the arteries, arterioles, and capillaries that supply the brain with oxygen and nutrients. This condition is called cerebral amyloid angiopathy, or CAA, and it is far more common than most people realize.

Neuropathology studies show that CAA is present in the brain tissue of nearly all patients with Alzheimer’s disease, especially in older patients and in those who carry the APOE4 genetic variant. Even in cognitively normal elderly adults, CAA can be found in 20 to 40 percent of brains examined at autopsy. It is, in this sense, a near-universal companion of aging — but in Alzheimer’s, it is particularly prominent and particularly consequential.

CAA is not one uniform condition. Researchers distinguish between two main subtypes based on which vessels are affected. Type 1 CAA involves amyloid deposits in the basement membranes of the tiny capillaries — the smallest blood vessels deep in the brain tissue. Type 2 CAA, which is more common in older, cognitively normal individuals, involves amyloid depositing in the walls of larger leptomeningeal and cortical arteries. These two subtypes have different relationships to Alzheimer’s pathology: Type 1, capillary CAA, is more specifically linked to AD and to the APOE4 genotype, and it is associated with more active perivascular inflammation.

During life, most CAA is silent. Patients with CAA often have no symptoms, and the condition is discovered incidentally — either on a brain MRI or, posthumously, at autopsy. But when CAA becomes symptomatic, the consequences can be serious: transient episodes of confusion or focal neurological symptoms, recurrent headaches, seizures, and a pattern of cognitive decline. The symptomatic inflammatory form, called CAA-related inflammation (CAA-ri), is characterized by perivascular immune activation — the body’s immune cells attacking the amyloid-laden vessels — and this process disrupts the blood-brain barrier (BBB), the tightly regulated interface that normally keeps blood-borne molecules out of the brain.

Diagnosing CAA in living patients relies almost entirely on brain MRI. The updated Boston Criteria version 2.0 provides a framework for classifying probable CAA based on imaging findings: lobar microbleeds (tiny hemorrhages appearing as dark spots on susceptibility-weighted MRI sequences), cortical superficial siderosis (iron deposits along the brain surface from prior small hemorrhages), and severely enlarged perivascular spaces in specific brain regions. No blood test or spinal fluid marker can currently diagnose CAA with certainty in a living person, and definitive diagnosis requires brain tissue — which is why advances in imaging biomarkers are so important for this field.

ARIA: When Treatment Triggers the Problem

Enter ARIA. When anti-amyloid antibody therapies clear amyloid from plaques and from vessel walls, the mechanical and inflammatory stress on already-fragile CAA-affected vessels can cause visible abnormalities on MRI. Clinicians divide ARIA into two types based on what appears on imaging. ARIA-E refers to edema or effusion — swelling around blood vessels visible as bright signal on FLAIR MRI sequences. ARIA-H refers to hemorrhagic changes — microbleeds or superficial siderosis appearing as dark lesions on susceptibility-weighted imaging.

The majority of ARIA events detected on monitoring MRI scans are asymptomatic. The patient feels nothing, and the abnormalities resolve on their own, often within weeks to a few months. But a meaningful minority of patients develop symptomatic ARIA, which can include headache, confusion, dizziness, visual disturbances, focal neurological symptoms resembling a stroke, and in severe cases, seizures or hospitalization. Symptomatic ARIA requires drug hold and sometimes permanent discontinuation, which eliminates the therapeutic benefit the patient was just beginning to receive.

The rates of ARIA with the current generation of anti-amyloid antibodies are substantial. In the pivotal clinical trial of lecanemab, approximately 21 percent of treated patients developed ARIA-E and 36 percent developed ARIA-H at some point during treatment. With donanemab, similarly high rates were observed. These numbers are already high across the general trial population — but they are dramatically higher in specific subgroups.

The strongest risk factor for ARIA, by a considerable margin, is the APOE4 genotype. APOE4 is the most common genetic risk factor for late-onset Alzheimer’s disease, and carrying one copy raises the risk of developing Alzheimer’s roughly threefold. Carrying two copies — being a homozygote, designated APOE4/4 — raises the risk by eight to twelve times. In the anti-amyloid trials, APOE4/4 homozygotes face ARIA rates of 33 to 67 percent, depending on the drug and the dose. In the APOLLOE4 trial specifically designed to study this population, 32 percent of APOE4/4 participants with early Alzheimer’s already had at least one lobar microbleed at baseline — before receiving any treatment — reflecting how extensive the underlying vascular disease already is. After treatment, the vulnerability compounds dramatically.

Other risk factors for ARIA include higher antibody doses, the presence of pre-existing CAA on baseline MRI, and treatment earlier in the disease course. But APOE4 status dominates all of them. This genetic specificity strongly suggests there is a biology underlying ARIA vulnerability that is tied to APOE4’s effects on the vasculature — and understanding that biology might reveal how to mitigate the risk.

Why APOE4 Makes Blood Vessels So Vulnerable

The APOE4 protein — the product of the APOE4 gene — has several well-established functions in the brain, most notably in transporting cholesterol and facilitating the clearance of amyloid-beta from the brain and from blood vessel walls. APOE4 performs these functions less efficiently than the more common APOE3 variant, which is part of why APOE4 carriers accumulate more amyloid. But APOE4’s effects on blood vessels go beyond amyloid clearance.

APOE4 promotes BBB dysfunction through several mechanisms. It activates a cellular pathway involving matrix metalloproteinase-9 (MMP9), an enzyme that degrades the proteins holding the BBB’s tight junctions together. It is associated with the loss of pericytes — the specialized cells that wrap around blood vessel walls and are essential for BBB maintenance. APOE4 also shifts the endothelium toward a chronic low-grade inflammatory state, even before significant amyloid deposits have formed. The result, in APOE4 carriers, is a blood-brain barrier that is pre-existing compromised — more permeable, more inflamed, and more structurally fragile — before any drug or disease complication adds further stress.

This vascular vulnerability is not just theoretical. In human brain tissue, APOE4 carriers with high CAA burden show measurably reduced astrocyte end-foot coverage of blood vessels, impaired tight junctions, increased MMP9 activity, and lower PDGFRβ levels (a marker of pericyte health) in their cerebrospinal fluid. When anti-amyloid antibodies begin to strip amyloid from these already-vulnerable vessel walls, the resulting inflammatory response occurs on top of a compromised foundation.

The cPLA2 Hypothesis: A Proposed Molecular Culprit

This is where the new perspective paper enters with a specific mechanistic proposal. We hypothesize that an enzyme called cytosolic phospholipase A2 — cPLA2, encoded by the gene PLA2G4A — sits at the intersection of these vascular problems and may be a central driver of the vascular inflammation underlying CAA-ri and ARIA susceptibility in APOE4 carriers.

It is important to say upfront: this is a scientific hypothesis. The evidence marshaled in this perspective is compelling enough to justify serious investigation, but it does not yet prove that cPLA2 causes ARIA or that inhibiting it will prevent ARIA in humans. We argue that the existing evidence is strong enough to propose cPLA2 as a priority target and to outline how the hypothesis should be tested.

The figure above shows cPLA2 protein (red) covering the proximal areas to abeta (green) in blood vessels (white). Microglia and macrophages (brain immune cells) are lining up along the blood vessel, together with the enzyme MMP9, which breaks down the blood-brain barrier junctions. Credit to Bilal Kerman for creating these high-resolution confocal images.

So what is cPLA2, and why does it matter? cPLA2 is an enzyme that sits inside cells — including brain endothelial cells, astrocytes, microglia, and pericytes — and cleaves fat molecules from cell membranes. Specifically, it liberates arachidonic acid (AA) from membrane phospholipids when it is activated by calcium and inflammatory signals. AA is the starting material for a large family of pro-inflammatory signaling molecules called oxylipins, which include prostaglandins, leukotrienes, and hydroxyeicosatetraenoic acids (HETEs). These molecules recruit immune cells, activate MMP9 (which degrades the BBB), and amplify the inflammatory cascade.

But cPLA2’s effects are not purely through what it releases. There is also the matter of what it removes. The same membranes that contain arachidonic acid also contain protective lipids — including plasmalogens (a special type of fat with a vinyl-ether bond that confers antioxidant properties and structural integrity) and docosahexaenoic acid (DHA), the omega-3 fatty acid essential for neuronal membrane health. cPLA2, when overactive, depletes these protective lipids while simultaneously generating pro-inflammatory ones. It is, in effect, a molecular switch that simultaneously amplifies the fire and consumes the fireproofing.

Elevations in the downstream products of cPLA2 — particularly 12-HETE and 15-HETE, measurable in blood and cerebrospinal fluid — have been found in Alzheimer’s patients and correlate with microglial activation and cognitive decline. In APOE4 carriers and in APOE4 mouse models, cPLA2 activity and cPLA2 phosphorylation (the activated form of the enzyme) are measurably higher compared to non-APOE4 controls. These are associations, observed in tissue samples and animal models — they do not prove cPLA2 is the driver of disease, but they establish that the enzyme is more active in precisely the context where vascular vulnerability is greatest.

The perspective paper further points to data from human post-mortem brain tissue: in brains with high CAA burden (confirmed AD patients with CAA scores of 2 or 3 out of 3), activated cPLA2 clusters visibly in and around the blood vessel walls at the sites of amyloid deposition — seen in high-resolution three-dimensional microscopy images included in the paper. Additionally, the level of cPLA2 activity in the vessel walls correlates with evidence of BBB leakage measured by extravascular fibrinogen staining. APOE4 carriers with definite CAA show significantly higher perivascular cPLA2 activity than those without CAA, independent of amyloid and tau pathology.

Animal model experiments add mechanistic plausibility. Genetic knockout of PLA2G4A in mouse models of Alzheimer’s disease reduces neuroinflammation, improves learning and memory, and decreases premature death. Amyloid-oligomer-induced neurotoxicity in neurons can be partly blocked by cPLA2 inhibition in culture. In the E4FAD mouse model — a mouse carrying human APOE4 and familial AD mutations — pharmacological inhibition of cPLA2 reduced amyloid accumulation in vessel walls and reduced hemorrhagic load as measured by MRI. These experiments show that the pathway is tractable, but mice are imperfect models of human Alzheimer’s disease, and such findings do not guarantee that the same results will hold in human clinical trials.

The paper also situates cPLA2 within the complement cascade — the innate immune system’s rapid-response arm. In CAA, amyloid deposits in vessel walls activate complement through the classical pathway, and complement components including MAC (membrane attack complex) cause direct cell lysis. Components C5b-9 and C6, downstream of this cascade, are associated with subcortical hemorrhage and cortical superficial siderosis. Activation of complement by amyloid and APOE may further activate cPLA2, potentially creating a self-reinforcing cycle of vascular injury. Again, this remains mechanistically proposed — the convergence is biologically coherent but not yet causally proven in humans.

Why Previous Anti-Inflammatory Approaches Failed

One of the most instructive threads in the perspective paper is its analysis of why previous anti-inflammatory treatments have not worked in Alzheimer’s disease — and what that failure tells us about where to look next.

The most extensively studied approach has been COX inhibitors: drugs like aspirin, naproxen, and celecoxib, which block the cyclooxygenase enzymes that convert arachidonic acid into prostaglandins. The reasoning seemed sound: if prostaglandins cause inflammation, blocking their production should be protective. The Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) randomized over 2,500 cognitively normal older adults to naproxen, celecoxib, or placebo and followed them for two years — until the trial was halted early because both active treatment arms trended toward higher AD rates and showed worse performance on global cognitive scores compared to placebo.

The failure of COX inhibitors is actually informative. These drugs work downstream of cPLA2 (As shown in Figure above), blocking only one branch of the arachidonic acid cascade. But when you block COX enzymes, the freed arachidonic acid is still being produced by cPLA2, and it can be redirected into the lipoxygenase (LOX) pathway, generating leukotrienes and HETEs — other pro-inflammatory oxylipins that COX inhibitors do not touch. You may also inhibit the COX-1 pathway, which produces some beneficial prostaglandins, and you leave intact the cytochrome P450 pathway, which generates yet another class of oxylipins. The result is a pharmacologically incomplete intervention that can cause compensatory activation of the very pathways it is trying to suppress. Furthermore, COX inhibitors have well-documented cardiovascular risks with long-term use, complicating their use in elderly patients.

The perspective paper argues that this history supports moving further upstream — to cPLA2 itself, which sits at the branch point before all these pathways diverge. Inhibiting cPLA2 would simultaneously suppress the lipoxygenase pathway, the COX pathway, and the production of lysophosphatidylcholine (LPC), while also — if the enzyme is sufficiently inhibited — preserving more of the protective membrane lipids that cPLA2 otherwise depletes. The logic is appealing. Whether it holds in human trials remains to be seen.

What Would It Take to Test This Hypothesis?

The perspective paper devotes considerable space to biomarker development and patient stratification — the infrastructure needed to actually test whether cPLA2 inhibition does anything useful in humans.

The proposed biomarker strategy has several layers. In the blood and cerebrospinal fluid, oxylipin profiling can measure the direct products of cPLA2 activity: PGE2, LTB4, 12-HETE, and 15-HETE. Elevated levels of these molecules in APOE4 carriers and their correlation with CAA severity and ARIA susceptibility would strengthen the hypothesis. Plasma oxylipin profiling offers a practical non-invasive readout; CSF sampling provides more direct access to what is happening near brain tissue.

Plasmalogen levels — the protective lipids depleted by overactive cPLA2 — offer a complementary readout. Plasmalogen deficiency is already recognized as a metabolic signature of Alzheimer’s disease progression. If cPLA2 inhibition restores membrane plasmalogens, this would provide mechanistic confirmation of target engagement in the right direction.

Imaging offers the most direct window into the brain. The paper describes PET tracers labeled with fluorine-18 attached to arachidonic acid and DHA. In preliminary studies in APOE4 knock-in mice, these tracers show elevated arachidonic acid uptake in regions consistent with heightened cPLA2 activity, particularly in cortical and perivascular regions. If these tracers can be validated in humans, they would allow clinicians to identify which patients have the most active cPLA2-mediated lipid dysregulation in their brain vessels, and to monitor directly whether a treatment is having an effect on that activity.

A clinical trial testing this hypothesis would ideally enrich for APOE4/4 homozygotes with imaging-confirmed CAA — precisely the patients at highest ARIA risk — and would measure oxylipin and plasmalogen biomarkers as primary pharmacodynamic endpoints before moving to clinical outcomes like ARIA incidence. The question at the center of such a trial would not be “does this drug slow cognitive decline?” (too hard, too long, too expensive for an early-phase trial) but rather “does inhibiting cPLA2 reduce the biochemical and imaging evidence of vascular inflammation in these patients?” That is a testable hypothesis with defined biomarkers and a realistic timeline.

Uncertainty and Future Directions

The cPLA2 hypothesis is scientifically well-constructed, biologically coherent, and supported by a convergence of associative and experimental evidence. It is not yet proven. The gap between a compelling mechanistic framework and a validated human therapeutic is wide, and the history of Alzheimer’s drug development is filled with hypotheses that survived every preclinical test and then failed in people.

Several specific uncertainties deserve emphasis. First, all the human tissue evidence is associative: elevated cPLA2 activity near amyloid deposits in vessel walls could reflect cPLA2 as a cause of vascular damage, or it could reflect cPLA2 activity as a consequence of damage caused by something else — or both, in a feedback loop. The causal arrow is not yet established.

Second, complete inhibition of cPLA2 could be problematic. cPLA2 has normal physiological roles in immune function, wound healing, and lipid metabolism. Loss-of-function mutations in humans cause a platelet dysfunction disorder and intestinal problems. The expectation is that partial inhibition — enough to dampen pathological vascular inflammation without eliminating normal immune signaling — will be both safe and effective, but this therapeutic window has not been established in humans.

Third, the oxylipin and plasmalogen biomarkers, while promising, have not yet been prospectively validated as predictors of ARIA risk in individual patients. The correlations observed in patient cohorts are encouraging, but whether a low-HETE or high-plasmalogen signature in a given patient’s blood or CSF reliably predicts that they will or won’t develop ARIA remains to be tested.

Looking ahead, the paper identifies three areas where progress is needed in parallel. Brain-penetrant cPLA2 inhibitors are the prerequisite — drugs that can reach the perivascular space in adequate concentrations, are selective for cPLA2 over related enzymes, and have a tolerable side effect profile with long-term use. (A companion paper in npj Drug Discovery describes early-stage compounds along these lines, which we covered in a previous post.) Biomarkers for target engagement must be validated — particularly plasma oxylipin profiling and the [18F]-labeled PET tracers — so that clinical trials can confirm drug activity before committing to large, expensive outcome studies. And the most immediate opportunity may lie in clinical integration with the existing anti-amyloid immunotherapy trials: APOE4/4 patients starting lecanemab or donanemab represent a precisely defined high-risk group where an ARIA-prevention trial could be conducted with a meaningful primary endpoint within 12 to 18 months.

The paper also raises an intriguing possibility about timing. Recent scholarship suggests there may be two distinct stages of inflammation in Alzheimer’s disease — an early, pre-clinical stage that is still amenable to anti-inflammatory intervention, and a later stage that has progressed beyond the reach of simple suppression. If that model is correct, earlier intervention targeting cPLA2 in presymptomatic APOE4 carriers with elevated amyloid burden might be far more effective than intervening after established CAA-ri.

Take-Home Messages

CAA — amyloid in the brain’s blood vessels — is nearly universal in Alzheimer’s disease, especially in APOE4 carriers. It is mostly silent, but it creates a vulnerable vascular environment that predisposes to ARIA when anti-amyloid therapies are given. APOE4/4 homozygotes face the highest burden of both CAA and ARIA, with rates of brain hemorrhage-related imaging abnormalities between 33% and 67% on current therapies.

Understanding why APOE4 carriers are so much more vulnerable requires understanding the specific molecular biology that makes their vessel walls fragile and inflamed. The new perspective paper proposes that the enzyme cPLA2 is a key upstream driver of that process, converting amyloid deposits in vessel walls into a chemical cascade of inflammatory lipid mediators while simultaneously depleting the protective fats that keep membranes resilient.

This is a hypothesis, not yet a proven mechanism. The evidence supporting it — from post-mortem human brain tissue, from mouse models, and from cell biology experiments — is substantial and convergent. But demonstrating causality in humans will require the development of validated biomarkers and a well-designed clinical trial in the right patient population.

The failure of COX inhibitors and aspirin in Alzheimer’s trials is reframed by this hypothesis not as evidence that inflammation doesn’t matter, but as evidence that targeting inflammation too far downstream is pharmacologically incomplete. Going upstream — to cPLA2 itself — offers a more comprehensive suppression of the pro-inflammatory oxylipin cascade, combined with the potential benefit of preserving protective membrane lipids.

The ultimate test of this idea will come from humans. We are working on candidate drugs that penetrate the brain in sufficient concentrations and inhibit cPLA2 with the potency and selectivity needed for a rigorous trial.

About the Paper

Kanwal A, Kerman BE, Wang S, Camey K, Li B, Flores-Aguilar L, Ali N, McIntire LB, Shu CA, Louie SG, Head E, Arvanitakis Z, Yassine HN. “A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer’s disease.” Alzheimer’s & Dementia. 2026;22:e71320. https://doi.org/10.1002/alz.71320

Ambreen Kanwal and Bilal E. Kerman are co-first authors.

Acknowledgments

This work was supported by the National Institute on Aging (RF1AG076124, R01AG055770, R01AG067063, R01AG054434, R21AG056518, P30AG066530, R01AG082362, P30AG10161, P30AG72975, and R01AG15819), the Alzheimer’s Drug Discovery Foundation (ADDF; GC-201711-2014197), donations from the Vranos and Tiny Foundations, and Ms. Lynne Nauss. Additional support was provided by the National Institutes of Health (P50AG05142, R01AG074549, R01AG078800, R01AG072794, and RF1AG059621).

What made her remarkable was not just how long she lived but how. Despite her extraordinary age, she never developed Alzheimer’s disease, never had cancer, and showed no cardiovascular disease. A team of researchers in Spain performed what may be the most comprehensive biological study ever conducted on a single human being — analyzing her genome, transcriptome, metabolome, proteome, gut microbiome, and epigenome, comparing results against multiple matched cohorts. They published their findings in October 2025 in Cell Reports Medicine.¹ What emerged was not a simple formula for longevity. It was a portrait of a life in which many biological systems remained, against considerable odds, in functional equilibrium.

Aging and disease can be decoupled

The data revealed an immediate paradox. This woman showed clear molecular signatures of extreme old age: her telomeres — the protective caps at chromosome ends that shorten with each cell division — were the shortest ever recorded in a healthy person. Her blood showed clonal hematopoiesis, in which a mutated blood stem cell expands over decades and is associated with elevated risk of hematological malignancy and cardiovascular disease. Her immune cells included an expanded population of age-associated B cells, which accumulate with aging and are linked to pro-inflammatory and autoimmune activity.

And yet she had none of the diseases these markers are associated with. The paper’s most important conceptual contribution is demonstrating that molecular aging and age-associated disease are not synonymous. They can be decoupled. The hallmarks of aging — telomere attrition, clonal mutations, immune cell remodeling — can accumulate while the body maintains functional health, provided that something is holding the downstream pathological consequences at bay.

Across every layer of her biology, that something kept appearing.

Low inflammation as the common signal

Measured across blood proteins, lipid particles, metabolites, and gene expression, one feature of her biology was consistently preserved: remarkably low systemic inflammation.

The most direct evidence came from two composite markers, GlycA and GlycB, measured by proton nuclear magnetic resonance spectroscopy. These signals reflect the circulating concentration of acute-phase glycoproteins — including haptoglobin, α1-antitrypsin, and transferrin — that the liver releases in response to inflammatory stimuli. In short-term immune responses, this is adaptive. When chronically elevated even at low levels, it reflects what researchers call inflammaging: the persistent, low-grade, unresolved inflammation that accumulates with age and drives deterioration across organ systems.

In large prospective cohort studies — including analyses of over 250,000 individuals from the UK Biobank — elevated GlycA independently predicts cardiovascular mortality, all-cause mortality, and dementia, beyond traditional risk markers.² Her GlycA and GlycB were both exceptionally low at age 116. Her acute-phase inflammatory response was minimal.

This is not a trivial finding. It is the biological output of an entire life. And when examined alongside how she actually lived, it begins to make sense.

Diet: pattern, not protocol

She followed a Mediterranean dietary pattern and consumed three yogurts daily for at least the final two decades of her life.

The researchers found her gut microbiome was dominated by Bifidobacterium, particularly the family Bifidobacteriaceae — a pattern more typical of younger individuals. Most older adults show progressive Bifidobacterium decline with age, replaced by more pro-inflammatory species. In her case, this was reversed, and the abundance of Bifidobacterium tracked closely with her low-inflammation metabolomic profile. Bifidobacterium produces short-chain fatty acids and conjugated linoleic acid, both of which dampen inflammatory signaling in the gut mucosa and systemically. The researchers drew a direct link between her microbial composition and her low GlycA and GlycB values.

The yogurt strains she consumed — Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus — are known to support Bifidobacterium growth. But the yogurt did not function in isolation. It was embedded in a broader Mediterranean pattern: olive oil, vegetables, legumes, fish, minimal ultra-processed food. The anti-inflammatory lipid profile she displayed — very low VLDL and triglycerides, high HDL, favorable lipoprotein particle size distribution — is consistent with decades of this dietary pattern, not with any single food or nutrient.

Movement: habitual, not structured

She did not follow a structured exercise program. She walked, gardened, played piano, and cared for her dogs — continuous, low-intensity, purposeful movement embedded in daily life.

The distinction between habitual movement and structured exercise is biologically meaningful. Evidence from large cohort studies and accelerometry data suggests that reducing prolonged sedentary time and increasing low-intensity habitual movement confer substantial cardiovascular and metabolic benefits, including reductions in circulating TNF-α and IL-6, improved insulin sensitivity, and myokine-mediated anti-inflammatory signaling — effects that do not require high exercise intensity and that accumulate with consistency over years rather than sessions.³

Her movement was also cognitively rich. Piano performance engages motor control, auditory processing, working memory, attention, and emotional regulation simultaneously. Gardening requires ongoing problem-solving, seasonal planning, and fine motor adaptation. This overlap between physical and cognitive engagement is unlikely to be incidental.

Sleep: glymphatic clearance and immune maintenance

The paper notes that she maintained good sleep habits throughout her life. The biological significance of this extends well beyond rest.

During slow-wave sleep, the glymphatic system — a network of perivascular channels that becomes dramatically more active during sleep — clears metabolic waste from the brain, including amyloid-beta and tau, the proteins that aggregate into Alzheimer’s pathology. Even a single night of sleep deprivation measurably elevates amyloid-beta in cerebrospinal fluid. Chronic sleep disruption accelerates epigenetic aging, raises inflammatory markers including GlycA, impairs immune consolidation, and substantially increases dementia risk. The 2024 Lancet Commission on dementia prevention identifies sleep-disordered conditions among its 14 modifiable risk factors, which together account for approximately 45% of dementia cases worldwide.⁴

Sleep is also when the immune system consolidates memory and regulates inflammatory tone. As we discussed in our previous post, VZV reactivation — a driver of chronic inflammaging — is itself promoted by sleep disruption, creating a bidirectional loop between poor sleep and elevated systemic inflammation.

Chronic stress and psychological resilience

Her personal history included significant adversity, including the death of a son. The authors note she maintained strong physical and mental health throughout, remaining socially engaged and purposeful.

Chronic psychological stress activates the hypothalamic-pituitary-adrenal axis, sustaining elevated cortisol that progressively dysregulates immune function. Prolonged cortisol elevation activates NF-κB — the central transcription factor driving inflammatory gene expression — in circulating immune cells, accelerates telomere attrition, promotes hippocampal atrophy via reduced neurogenesis, and advances epigenetic aging. In longitudinal studies, high perceived stress in midlife independently predicts dementia decades later.⁵ Psychological resilience, operationally defined as the capacity to maintain regulatory function under adversity, is associated with lower cortisol reactivity, preserved immune regulation, and slower biological aging by multiple epigenetic clock measures.

Her resilience — likely supported by the same social network, sense of purpose, and daily structure that characterized her life more broadly — appears to have attenuated this pathway. These are not independent factors. Chronic stress disrupts sleep. Poor sleep elevates cortisol and inflammatory markers. Both impair glymphatic clearance and immune resolution. The feedback between stress, sleep, and inflammation is one of the most important amplification loops in biological aging.

Social connection and its biological effects

She remained embedded in a social network — family, friends, and caregivers — throughout extreme old age, including contact with animals.

Social isolation activates the same hypothalamic-pituitary-adrenal stress axis as physical threat, raising circulating inflammatory cytokines, accelerating telomere shortening, and predicting faster epigenetic aging. A major meta-analysis found loneliness associated with a 26% increase in all-cause mortality.⁶ The Lancet Commission identifies social isolation as a modifiable dementia risk factor. Mechanistically, perceived social connection downregulates NF-κB activity in immune cells, reduces cortisol, and promotes oxytocin signaling, which has direct anti-inflammatory effects. The biology does not appear to respond primarily to physical proximity but to the subjective experience of meaningful, reciprocal connection.

Cognitive engagement and reserve

She read books and played piano into her final years, and tended a garden that required continuous adaptation and problem-solving.

Formal education — measured by years of schooling — is identified by the Lancet Commission as the single largest modifiable dementia risk factor. The operative mechanism, however, is cognitive reserve: the brain’s accumulated capacity to sustain function in the presence of neuropathological damage. A brain with more synaptic redundancy and practiced cognitive flexibility can absorb more amyloid deposition, vascular injury, and neuronal loss before clinical symptoms appear. Post-mortem studies consistently show that individuals with high cognitive reserve may carry full Alzheimer’s pathology without clinical diagnosis.

Cognitive reserve is not fixed by formal schooling. It accrues across the lifespan through any genuinely demanding mental engagement. Piano performance is among the most neurologically complex activities available, requiring concurrent engagement of motor, auditory, mnemonic, attentional, and emotional systems. Her sustained engagement with cognitively demanding activities well past conventional retirement age likely continued building and maintaining the neural redundancy that may have protected her from symptomatic neurodegeneration.

A lifetime of infections, resolved

Her immune profile bore the signature of long experience. T cells were dominated by effector and memory subtypes. Immunoglobulin G levels — particularly IGHG2 and IGHG4 — were elevated, consistent with efficient and mature humoral memory. This immune phenotype reflects an organism that has encountered many pathogens, resolved the encounters, and consolidated the memory.

This is distinct from immune exhaustion, which we described in our previous post on microglial biology and Alzheimer’s disease: chronic, unresolved immune stimulation — from VZV reactivation, persistent amyloid burden, or other sources — drives immune cells toward a dysfunctional, pro-inflammatory, senescent state. Her immune system appeared experienced rather than exhausted: it had fought and cleared, repeatedly, across a century. This is consistent with the evolutionary framing introduced in our previous post — that APOE4 confers protection in high-pathogen environments by enhancing immune responsiveness, and becomes a liability in low-pathogen modern environments where the same responsiveness generates unresolved chronic inflammation.

She did not carry APOE4. Her APOE genotype was at the protective end of the spectrum, which almost certainly mattered for her lipid metabolism and neurological resilience.

Genetics helped, but gene-environment interaction was the mechanism

The researchers identified seven rare homozygous variants in her genome absent from European control populations, and protective configurations at APOE, FOXO3A, and genes involved in immune regulation, mitochondrial oxidative phosphorylation, cardiovascular function, and DNA repair.

Her genome was unusually favorable. But the paper is explicit: no single genetic variant explains her longevity. The identified variants span disparate biological processes — immune surveillance, energy metabolism, cardiovascular resilience, neuroprotection — and none appears individually sufficient. All appear to have operated in concert with each other and with her environment. MAP4K3, a longevity-regulating gene whose variant she carried, regulates lifespan in C. elegans through pathways that are sensitive to diet, stress, and metabolic state. The gene does not act independently of the environment in which it is expressed.

Gene-environment interaction is a core principle of quantitative genetics. The same variant that is protective in one environment may be neutral or deleterious in another. Her protective genome was expressed through — and likely required — the environmental context of her life: diet, physical activity, sleep, stress management, social engagement, and a century of immune experience.

The epigenetic clocks: an integrated readout

When the researchers estimated her biological age using six different epigenetic clocks — algorithms that infer biological age from DNA methylation patterns — every clock placed her substantially below her chronological age of 116. The discrepancy ranged from approximately 10 to 27 years across methods and tissues. Using the rDNAm clock, her biological age deceleration was 23.17 years.

Epigenetic clocks are accelerated by chronic inflammation, sleep disruption, psychological stress, social isolation, sedentary behavior, poor diet, and chronic unresolved infection — the same factors addressed throughout this post. Her 23-year deceleration represents the integrated biological output of a life in which these inputs were consistently attenuated. It is not attributable to any single variable. It reflects the cumulative effect of many factors operating in concert over a very long time.

What we do not know

Before drawing conclusions, it is important to be direct about the limits of this evidence.

This is a study of a single individual. No causal inferences can be drawn from an N of 1. We cannot determine whether her lifestyle choices produced her low inflammatory state, or whether her genetic endowment independently determined that state and also happened to promote the behaviors we observed — an instance of reverse causation that cannot be resolved in a cross-sectional study of one person.

We do not know the relative contribution of each factor discussed here. The multiomics data reveal associations between her biological profile and various features of her life and genome; they cannot quantify how much each factor mattered. The gut microbiome findings, for instance, are from a single time point late in life. We do not know whether her Bifidobacterium dominance was lifelong, whether it was a cause or consequence of her metabolic health, or whether it would have the same implications in a genetically different individual.

Epigenetic clocks, while powerful population-level tools, have been trained primarily on datasets that do not include many individuals past age 100. Their accuracy and interpretation at extreme ages remains uncertain. The variability and predictive power of these clocks are uncertain.

It is also worth noting that supercentenarians are not a homogeneous group. Other individuals who have lived to comparable ages have smoked, consumed alcohol heavily, and been largely sedentary. Extreme longevity likely has multiple biological routes, and the profile described here may represent one path among several. Survivorship bias is a genuine concern: we study those who reached extreme age, but we cannot easily study the many individuals who adopted similar lifestyles and did not.

Finally, most of the lifestyle factors described — diet, exercise, sleep, social connection — have been studied in relatively short-term randomized trials or observational studies spanning years to decades. Whether the effect sizes from those studies compound as expected over a full human lifespan is not established.

What the paper offers is not a proof of mechanism or recommendations for certain tests. It is a richly detailed portrait of one person whose biology was measurably younger than her age, in which low systemic inflammation emerges as the most consistent cross-cutting feature. That observation is worth taking seriously, even in the absence of causal certainty.

The sum is greater than the parts

What is most striking about this biological portrait is its refusal to yield a single active ingredient.

Not the yogurt. Not the Mediterranean diet. Not the walking. Not the piano. Not the protective genome. Not the Bifidobacterium. Not the good sleep. Not the family connections. No single factor, isolated, accounts for 117 years of health. The biology supports a systems view: these factors are mutually reinforcing, operating through shared mechanisms — principally, the regulation of chronic inflammation — and their combined effect is greater than any individual contribution.

A good high fiber fermented diet with an active lifestyle supports a healthy microbiome, which reduces systemic inflammation, which preserves epigenetic stability, which maintains mitochondrial function, which supports immune competence, which allows infections to resolve rather than persist, which protects sleep quality, which lowers cortisol, which further attenuates inflammation. These are not parallel pathways. They are a network. Single interventions improve one node in the network; a lifetime of consistent, modest, mutually reinforcing inputs keeps the network itself functional.

She did not optimize. She lived — with consistency, engagement, connection, and purpose — and the biology reflects it.

Illustration made using Claude

Take-home messages

There is no single intervention that confers longevity or health span. The most comprehensive biological study of an extreme long-liver found a confluence of genetic, dietary, microbial, immunological, and behavioral factors. The evidence does not support a protocol-based view of aging.

Inflammation is the final common pathway. Poor sleep, chronic stress, social isolation, physical inactivity, unresolved infection, and poor diet each generate chronic low-grade inflammation through overlapping mechanisms. Reducing the sources of that inflammation — rather than pharmacologically suppressing the immune response — is the central challenge of healthy aging.

Acute, resolving inflammation is not the problem — chronic, unresolved inflammation is. The immune system requires activation. Acute infections that clear, physical effort that triggers repair, and transient physiological stress that drives adaptation are all beneficial. The harmful signal is the one that never resolves.

Diet operates as a pattern over decades, not as an ingredient. The gut microbiome responds to the cumulative input of dietary diversity, fermented foods, fiber, and reduced ultra-processed intake. The evidence does not support supplementing individual components as a substitute for the overall pattern.

Habitual movement — independent of structured exercise — has measurable anti-inflammatory effects. Reducing prolonged sedentary time and sustaining low-intensity daily movement consistently improves metabolic and inflammatory biomarkers. Duration and consistency appear to matter more than intensity for most of the outcomes relevant to aging.

Sleep quality and duration affect amyloid clearance, immune regulation, and epigenetic aging. These are not independent consequences of aging — they are modifiable inputs that feed back into the aging process itself.

Chronic stress activates inflammatory signaling and accelerates biological aging by measurable epigenetic and telomeric markers. Psychological resilience and a sense of sustained purpose appear to attenuate this pathway.

Social connection downregulates NF-κB-mediated inflammatory signaling and is independently associated with dementia risk, cardiovascular outcomes, and mortality. The effect appears to be mediated by perceived meaningful connection rather than physical proximity alone.

Cognitive reserve — built by sustained engagement with mentally demanding activities — provides measurable protection against the clinical expression of neurodegeneration, even in the presence of pathological burden. It is not fixed by formal education and accumulates throughout the lifespan.

Genetics shapes vulnerability and resilience but does not determine outcomes independently of environment. Gene-environment interactions, particularly for variants like APOE4, mean that lifestyle factors may matter more — not less — for individuals with elevated genetic risk. The environment is where the greatest modifiable leverage lies.

The goal is the compression of morbidity — maintaining biological function close to the end of life — not the maximization of lifespan per se. She spent her final months managing bronchiectasis and osteoarthritis but reached that point without Alzheimer’s disease, cancer, or cardiovascular disease. That trajectory, more than the final number, is what the evidence points toward.

This post draws on: Santos-Pujol et al., “The multiomics blueprint of the individual with the most extreme lifespan,” Cell Reports Medicine 6, 102368 (2025); the Lancet Commission on Dementia Prevention, Intervention, and Care (2024 update); and concepts from our previous post on immune exhaustion and Alzheimer’s disease, including Kim & Crimmins (J Gerontol, 2026) and Millet et al. (Immunity, 2024). The post was constructed using Claude, Sonnet 4.6.

Footnotes

1. Santos-Pujol E et al. The multiomics blueprint of the individual with the most extreme lifespan. Cell Rep Med. 2025;6:102368. ↩

2. Wang Z et al. Plasma metabolomic profiles associated with mortality and longevity in a prospective analysis of 13,512 individuals. Nat Commun. 2023;14:5744.

3. Church S et al. Glycoprotein acetyls as a novel inflammatory biomarker of early cardiovascular risk. J Am Heart Assoc. 2022;11:e024380. ↩

4. Ungvari Z et al. The multifaceted benefits of walking for healthy aging. Geroscience. 2023;45:3211–3239. ↩

5. Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024. ↩

6. Johansson L et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain. 2010;133(8):2217–2224. ↩

7. Holt-Lunstad J et al. Loneliness and social isolation as risk factors for mortality. Perspect Psychol Sci. 2015;10(2):227–237. ↩

Over the past ten years, a new picture has emerged from genetics, from single-cell biology, and from some surprising places — the Bolivian Amazon, a Norwegian natural experiment on shingles, a ward of bladder cancer patients getting TB vaccines. The evidence is pointing toward a unified idea: that Alzheimer’s disease is, at least in part, a disease of immune exhaustion. The brain’s immune cells — microglia — become overwhelmed, worn out, and eventually unable to do the maintenance work that keeps Alzheimer’s pathology from taking hold. And some of our most powerful genetic risk factors, including the notorious APOE4 gene, may be accelerating exactly that process.

Understanding this reframes a lot of things: what our most recent drugs are actually doing, why certain vaccines seem to protect against dementia, and most importantly, what we should be developing next.

The Alzheimer’s Genome Is a Microglia Blueprint

To understand why the immune system matters so much in Alzheimer’s, start with genetics. Over the past fifteen years, genome-wide association studies (GWAS) — massive hunts through the DNA of hundreds of thousands of people for variants linked to disease — have uncovered more than 40 genetic locations associated with late-onset Alzheimer’s disease risk.

When researchers look at what those genes actually do, a striking pattern emerges. A large fraction of them are not expressed primarily in neurons. They are expressed in microglia — the resident immune cells of the brain. Genes like TREM2, CD33, BIN1, INPP5D, ABI3, CR1, and SPI1 all have primary functions in microglial biology: regulating how these cells respond to danger, how they engulf and degrade debris, how they signal to one another and to neurons.

The GWAS picture, in other words, tells us that the genetic architecture of Alzheimer’s is, to a remarkable degree, an immune architecture. Whatever is going wrong in the disease, the immune system is centrally implicated — not as a bystander, but as a principal actor.

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) deserves special mention. Rare variants in TREM2, particularly the R47H variant, confer a risk of late-onset Alzheimer’s roughly comparable to carrying one copy of APOE4. TREM2 is a receptor that sits on the surface of microglia and helps them sense and phagocytose — essentially, eat — cellular debris including amyloid plaques. When TREM2 is impaired, microglia lose their ability to effectively wrap around and dismantle plaques. They also struggle to survive in the inflammatory milieu of the Alzheimer’s brain. The result is a brain that is literally less capable of cleaning itself.

Microglia: The Brain’s Tireless Caretakers

To appreciate what goes wrong, it helps to appreciate what goes right — at least when things are working well.

Microglia make up roughly 10–15% of all brain cells. They are the central nervous system’s resident immune cells, derived from progenitor cells in the yolk sac during fetal development and maintained largely independently of the circulating bloodstream thereafter. They are, in the most literal sense, the brain’s dedicated immune workforce — present throughout life, patrolling constantly, responding to disturbances.

In a healthy brain, microglia perform ongoing surveillance. They extend fine processes that probe the local environment, sensing cellular damage, pathogen-associated signals, or the accumulation of abnormal proteins. When they detect a problem, they can migrate to the site, engulf and degrade the problematic material, and coordinate a local immune response to resolve the threat. They also play important roles in normal brain homeostasis — pruning synapses during development, supporting neuronal survival, and maintaining the extracellular environment.

In the context of Alzheimer’s disease, microglia are responsible for surveilling and clearing amyloid-beta plaques and tau tangles — the canonical hallmarks of the disease. When amyloid accumulates, microglia cluster around plaques in what is called a disease-associated microglia (DAM) state, upregulating genes involved in phagocytosis and inflammatory signaling. This response is protective, at least initially. It slows plaque expansion and contains the damage.

The problem is that this activated state has a cost. Sustained microglial activation is metabolically demanding and pro-inflammatory. If the stimulus — the accumulating amyloid, the chronic low-grade infection, the cellular stress — never resolves, the microglia cannot return to a resting homeostatic state. They are trapped in a cycle of activation without resolution.

When Immune Cells Run Out of Steam: Terminally Inflammatory Microglia

What does immune exhaustion look like in the brain? A landmark 2024 paper in Immunity by Millet, Ledo, and Tavazoie at Rockefeller University provides one of the most detailed answers yet (Millet et al., Immunity, 2024). Using single-cell RNA sequencing across an entire atlas of brain immune cells in Alzheimer’s model mice bearing different human APOE alleles, the researchers identified a distinct population of microglia they termed Terminally Inflammatory Microglia, or TIMs.

TIMs are characterized by simultaneous expression of inflammatory signaling markers and cellular stress markers. They are not simply “activated” microglia in the conventional sense — they appear to be something more advanced and more problematic: a population that has exhausted its adaptive capacity. Using trajectory analysis, the authors showed that TIMs represent a terminal state in microglial biology, arising from homeostatic microglia through acutely and chronically inflammatory intermediate states. Critically, once microglia reach the TIM state, it appears to be largely irreversible.

The frequency of TIMs was markedly elevated with age and with APOE4 genotype. In very old AD model mice, TIMs made up 45% of all microglia in APOE3 mice — but a striking 69% in APOE4 mice. This population was also detectable in human Alzheimer’s brains, with higher frequency in APOE4 carriers and at more advanced stages of disease (higher Braak score). Perhaps most damning: TIMs showed severely impaired capacity to phagocytose amyloid-beta. In direct ex vivo phagocytosis assays, TIMs were dramatically underrepresented among cells that successfully cleared amyloid. And in APOE4 mice, even TIMs that retained some phagocytic capacity were less effective than their counterparts in other genotypes.

The picture that emerges is stark. APOE4 does not merely accelerate amyloid production or impair its clearance through lipid metabolism. It also drives microglia faster toward a state of immune exhaustion — a state from which they cannot effectively do the work that might protect the brain.

Illustration created using Claude.

APOE4: A Risk Gene That Made Evolutionary Sense

The APOE4 story has long been puzzling from an evolutionary perspective. If the allele is so harmful — raising lifetime Alzheimer’s risk by 3-4 fold, reducing longevity — why does it exist in 20–25% of most human populations? Why hasn’t natural selection eliminated it?

A remarkable 2017 study by Trumble, Stieglitz, Blackwell, and colleagues at Arizona State University and UC Santa Barbara helps answer this question (Trumble et al., FASEB Journal, 2017). They studied 372 members of the Tsimane people — Amazonian forager-horticulturalists in Bolivia who live without access to sanitation, clean water, or modern medicine. More than two-thirds of Tsimane adults carry active intestinal helminth (parasite) infections at any given time.

The finding was startling. In industrial populations, APOE4 reliably predicts cognitive decline. But among Tsimane adults with high parasite burden, the opposite was true: APOE4 carriers showed better cognitive performance than non-carriers, particularly on measures of fluid cognition. The higher the parasitic load (measured by eosinophil counts, a biomarker of infection), the more pronounced the cognitive advantage of carrying APOE4. In parallel, APOE4 carriers in this population had significantly lower eosinophil counts overall — suggesting the allele was also helping to actually clear parasitic infections.

The interpretation is that APOE4 evolved in an environment of heavy pathogen burden. Its effects on immune function — including its effects on cholesterol metabolism, lipid transport, and immune signaling — were adaptive when the immune system was constantly challenged by real parasitic and infectious threats. These are conditions that characterized the vast majority of human evolutionary history. What has changed is the environment. In modern industrialized populations with low pathogen burden, the immune-stimulating properties of APOE4 no longer have a useful target. Instead of keeping a useful immune response calibrated against real threats, APOE4 may push microglia toward a state of chronic, unresolved inflammation — the very condition that drives immune exhaustion.

This is the mismatch hypothesis applied to the immune system: APOE4 was built for a world of worms and bacteria, and in a world of processed food and antibiotics, it may be driving the brain’s immune system toward burnout.

Microglial Senescence: When Tiredness Becomes Permanent

Immune exhaustion and cellular senescence are related but distinct concepts, and both are increasingly implicated in Alzheimer’s disease.

Cellular senescence is a state in which cells permanently exit the cell cycle, lose normal function, and begin secreting a cocktail of pro-inflammatory molecules — a phenomenon known as the senescence-associated secretory phenotype (SASP). Senescent microglia have been identified in aging human and mouse brains, and their numbers increase dramatically with age and in the presence of AD pathology. They are characterized by dystrophic morphology (fragmented, bulbous processes rather than the fine ramified extensions of healthy microglia), impaired phagocytic capacity, and elevated expression of stress-response genes.

There is a vicious cycle at work here. Chronic microglial activation in response to accumulating amyloid and tau generates persistent inflammatory signals. These signals promote cellular stress and, eventually, senescence. Senescent microglia then cannot clear pathology — allowing it to accumulate further — and actively contribute to neuroinflammation through SASP. The TIM population described by Millet et al. appears to represent something analogous: a late-stage, functionally compromised microglial state that can no longer effectively contribute to amyloid clearance, and that may be enriched for senescent markers.

The key point is that this is not simply “inflammation” in the cartoon sense of the immune system being turned on. It is chronic, unresolved, dysregulated inflammation — a system that has lost the capacity to mount and then resolve an effective immune response. It is inflammation as dysfunction, not inflammation as defense.

The Shingles Vaccine: An Accidental Experiment in Immune Rescue

One of the most intriguing recent threads in Alzheimer’s prevention comes not from neuroscience labs, but from large population studies of vaccination.

In 2025, a landmark natural experiment published in Nature Medicine exploited a Welsh policy quirk: the live-attenuated shingles vaccine (Zostavax) was rolled out in age-cohort order, meaning that people born just before a certain date were eligible and people born just after were not. This created a near-randomized comparison. The result: vaccine eligibility was associated with a roughly 20% reduction in dementia incidence over the next several years — a striking effect size for a vaccine not designed to protect against dementia.

This finding was complemented by a 2026 study by Kim and Crimmins in the Journals of Gerontology, using data from the Health and Retirement Study (Kim & Crimmins, J Gerontol, 2026). Among nearly 4,000 older Americans, those who had received the shingles vaccine showed significantly more favorable biological aging profiles, including lower systemic inflammation, slower epigenetic aging (as measured by DNA methylation clocks), and lower transcriptomic aging scores. Crucially, the inflammation reduction was robust even after adjusting for socioeconomic factors, health behaviors, and multimorbidity. The effect was most pronounced in the years immediately following vaccination, consistent with the hypothesis that suppressing varicella-zoster virus (VZV) reactivation reduces chronic immune stimulation.

The mechanism, the researchers propose, is one of immune recalibration. The herpes zoster virus lies dormant in nerve tissue after childhood chickenpox infection, and it periodically reactivates — sometimes producing shingles, often subclinically. Each reactivation triggers an immune response, elevating inflammatory cytokines like IL-6, TNF-alpha, and CRP. Over decades, this chronic, low-level immune activation contributes to inflammaging — the background hum of systemic inflammation that accelerates biological aging and may progressively exhaust immune capacity.

By suppressing VZV reactivation, shingles vaccination may reduce this chronic immune burden. Microglia, relieved of one source of sustained peripheral immune activation, may be better positioned to maintain homeostasis and respond effectively to amyloid and tau. In essence, the vaccine may be protecting the brain by giving the immune system one fewer thing to fight.

Importantly, Kim and Crimmins also note that influenza and pneumococcal vaccines showed some similar — if weaker — benefits, particularly in the cardiovascular domain. This raises the question of whether reducing the burden of latent and recurrent infections more broadly might constitute a strategy for preserving immune capacity in aging. Whether BCG vaccination (the tuberculosis vaccine, which has broad non-specific immune-modulating effects and has been associated with roughly a 20–45% reduction in Alzheimer’s risk in some retrospective studies), herpes simplex vaccines (not yet approved), or earlier pneumococcal vaccination might offer parallel protections is not yet known, but the hypothesis is increasingly testable.

What Anti-Amyloid Antibodies Are Really Doing

The approval of aducanumab in 2021 and lecanemab in 2023 brought the first disease-modifying treatments for Alzheimer’s disease to the clinic. These are monoclonal antibodies designed to bind amyloid-beta and accelerate its removal from the brain. They work — lecanemab reduced the rate of clinical decline by about 27% in phase 3 trials. But they also come with a significant side effect: Amyloid-Related Imaging Abnormalities, or ARIA.

ARIA manifests as brain edema (ARIA-E) or microhemorrhages (ARIA-H) on MRI. In clinical trials, ARIA-E occurred in about 12–35% of patients depending on the antibody and APOE4 genotype, with APOE4 carriers at substantially higher risk. It is usually asymptomatic but can cause headache, confusion, and in rare cases, serious neurological events.

The mechanism of ARIA illuminates something important about what these antibodies are actually doing. Anti-amyloid antibodies opsonize amyloid aggregates — they tag them for destruction. Microglia express Fc receptors that recognize the antibody-tagged amyloid and engulf it. But amyloid also accumulates extensively in cerebral blood vessels (cerebral amyloid angiopathy), and when the antibody binds this vascular amyloid, it triggers an immune response at the vessel wall — complement activation, microglial Fc receptor-mediated phagocytosis, and the resulting inflammation increases vascular permeability, producing the edema and microbleeds of ARIA.

The Millet et al. study sheds light on what happens to microglia during aducanumab treatment. Acute treatment drove microglia toward disease-associated (DAM) states and effector-hi TIMs — an expanded immune response. Crucially, aducanumab and APOE4 genotype were both associated with a higher number and strength of predicted cell-cell interactions in the microglial compartment, suggesting that the drug is doing more than simply tagging amyloid for clearance. It is engaging and reshaping the brain’s immune landscape, including expanding adaptive immune cell interactions (particularly CD8 T cells) in an APOE4-dependent manner.

This is both promising and cautionary. It suggests that anti-amyloid antibodies may be exerting some of their benefits — and their risks — by broadly engaging microglial biology beyond amyloid clearance. Whether they can help restore a more homeostatic microglial state, or whether they risk further exhausting already-compromised TIM populations, remains an important open question. In APOE4 carriers, where TIMs are more abundant and more profoundly impaired, these dynamics may be particularly consequential.

The Future: Restoring Microglial Biology

If the central problem in Alzheimer’s — at least through the lens of APOE4 and many GWAS hits — is the progressive exhaustion and senescence of microglia, what can we do about it?

Several approaches are in active development:

TREM2 agonists. TREM2 is a critical survival and activation signal for microglia, and its expression is reduced in aging and in advanced disease. Agonistic antibodies that activate TREM2 signaling — including AL002 (tested in the INVOKE-2 phase 2 trial) and VHB937 (currently in phase 2) — aim to restore microglial function by boosting this pathway. The INVOKE-2 results were disappointing on primary endpoints, raising questions about timing: TREM2 agonism may need to be applied earlier in disease progression, before the TIM state becomes dominant.

Senolytics. Drugs that selectively eliminate senescent cells are a rapidly growing field. In preclinical models, clearing senescent microglia reduced neuroinflammation and improved cognitive outcomes. Clinical trials in Alzheimer’s are in early stages, but the rationale is compelling: if a proportion of microglia have become permanently dysfunctional, removing them might allow the remaining healthy population — or newly recruited monocyte-derived cells — to function more effectively.

CSF1R modulators. CSF1R (Colony Stimulating Factor 1 Receptor) governs microglial survival and proliferation. Transient pharmacological depletion of microglia followed by withdrawal of the drug allows repopulation from progenitor cells — essentially resetting the microglial compartment. This approach has shown promise in preclinical settings, though getting the timing and context right for human application is an active area of investigation.

Cell therapy. More ambitiously, some researchers have explored transplanting healthy microglia or microglial precursors to replace exhausted resident populations. A recent study demonstrated that systemic hematopoietic cell transplantation can restore microglial TREM2 function in mouse models.

Metabolic support. TIMs, as Millet et al. showed, are characterized by profound metabolic derangement — depleted glycolysis, pentose phosphate pathway activity, and TCA cycle function. Whether interventions that restore microglial metabolic fitness (through mTOR modulation, NAD+ precursors, or other approaches) could help prevent or reverse the TIM state is an exciting but still largely unexplored question.

cPLA2 inhibition. One particularly compelling metabolic-inflammatory target is calcium-dependent phospholipase A2 (cPLA2), an enzyme that sits at the intersection of lipid metabolism and immune activation. When microglia are chronically stimulated, cPLA2 is activated — either by oxidative stress, MAPK signaling, or elevated intracellular calcium — and begins liberating arachidonic acid (AA) from membrane phospholipids. AA is then metabolized by cyclooxygenases and lipoxygenases into a cascade of pro-inflammatory eicosanoids: prostaglandins, leukotrienes, and thromboxanes. In the short term, this is part of a normal immune response. But when cPLA2 stays chronically active, the sustained eicosanoid output generates reactive oxygen species, promotes lipid accumulation in lysosomes, activates NF-κB, and drives microglia toward the very senescent phenotype described above — a vicious cycle of inflammation and cellular damage that is difficult to escape. Critically, APOE4 specifically activates cPLA2 through MAPK p38 signaling, a finding confirmed in both animal models and postmortem human brain tissue (Wang et al., 2022; Ebright et al., 2022, reviewed in Hugo et al., Antioxid. Redox Signal., 2024). In AD mouse models, cPLA2 protein levels are elevated in astrocytes surrounding amyloid plaques, and cPLA2 knockout mice show rescued cognition on maze tasks. This makes cPLA2 inhibition an attractive strategy — not simply to reduce inflammation downstream, but to interrupt the lipid-driven senescence program at its source, potentially before irreversible TIM states are reached. The key practical challenge is developing inhibitors that are potent, selective for cPLA2 over related phospholipase isoforms, and capable of crossing the blood-brain barrier. Several lead compounds exist (including ASB14780 and the structurally diverse series emerging from virtual screening platforms), and the goal is not to abolish cPLA2 activity entirely — which would impair normal immune signaling — but to bring its chronic overactivation back into a physiological range. APOE4 carriers, who show measurably higher brain cPLA2 activity, may represent the population most likely to benefit; [18F]fluoro-AA PET imaging, which tracks arachidonic acid kinetics as a surrogate of brain cPLA2 activity, is being developed as a companion biomarker to identify and monitor this at-risk group.

Neither Good nor Bad: Reframing Inflammation

Throughout this discussion, you may have noticed that we keep running into a paradox: inflammation is implicated in Alzheimer’s disease, but so is immune exhaustion. How can both be true?

The answer is that the popular framing of inflammation as simply “good” or “bad” is not adequate to describe what is happening in the aging brain.

In the context of Alzheimer’s disease, we need good inflammation: the acute, targeted, resolving immune response that allows microglia to detect, engulf, and degrade amyloid and tau, then stand down. This is the physiological function the system was designed for. We also need the capacity to resolve inflammation — to return to homeostasis after a threat has been addressed.

What we do not want — and what appears to be accumulating in aging APOE4 brains — is chronic, unresolved inflammation: the persistent low-grade immune activation that exhausts microglial capacity, drives cells into senescent and terminally inflammatory states, and ultimately impairs the very clearance functions that were supposed to protect against pathology.

This is why the shingles vaccine finding is so conceptually important. The vaccine is not directly anti-inflammatory — in fact, it triggers a robust immune response. But by resolving a source of chronic latent viral pressure, it may restore the immune system’s capacity to function effectively: acute responses that resolve, rather than chronic smoldering that never does.

The same logic applies to APOE4. In an environment of high pathogen burden (the Tsimane Bolivians with their helminth infections), the allele’s immune-enhancing properties are channeled into useful, targeted immune work that keeps cognitive function intact. In a modern, low-pathogen environment, the same properties may tip the immune system toward chronic activation without resolution — driving microglia toward burnout.

And it is the same logic that should guide how we think about the new anti-amyloid antibodies. They are not simply “reducing inflammation” — they are restructuring the brain’s immune response, engaging microglia, and reshaping cell-cell interactions. Whether they do so in a way that ultimately restores or further compromises microglial resilience will likely depend on when in the disease course they are given, in whom, and at what dose.

Where This Leaves Us

We are at an early but genuinely exciting moment in Alzheimer’s research. The convergence of GWAS genetics, single-cell biology, evolutionary medicine, and epidemiology is drawing us toward a coherent picture of what goes wrong in the most common genetic form of Alzheimer’s disease: the progressive failure of the brain’s immune workforce.

The discovery of TIMs — exhausted-like microglia that accumulate with age and APOE4 burden and cannot effectively clear amyloid — provides a compelling cellular mechanism for much of what we have observed clinically. The finding that APOE4 functioned differently — indeed, protectively — in environments with high parasite burden puts this in evolutionary context. The association between shingles vaccination and slower biological aging suggests that the immune system’s capacity to protect the brain may be more modifiable than we thought.

The implications for therapy are profound. Rather than asking only “how do we clear amyloid?” we should also be asking: “how do we keep the immune cells that clear amyloid from burning out?” Those are different questions, and they may call for different — and complementary — answers.

A brain in which the right inflammation happens at the right time, resolves completely, and leaves microglia refreshed and ready for the next challenge: that is what we are trying to preserve. Not a brain with no inflammation. Not a brain with relentless, unresolved inflammation. But a brain whose immune system can do its job — and then rest.

This post draws on four key papers:

• Millet, Ledo & Tavazoie. “An Exhausted-Like Microglial Population Accumulates in Aged and APOE4 Genotype Alzheimer’s Brains.” Immunity 57(1): 153–170, 2024.

• Trumble et al. “Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden.” FASEB Journal 31: 1508–1515, 2017.

• Kim & Crimmins. “Association between shingles vaccination and slower biological aging: evidence from a US population-based cohort study.” Journals of Gerontology, Series A, 81(3): glag008, 2026.

• Hugo, Asante, Sadybekov, Katritch & Yassine. “Development of Calcium-Dependent Phospholipase A2 Inhibitors to Target Cellular Senescence and Oxidative Stress in Neurodegenerative Diseases.” Antioxid. Redox Signal., 2024. DOI: 10.1089/ars.2024.0794

Additional references:

• Late-onset AD genetics implicates microglial pathways — Molecular Neurodegeneration, 2017.

• Functional characterization of AD genetic variants in microglia — Nature Genetics, 2023.

• Senescent microglial accumulation in AD — Neuron, 2024.

• Varicella-zoster reactivation and dementia risk — Nature Medicine, 2025.

• Vaccines and dementia — BCG and beyond — J Alzheimers Dis, 2024.

• TREM2 and sTREM2: mechanisms to therapies — Molecular Neurodegeneration, 2025.

• Aducanumab induces sustained microglial alterations — Journal of Experimental Medicine, 2024.

Claude Sonnet 4.6 (Anthropic) was used to help put this article together and create the illustration. AI is not used to generate content.

The honest truth is that academic life had swallowed me whole at the time. Grant deadlines, manuscript revisions, back-to-back committee meetings, study section, a clinical schedule that doesn’t pause for anyone. I saw her message, thought I need to think carefully about this one. So belatedly, here is my take:

What the Study Did and Found

“Meat Consumption and Cognitive Health by APOE Genotype” by Norgren, Carballo-Casla, and colleagues at Karolinska Institutet is a prospective cohort study published March 19, 2026 in JAMA Network Open, drawing from the Swedish National Study on Aging and Care, Kungsholmen (SNAC-K). Of 5,111 randomly selected adults aged 60 and older, 2,157 met inclusion criteria — no dementia at baseline, with available diet, cognition, and APOE data. Mean age was 71.2 years; 62% were women; 569 participants (26.4%) carried APOE ε3/ε4 or ε4/ε4 genotypes (APOE34/44). Follow-up extended up to 15 years, during which 296 participants developed dementia.

Dietary exposure was assessed using a validated 98-item food frequency questionnaire at baseline and at 3- and 6-year follow-ups, with total meat consumption expressed as grams per total kilocalories. Secondary exposures included the ratio of processed to total meat and the log ratio of unprocessed red meat to poultry. Covariates were selected using causal inference principles and included age, sex, education, physical activity, smoking, alcohol, total energy intake, morbidity, baseline cognition, and — methodologically important — the Alternative Healthy Eating Index (AHEI) score excluding meat items, ensuring the association was not simply a marker of overall dietary quality.

Cognitive trajectories (composite z-score across episodic memory, semantic memory, verbal fluency, and perceptual speed over 15 years, available in 1,680 participants) were analyzed by linear regression with quintile-based exposure. Dementia incidence was analyzed using Fine and Gray subdistribution hazard ratios (sHRs), treating non-dementia death as a competing risk. To address reverse causation, the authors used a triangulation approach — combining longitudinal between-participant, within-participant fixed-effects, and cross-sectional baseline analyses — and confirmed that dietary changes did not differ between those who did and did not develop dementia.

Main findings: in APOE34/44 carriers, the top versus bottom quintile of meat intake was associated with better cognitive trajectories (β = 0.32; 95% CI, 0.07–0.56; P = .01), most pronounced for episodic memory (β = 0.52; 95% CI, 0.12–0.92). No association was found in non-carriers (β = −0.11; P = .20). The APOE interaction on cognitive trajectory: P = .004. For dementia, the sHR in APOE34/44 carriers was 0.45 (95% CI, 0.21–0.95; P = .04) versus 0.95 in non-carriers — but the APOE-by-meat interaction on dementia did not reach statistical significance (P = .10). Processed meat increased dementia risk regardless of genotype (sHR, 1.14; 95% CI, 1.01–1.29, Figure below). Post-hoc analyses suggested a consistent APOE interaction for all-cause mortality (HR, 0.85; P = .04) and greater vitamin B12 absorption from meat in APOE34/44 carriers.

Does P = .10 for the Dementia Interaction Undermine the Whole Paper?

This is the right question to ask, and it deserves a direct answer.

The P = .10 for the APOE-by-meat interaction applies specifically to the dementia diagnosis endpoint. With only 569 APOE34/44 participants and 296 total dementia cases across all genotypes, the study was underpowered to reliably detect a genotype interaction for incident dementia — this is a harder, rarer endpoint than a continuously measured cognitive score. The directionality of the dementia finding is fully consistent with the cognitive trajectory result; it simply does not clear the significance threshold for that specific secondary outcome.

The paper’s primary pre-specified outcome was cognitive trajectory, analyzed in 1,680 participants with 15 years of longitudinal data, where the interaction is P = .004 and survives multiple sensitivity analyses including participants with higher HbA1c, lower AHEI scores, and higher vascular risk scores. The triangulation approach yielded consistent results across three analytical methods. The dementia result is best understood as directionally supportive but statistically inconclusive — not as evidence against the cognitive finding.

That said, the P = .10 is a legitimate reason for interpretive caution. The paper supports the hypothesis that APOE genotype modifies the association between meat consumption and cognitive aging trajectories in a Swedish elderly cohort. That is what it shows — not that red meat prevents Alzheimer’s disease.

Why This Paper Is Still Worth Taking Seriously

Beyond the pre-specified hypothesis and triangulation design, several features add credibility. The AHEI adjustment (excluding meat) means the cognitive signal is not merely reflecting that high meat consumers also eat more vegetables and fish. The effect was robust among women, participants under 72, those with higher HbA1c, and those with higher cardiovascular risk scores — subgroups where confounding by general healthiness is less likely. Post-hoc findings for mortality and B12 absorption point in the same direction. And the distinction between processed and unprocessed meat — with processed meat conferring risk regardless of genotype — is internally coherent and consistent with the broader literature.

The limitations are real: self-reported diet, a single urban Swedish cohort with limited generalizability across ancestries, a modest APOE34/44 subgroup, and the inherent inability of observational data to establish causality despite the methodological care. The study is best received as a well-grounded hypothesis-generating contribution that makes a compelling case for APOE-stratified randomized trials.

The Biology: Why APOE4 Carriers May Respond Differently to Dietary Fat

The observational finding has a plausible biological basis, though the mechanism points somewhere more specific than “APOE4 carriers need more fat.”

In a review I wrote with Caleb “Tuck” Finch in Frontiers in Aging Neuroscience, we examined what apoE4’s cell biology implies for brain energy metabolism. APOE4 impairs the brain’s ability to use glucose efficiently — APOE4 astrocytes have roughly half the glucose uptake capacity of APOE3 astrocytes, and neuroimaging confirms regional brain glucose hypometabolism in APOE4 carriers detectable decades before symptoms. In response, the APOE4 brain shifts toward dietary fat as its preferred energy source. This may be one reason why older APOE4 carriers who lose significant weight show accelerated cognitive decline — adipose fat stores appear to serve as an important fuel reservoir for a brain that can no longer rely as heavily on glucose.

This energy-preference hypothesis has direct clinical support. Hanson and colleagues (2015) showed in a blinded feeding study that an acute high-fat meal improved cognitive performance and plasma Alzheimer’s disease biomarkers in APOE4 carriers with mild cognitive impairment — while non-carriers showed the opposite pattern. Fat, in a glucose-deprived APOE4 brain, appears to be a better fuel.

This provides a biologically coherent explanation for the SNAC-K finding: if the APOE4 brain runs better on fat, a dietary pattern that includes more fat — including from unprocessed meat — may support cognitive function in ways that do not apply to non-carriers.

The important qualification: the APOE4 brain’s preference for fat does not translate into a recommendation to eat more red meat or to adopt a ketogenic diet. The fat that matters most for the APOE4 brain is high-quality polyunsaturated fat, particularly the omega-3 fatty acid DHA. Using PET imaging, we showed that brain DHA uptake is approximately 20% greater in younger cognitively normal APOE4 carriers versus non-carriers — a signal of heightened biological demand. That demand is best met through fish and seafood. Red meat, particularly unprocessed, may contribute to overall fat and protein intake in ways that modestly support this, but it is not the primary source, and processed red meat — high in sodium, nitrates, and additives — increases dementia risk across all genotypes and should be minimized regardless of APOE status.

Dietary Patterns, Not Individual Foods

The most important and most frequently overlooked principle in nutrition and dementia research is that the relevant unit of analysis is a dietary pattern, not a single food. In our Lancet Healthy Longevity paper, we reviewed the full evidence base — observational studies, clinical trials, and mechanistic data — and found that no individual nutrient or food has demonstrated consistent cognitive benefit in adequately powered randomized trials when evaluated in isolation. The Mediterranean and MIND dietary patterns show the most consistent associations with cognitive health, not because of any single component but because of their structural coherence: high vegetables, whole grains, legumes, fish, olive oil, moderate unprocessed animal protein, and minimal processed food and added sugar. The SNAC-K finding that processed meat increases dementia risk regardless of genotype fits squarely within this framework. For APOE4 carriers, the most evidence-supported approach is a pattern that provides adequate omega-3 fatty acids, preserves insulin sensitivity, and minimizes ultra-processed foods — not one defined by a target intake of any single protein source.

There is, however, a complication in applying Mediterranean diet evidence to the SNAC-K cohort that is worth naming. Sweden is not a Mediterranean country, and long-term adherence to a Mediterranean dietary pattern in Scandinavian populations is low. In a cohort where few participants habitually consume olive oil, legumes, and fish in the combinations that define Mediterranean eating, the comparison group for "high meat consumers" is not people eating a Mediterranean diet — it is people eating less meat within a Northern European dietary context, which may look quite different nutritionally. This makes it difficult to use Mediterranean diet evidence as the interpretive frame for what the SNAC-K results mean in practice. It also underscores a broader point that our field has been slow to act on: dietary recommendations need to account for cultural and regional food environments. A precision nutrition approach for APOE4 carriers cannot simply export one population's dietary pattern to another; it must identify the underlying nutritional principles — adequate high-quality fat, omega-3 sufficiency, low processed food burden — and allow those to be achieved within the foods and traditions that people actually eat.

Take-Home Messages

• The primary finding — a statistically significant APOE interaction for cognitive trajectories (P = .004) — is the paper’s substantive claim. The dementia interaction did not reach conventional significance (P = .10), which reflects limited power for that secondary endpoint rather than evidence against the cognitive finding.

• The study is observational. Self-reported diet, a single Swedish cohort, and modest APOE34/44 subgroup sizes constrain interpretation. The triangulation design partially addresses reverse causation, but residual confounding cannot be excluded.

• Processed and unprocessed red meat are not the same exposure. The cognitive benefit was most pronounced for unprocessed meat; processed meat increased dementia risk regardless of genotype. This distinction is often lost in coverage of this study.

• There is biologically plausible support for APOE4-specific dietary fat responses. The APOE4 brain has impaired glucose metabolism and compensates by preferring fat as an energy substrate. Hanson and colleagues showed that an acute high-fat meal improved cognition and AD biomarkers in APOE4 carriers with MCI but worsened them in non-carriers — exactly the kind of genotype-specific response the SNAC-K data reflect at a population level.

• This does not mean APOE4 carriers should eat more red meat or adopt a ketogenic diet. The fats that matter most for the APOE4 brain are heart-healthy good fats, obtained from fish and seafood, but also from unprocessed red meat or plant-based foods. Processed red meat increases dementia risk regardless of genotype and should be avoided.

• Dietary patterns are more important than individual foods. No single food drives or prevents Alzheimer’s disease. One example of a healthy pattern is the Mediterranean-style pattern — rich in fish, vegetables, whole grains, and olive oil, with modest unprocessed animal protein — remains the best-supported framework for cognitive health, including in APOE4 carriers.

• “Mediterranean pattern” evidence does not map cleanly onto a Swedish cohort. Few SNAC-K participants habitually follow a Mediterranean dietary pattern, so the high-meat comparison group is not eating Mediterranean — it is eating less meat within a Northern European food context. This limits cross-study interpretation and highlights the need for personalized, culturally adapted dietary guidance that identifies the underlying nutritional principles — adequate high-quality fat including red meat, omega-3 sufficiency, low processed food burden — and allows people to meet them through the foods and traditions they actually live with.

• The right response to this paper is to design better trials, not to change dietary recommendations. Genotype-stratified randomized nutrition trials are urgently needed. This study makes a compelling case for them.

References

1. Norgren J, Carballo-Casla A, Grande G, et al. Meat Consumption and Cognitive Health by APOE Genotype. JAMA Network Open. 2026;9(3):e266489. doi:10.1001/jamanetworkopen.2026.6489

2. Yassine HN, Finch CE. APOE Alleles and Diet in Brain Aging and Alzheimer’s Disease. Front Aging Neurosci. 2020;12:150. doi:10.3389/fnagi.2020.00150

3. Yassine HN, et al. Nutrition State of Science and Dementia Prevention: Recommendations of the Nutrition for Dementia Prevention Working Group. Lancet Healthy Longevity. 2022;3(8):e501–e512.

4. Hanson AJ, Bayer JL, Baker LD, et al. Differential effects of meal challenges on cognition, metabolism and biomarkers for apolipoprotein E varepsilon4 carriers and adults with mild cognitive impairment. J Alzheimers Dis. 2015;48(1):205–218. doi:10.3233/jad-150218

5. Yassine HN, Braskie MN, Mack WJ, et al. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017;74(3):339–347. doi:10.1001/jamaneurol.2016.4899

6. Yassine HN, Croteau E, Rawat V, et al. DHA Brain Uptake and APOE4 Status: A PET Study With [1-11C]-DHA. Alzheimers Res Ther. 2017;9(1):23. doi:10.1186/s13195-017-0250-1

To understand why the field of Alzheimer’s research has spent three decades pursuing a single protein, you need to appreciate how consistent the original clues were. In 1992, John Hardy and Gerald Higgins formally proposed what became known as the amyloid cascade hypothesis—the idea that the abnormal buildup of a protein fragment called amyloid-beta (Aβ) in the brain is the earliest and most critical trigger of Alzheimer’s disease (AD). This was not speculation. It was a framework built on converging lines of genetic evidence that, taken together, pointed toward amyloid as the initiating event.

The first and perhaps most powerful piece of evidence came from people with Down syndrome. Individuals with trisomy 21 carry three copies of chromosome 21, which also happens to be where the gene encoding the amyloid precursor protein (APP) resides. Because of this gene-dosage effect, people with Down syndrome produce more Aβ throughout their lives—and virtually all of them develop the hallmark plaques and tangles of Alzheimer’s pathology by their late thirties and forties. Those who die young from other causes in their early-to-mid teens already show diffuse amyloid deposits in the brain, with tangles and neurodegeneration following later. This natural experiment—triple the dose of APP, and you observe early, progressive Alzheimer’s pathology—provided a foundational biological anchor for the hypothesis.

The second line of evidence came from rare inherited forms of early-onset Alzheimer’s disease (familial AD, or FAD). Scientists discovered that mutations in the APP gene itself, or in proteins called presenilin-1 and presenilin-2 (the enzyme that cuts APP to generate Aβ), all caused aggressive Alzheimer’s in people in their forties and fifties. These mutations share a unifying biochemical consequence: they shift the balance of Aβ production toward longer, stickier, more aggregation-prone forms, particularly Aβ42. Strikingly, a rare protective mutation in the APP gene (A673T) was later identified in Icelandic families: carriers produced slightly less Aβ throughout their lives and were substantially protected from both Alzheimer’s dementia and age-related cognitive decline, with some showing very few amyloid plaques even at age 100. As Selkoe and Hardy wrote at the 25-year anniversary of the hypothesis, “definitive proof... could only come from clinical trials that selectively target Aβ and produce slowing and ultimately arrest of cognitive decline.” The hypothesis also gained important genetic credibility when the discovery of ApoE4 as a major risk factor for late-onset AD was found to act, at least in part, by impairing the brain’s ability to clear Aβ effectively. Taken together, these observations across Down syndrome, inherited mutations, protective variants, and population genetics built a coherent biological case: Aβ dyshomeostasis—too much production, too little clearance, or both—sits at the beginning of the Alzheimer’s disease cascade, preceding tangles, neurodegeneration, and cognitive decline by years or even decades.

Validation at Last: How Recent Clinical Trials Supported the Amyloid Cascade Hypothesis

The road from biological hypothesis to therapeutic validation was long and littered with failure. For roughly two decades, nearly every major pharmaceutical effort targeting amyloid came up empty. Anti-amyloid vaccines were halted due to dangerous brain inflammation. Drugs designed to block the enzymes that produce Aβ (beta- and gamma-secretase inhibitors) either failed to show benefit or actually worsened outcomes. Dozens of monoclonal antibodies—proteins designed to bind and clear Aβ from the brain—missed their primary endpoints in large Phase 3 trials, including failures for solanezumab, bapineuzumab, crenezumab, gantenerumab, and others. These repeated setbacks raised serious questions about whether targeting amyloid was a viable therapeutic strategy at all.

But the failures contained instructive lessons. They indicated that treating patients who already had moderate-to-severe dementia was likely too late, and that not all anti-amyloid antibodies were equivalent—those that powerfully cleared fibrillar plaque, the dense aggregated form most associated with downstream pathology, appeared more likely to produce measurable biological effects. Armed with these refinements, a new generation of trials targeting earlier disease stages with more potent plaque-clearing antibodies produced the long-awaited result. The CLARITY AD trial of lecanemab (2022) enrolled 1,795 patients with early symptomatic Alzheimer’s and demonstrated a statistically significant 27% slowing of clinical decline at 18 months, as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB). The TRAILBLAZER-ALZ 2 trial of donanemab (2023) enrolled 1,736 early-stage patients and showed a 35% slowing of decline. Both drugs not only cleared amyloid plaques robustly—they also produced reductions in phosphorylated tau (p-tau) biomarkers in blood and cerebrospinal fluid. This biomarker finding was among the most scientifically significant: if reducing Aβ also lowers downstream p-tau—a protein that becomes pathologically modified and spreads through the brain as a consequence of amyloid accumulation—it provides biological support for amyloid’s position upstream in the disease cascade, rather than as a parallel or unrelated process.

Not the Whole Story: Why Amyloid Doesn’t Fully Explain Alzheimer’s Dementia

Validating the amyloid cascade hypothesis is not the same as claiming it fully explains the clinical syndrome of Alzheimer’s dementia across all affected people. There are several important reasons to interpret the clinical trial results with measured expectations.

Even in the genetic forms of Alzheimer’s that originally anchored the hypothesis, the disease mechanism appears more complex than Aβ overproduction alone. In Down syndrome, the extra copy of APP on chromosome 21 was long assumed to cause AD primarily by increasing Aβ42 production. But work from Ralph Nixon’s laboratory has shown that the β-secretase-cleaved carboxyterminal fragment of APP (APP-βCTF, or C99)—generated from the same excess APP—directly elevates lysosomal pH by approximately 0.6 pH units in cells from individuals with Down syndrome, inactivating cathepsin D and other lysosomal hydrolases that depend on acidic conditions to function. This lysosomal dysfunction is detectable perinatally, preceding amyloid plaque formation by years, and is reversed by normalizing lysosomal pH or by reducing APP expression with siRNA or BACE1 inhibition. Similarly, in familial AD caused by PSEN1 mutations, the presenilin-1 protein has a role in lysosomal acidification entirely separate from its function in the γ-secretase complex that cleaves APP: PSEN1 acts as a chaperone for the v-ATPase V0a1 subunit and is required for proper lysosomal acidification. Disease-causing PSEN1 mutations impair this function, elevating lysosomal pH and creating a cascade of autophagic substrate accumulation and progressive neurodegeneration that Nixon and Rubinsztein characterize as a primary driver of AD pathogenesis, not merely a consequence of Aβ . These findings introduce a meaningful qualification: even in the most penetrant genetic forms of Alzheimer’s, the path from gene mutation to neurodegeneration may run through lysosomal failure in parallel with—or even upstream of—Aβ accumulation. The distinction between “amyloid-driven” and “endolysosomal-driven” pathology may be less clean than the original formulation assumed.

More than 99% of Alzheimer’s cases are nonetheless late-onset and sporadic, arising from the complex interaction of genetics, aging, lifestyle, vascular health, and environmental factors. In this much larger population, amyloid accumulation appears to be a contributing factor but not the sole sufficient cause of dementia, and other pathological processes operate in parallel.

The first consideration is the magnitude of clinical benefit from anti-amyloid therapies. The CDR-SB is a scale ranging from 0 (no impairment) to 18 (severe dementia), where clinicians rate how well a person manages six life domains: memory, orientation, judgment, community activities, home life, and personal care. In early Alzheimer’s, scores typically fall between 2 and 8. The minimum difference on this scale that most clinicians consider meaningful to a patient’s daily life is estimated at 1 to 2 points. Lecanemab slowed decline by approximately 0.5 points over 18 months relative to placebo; donanemab by approximately 0.7 points over roughly 20 months. In plain terms: treated patients declined somewhat more slowly, but both groups continued to decline, and the average difference between treated and untreated patients was below what most clinicians or caregivers would detect day to day. For any individual patient, the chance of experiencing a perceptible benefit is modest, and it must be weighed against the risk of ARIA—amyloid-related imaging abnormalities including brain swelling and microbleeds—that affected 13–37% of treated patients across the trials, with a subset requiring discontinuation or hospitalization. This does not diminish the scientific significance of a positive trial, which after decades of failure is genuinely important. It does, however, raise a practical and conceptual question: if amyloid is the central driver of Alzheimer’s dementia, why does substantially clearing it from the brain produce relatively small effects on the rate of cognitive decline? The most likely answer is that by the time patients are enrolled in these trials—even at the “early” stage—substantial neurodegeneration, tau pathology, and inflammation have already accumulated, and removing amyloid at that point is analogous to extinguishing a fire after the structure has burned. The disease has become self-sustaining through mechanisms that are no longer amyloid-dependent.

This complexity becomes further apparent when we examine racial and ethnic diversity in Alzheimer’s presentation. A 2026 study by Wheeler and colleagues examined 1,181 cognitively unimpaired and 383 mildly cognitively impaired participants from the Health and Aging Brain Study–Health Disparities (HABS-HD), encompassing non-Hispanic White (NHW), Hispanic, and Black older adults. Using tau PET imaging to map tau pathology in the medial temporal lobe (MTL)—a brain region critical for memory—and amyloid PET to characterize amyloid burden, the study revealed important group differences. After controlling for age, sex, and education, Black and Hispanic participants showed significantly higher MTL tau levels than NHW participants, even after accounting for choroid plexus off-target signal (a technical artifact that can artificially inflate tau measurements in certain brain regions). More notable still was the nature of the amyloid-tau-cognition relationship across groups: in NHW and Hispanic participants, amyloid positivity significantly amplified the relationship between tau and memory impairment—amyloid-positive individuals with high tau showed substantially lower cognitive scores. But in Black participants, this interaction between amyloid positivity and the tau-cognition relationship was attenuated and did not reach statistical significance (p = 0.067). Additionally, APOE4 significantly predicted higher MTL tau in NHW participants but showed no significant association with tau in Black or Hispanic participants. These findings suggest that in Black participants, factors other than amyloid and tau may be more dominant contributors to cognitive impairment—possibly cerebrovascular disease, greater burden of cardiometabolic risk factors like hypertension and diabetes, chronic stress exposure (which animal models show can promote tau hyperphosphorylation), or mixed brain pathologies. Prior neuropathological studies have shown that mixed pathology is more common in Black decedents with dementia. The amyloid cascade hypothesis, developed primarily from data in predominantly NHW populations, requires expansion to adequately account for the etiological diversity of Alzheimer’s dementia across different populations.

What Genetics Is Telling Us: Endolysosomal Dysfunction and Lipid Metabolism as Underlying Risk Factors

If amyloid does not fully account for Alzheimer’s dementia—particularly in late-onset, sporadic cases—where should we look for a more complete explanation? An important set of answers has been emerging from genome-wide association studies (GWAS), large-scale genetic analyses that identify common genetic variants associated with increased Alzheimer’s risk across tens of thousands of people. When researchers catalogued the genes most consistently implicated in late-onset AD risk, they found not a collection of genes involved primarily in amyloid production or clearance, but rather two distinct biological themes: lipid transport and metabolism, and endolysosomal trafficking—the cellular machinery responsible for sorting, recycling, and degrading molecular cargo inside cells.

The landscape of late-onset GWAS genes reads like a chapter on cellular waste management and membrane biology. APOE itself—encoding the brain’s primary lipid carrier—represents by far the strongest genetic signal. SORL1 regulates the trafficking of amyloid precursor protein through endolysosomal compartments. BIN1 facilitates membrane trafficking and endocytosis. PICALM coordinates clathrin-mediated endocytosis relevant to Aβ removal. TREM2 is a receptor expressed by microglia—the brain’s immune cells—that governs their capacity to phagocytose cellular debris, including Aβ and damaged lipid-laden membranes. ABCA7, a lipid transporter closely related to ABCA1, carries loss-of-function mutations that substantially increase AD risk, likely by impairing cellular lipid efflux. CLU (clusterin) participates in lipid metabolism and Aβ clearance. GRN (granulin) is required for lysosomal function and inflammatory regulation. CTSF is a lysosomal protease involved in intracellular protein degradation. Taken together, these genes point consistently toward a shared biological pathway: the endolysosomal system—the cell’s internal sorting and disposal apparatus—is disturbed in Alzheimer’s disease in ways that may operate in parallel to, or upstream of, amyloid accumulation. The enlargement of early endosomes is among the earliest cytopathological features of AD, observable years before plaques appear, and is exacerbated by APOE4. This pattern suggests a complementary framework: that failure of endolysosomal recycling (Figure below), particularly in the astrocytes and microglia responsible for lipid transport and waste clearance, represents a biologically distinct pathway to Alzheimer’s pathology—one that the amyloid hypothesis was not designed to capture. Here, we can conclude that amyloid contributes to the endolysosomal recycling failure but is one of many drivers, and vice versa, endolysosomal failure accelerates amyloid accumulation.

Figure from Scott and Petsko, Science Translational Medicine, 2020

APOE4: A Gene With Many Faces, Neuroinflammation Foremost Among Them

Of all the genetic factors in late-onset Alzheimer’s disease, none has a larger population-level impact than APOE4. Carrying one copy of the APOE4 allele roughly triples the lifetime risk of Alzheimer’s; carrying two copies increases risk more than tenfold. The initial explanation for this risk centered on amyloid: APOE4 impairs the brain’s ability to clear Aβ, contributing to earlier and more abundant plaque accumulation. That relationship is well-supported. But APOE4’s contribution to Alzheimer’s risk involves multiple interconnected biological mechanisms—organized around three distinct but overlapping “hits” on brain health.

The first hit is disrupted lipid handling. ApoE is the brain’s primary lipid transport protein, produced mainly by astrocytes and microglia to deliver cholesterol and other lipids essential for synaptic maintenance and membrane repair. The APOE4 isoform has an altered protein conformation that reduces its lipid-loading efficiency, particularly through a transporter called ABCA1. Research from our lab demonstrated that in APOE4 astrocytes, ABCA1 becomes abnormally retained in lysosomes rather than recycling to the cell surface, impairing the formation of small, lipidated HDL particles that are associated with protection against amyloid accumulation. This lysosomal sequestration is driven in part by co-aggregation of ApoE4 and ABCA1 proteins in an environment enriched with oxysterols (oxidized cholesterol metabolites), which are elevated in APOE4 brain tissue. The resulting cholesterol dyshomeostasis sets off a compensatory over-expression of ABCA1—which then activates mTORC1 in lysosomes, triggering cellular senescence in astrocytes and microglia. Senescent brain cells surrounding amyloid plaques have been observed in human AD brain tissue, staining positive for lipofuscin and GPNMB (classical senescence markers), suggesting that APOE4-driven lipid dysregulation accelerates cellular aging in the very cells whose function is to protect neurons.

The second hit is neurovascular inflammation. APOE4-expressing microglia are oriented toward a chronically activated, pro-inflammatory state. In the brain, APOE4 amplifies activation of the classical complement cascade—a molecular immune recognition system—which, when chronically overactivated, accelerates excessive synaptic pruning by microglia and promotes neurodegeneration. APOE4 also upregulates matrix metalloproteinase-9 (MMP9), an enzyme that degrades the tight junctions of the blood-brain barrier, allowing inflammatory molecules to enter the brain parenchyma and fibrinogen to accumulate near neurons. These neurovascular effects appear to operate at least partly independently of amyloid pathology and may help explain why Alzheimer’s dementia in APOE4 carriers has been more difficult to treat with amyloid-targeted therapies alone.

The third hit is neuronal dysfunction, including impaired insulin receptor trafficking (APOE4 sequesters insulin receptors in early endosomes), reduced apoE receptor signaling important for synaptic plasticity, and mitochondrial vulnerability. Together, these three hits illustrate why clearing amyloid from an APOE4 carrier’s brain may not be sufficient to reverse or halt dementia: the biological disruption involves lipid pathways, immune activation, and vascular integrity in ways that extend well beyond what the amyloid hypothesis alone was designed to address.

What We Still Don’t Know—and Where the Science Is Heading

Three decades after the amyloid hypothesis was formalized, the field of Alzheimer’s research is confronting a more complex biological reality than the original framework anticipated. Evidence now supports that amyloid is an important upstream contributor to Alzheimer’s pathology—at least in the populations and disease stages studied to date. But several major uncertainties limit our ability to translate this understanding into broadly effective therapies.

A central open question concerns treating people before symptoms develop. The trajectory of Alzheimer’s pathology is now understood to unfold over 15 to 20 years before cognitive symptoms appear, with amyloid accumulating silently in the brain throughout midlife and late life. This raises a logical but practically challenging question: would removing amyloid at this pre-symptomatic stage—before tau pathology spreads and neurons begin to die—produce substantially larger clinical benefits? The A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s) trial tested this directly, enrolling cognitively normal older adults with elevated amyloid on PET imaging and treating them with solanezumab for 4.5 years. The result was negative—no significant slowing of cognitive decline—though solanezumab was a relatively weak amyloid-clearing agent. Ongoing trials are now testing more potent antibodies, including lecanemab, in cognitively normal individuals with elevated amyloid (the AHEAD 3-45 and A45 trials). The scientific rationale is sound, but the practical challenges are formidable. Because the base rate of progression from amyloid positivity to dementia is low in any given multi-year window, extremely large trials over many years are required to detect a meaningful difference—and most participants who receive treatment (and its risks) may not have developed dementia within the trial period regardless. Identifying who carries silent amyloid accumulation at scale requires either amyloid PET imaging, which is expensive and not universally accessible, or emerging blood-based biomarkers for Aβ and phospho-tau that are still being validated for broad clinical use. The ARIA risks from potent anti-amyloid antibodies in a population that currently has no symptoms—and no guarantee they would develop dementia—raises difficult questions about acceptable risk-benefit balance. Prevention is the intellectually compelling endpoint for the amyloid hypothesis, but achieving it equitably and safely remains one of the field’s most pressing unresolved challenges.

Beyond prevention, significant uncertainty remains about which forms of Aβ and tau are most toxic, and through what precise molecular mechanisms. We do not yet adequately understand how amyloid pathology interacts with cerebrovascular disease, neuroinflammation, and metabolic disruption in the complex mix of causes that characterizes most late-onset dementia. We do not know why amyloid appears to drive tau pathology with different efficiency across racial and ethnic populations, or whether ancestral differences in APOE4 haplotype structure (documented across African and Latin American populations) modify the downstream consequences of amyloid accumulation. We do not yet know whether therapies targeting the endolysosomal system, APOE4 lipidation, neuroinflammation, or cholesterol metabolism will demonstrate clinical efficacy—though first-generation therapies directly targeting APOE4 biology, including APOE4 structure correctors that convert APOE4 toward a less pathogenic conformation and lipidation-enhancing agents designed to restore ABCA1-mediated cholesterol transport, are now in early clinical testing. And we face a persistent practical dilemma: the therapies currently approved for disease modification are expensive, require intravenous infusion, carry meaningful safety risks, and provide modest average benefit that may not be detectable in individual patients.

Take-Home Messages

• The amyloid cascade hypothesis has now been clinically validated. Anti-amyloid clinical trials demonstrated that clearing Aβ from the brain slows cognitive decline and simultaneously lowers downstream phospho-tau biomarkers—supporting the position of amyloid as an upstream driver in the disease cascade.

• The clinical benefits of current anti-amyloid therapies are real but modest. Lecanemab and donanemab slowed decline by approximately 0.5–0.7 points on an 18-point scale over 18–20 months—below the threshold many clinicians consider perceptible to patients and caregivers. Both groups continued to decline. This likely reflects that by the time patients enroll in trials, the disease has progressed beyond amyloid dependence.

• Average trial results do not tell the whole story: some individuals may respond meaningfully. Population averages can obscure the fact that a subset of patients may derive substantially greater benefit from anti-amyloid therapy—particularly those treated earliest, with lower tau burden. Identifying who is most likely to respond is an active and critical area of research. These approvals represent the first disease-modifying treatments in Alzheimer's history and reflect decades of hard-won scientific progress that should not be minimized.

• Amyloid may be necessary but not sufficient for dementia. In late-onset, sporadic Alzheimer’s—which represents over 99% of cases—amyloid accumulation interacts with vascular disease, mixed pathology, neuroinflammation, and other factors that the amyloid hypothesis alone does not fully account for.

• Alzheimer’s dementia is not the same disease in all populations. Black participants showed a distinct relationship between amyloid, tau, and cognition compared to non-Hispanic White participants, suggesting that other biological or sociostructural factors may be primary contributors to cognitive decline in this group. The vast majority of foundational Alzheimer’s research has been conducted in predominantly White cohorts.

• Late-onset GWAS genes tell a story that extends beyond amyloid. Risk variants in APOE, BIN1, SORL1, PICALM, TREM2, and ABCA7 collectively implicate endolysosomal dysfunction and lipid metabolism as major disease pathways—suggesting that cellular waste clearance and lipid transport are as central to AD risk as amyloid dynamics, and open the path for new drug targets.

• APOE4 drives Alzheimer’s risk through at least three parallel mechanisms: disrupted lipid handling and HDL formation, neurovascular inflammation and blood-brain barrier disruption, and direct neuronal dysfunction. Anti-amyloid therapies may be less effective in APOE4 carriers partly because they do not address these additional pathways.

• Neuroinflammation is a central and potentially modifiable driver of disease, particularly in APOE4 carriers. Chronically activated microglia, primed by lipid dysregulation, may propagate tau pathology and neurodegeneration independently of ongoing amyloid accumulation.

• Prevention is the most scientifically compelling application of the amyloid hypothesis, but also the most difficult to achieve. Treating cognitively normal individuals with elevated amyloid requires very large, long trials; effective and accessible screening tools; and a careful reassessment of acceptable risk-benefit balance in a population that currently has no symptoms.

• The next generation of Alzheimer’s therapies will likely need to be combinatorial—addressing amyloid and tau alongside lipid metabolism, endolysosomal function, neuroinflammation, and cerebrovascular health. The validation of the amyloid hypothesis is a scientific milestone, but the path to broadly effective dementia prevention will require a substantially broader biological framework.

A 63-year-old woman came to see me with questions about hormone replacement therapy (HRT) and brain health. She recently found out that she has two copies of APOE4.

She began using a transdermal estrogen patch with micronized progesterone at age 56, around the time she entered menopause. Like many women at that stage, she was experiencing hot flashes, night sweats, and disrupted sleep. Her gynecologist prescribed hormone therapy and her symptoms improved significantly.

She has now been on therapy for seven years without complications.

Recently, however, she began noticing changes in memory, occasionally forgetting names or pausing to remember why she walked into a room. Nothing dramatic, but enough to make her concerned.

She came to the clinic with three straightforward questions:

• Is hormone therapy safe for the brain?

• Can it prevent dementia?

• How long should I stay on it?

These questions are becoming increasingly common as more women remain on hormone therapy longer and awareness of Alzheimer’s disease grows.

But answering them leads to a careful discussion on benefit versus risk.

A conversation with Dr. Howard Hodis

Shortly after seeing this patient, I discussed the case with Dr. Howard Hodis, Director of the Atherosclerosis Research Unit at the University of Southern California and one of the leading investigators studying the cardiovascular biology of menopausal hormone therapy.

Dr. Hodis has spent decades studying how estrogen interacts with vascular aging, particularly how the timing of hormone therapy relative to menopause may determine whether it helps or harms the cardiovascular system.

One of the key points from our conversation was that hormone therapy is often discussed as if it were a single treatment with a single risk profile.

Biologically, it is not.

The effects of estrogen depend on several factors:

• when therapy begins

• the health of the vascular system

• the hormone formulation

• the biology of the individual patient

And when the discussion shifts from the cardiovascular system to the brain, the uncertainty increases even further.

Why Hormone Therapy Exists

Hormone therapy was originally developed to treat symptoms of menopause.

As ovarian estrogen production declines, many women develop:

• hot flashes

• night sweats

• sleep disruption

• mood changes and depression

• vaginal dryness

• accelerated bone loss

Among available treatments, estrogen therapy remains the most effective therapy for vasomotor symptoms.

Hormone therapy also plays an important role in bone health. After menopause, bone loss accelerates rapidly. Roughly one in two women will experience an osteoporotic fracture during their lifetime. Hip fractures in particular can be devastating—about one-third of women die within a year, and many never fully recover functional independence.

Randomized trials show estrogen therapy reduces fractures by 30–50% in postmenopausal women.

For symptom relief and bone protection, the benefits of hormone therapy are well established.

The controversy arises when hormone therapy is discussed as a preventive therapy for chronic diseases, particularly cardiovascular disease and dementia.

Who Should Not Take Hormone Therapy

Although hormone therapy is highly effective for menopausal symptoms, it is not appropriate for everyone.

Most clinical guidelines recommend avoiding systemic estrogen therapy in women with certain conditions where risks may outweigh benefits.

These include:

• Estrogen-dependent cancers, particularly breast cancer

• A history of venous thromboembolism (blood clots) such as deep vein thrombosis or pulmonary embolism

• Stroke or significant cardiovascular disease

• Active liver disease

• Unexplained vaginal bleeding

The concern in these situations is that estrogen can influence coagulation pathways, hormone-sensitive tissues, and vascular biology, potentially increasing the risk of recurrent disease.

For women with a history of breast cancer, systemic hormone therapy is generally avoided because of concerns that estrogen could stimulate hormone-sensitive tumor cells.

Similarly, women with a history of blood clots may have increased thrombotic risk with oral estrogen therapy, although some studies suggest that transdermal estrogen may carry lower clotting risk.

Importantly, these recommendations apply primarily to systemic hormone therapy. In some cases, local vaginal estrogen preparations may still be considered because systemic absorption is minimal.

As with many areas of menopause care, decisions often require individualized risk assessment and shared decision-making between patient and clinician.

The Cardiovascular Context

One key fact about women’s health is often overlooked:

Cardiovascular disease is the leading cause of death in women.

Before menopause, women experience significantly lower rates of coronary heart disease than men. After menopause, that protection declines.

This observation led researchers decades ago to propose the estrogen cardioprotective hypothesis.

Early observational studies suggested women using hormone therapy had 30–50% lower rates of coronary heart disease.

To test this hypothesis more rigorously, researchers launched one of the largest clinical trials ever conducted.

The Women’s Health Initiative

The Women’s Health Initiative (WHI) randomized more than 27,000 postmenopausal women to hormone therapy or placebo.

Initial results suggested increased risks of:

• stroke

• blood clots

• breast cancer (with combined therapy)

These findings dramatically changed clinical practice.

However, an important detail emerged later: most participants were older, with an average age of 63, and had begun therapy more than a decade after menopause.

This raised a critical question:

Does the timing of hormone therapy matter?

The Timing Hypothesis

The timing hypothesis proposes that estrogen’s effects depend on the stage of vascular—and possibly other organ—health when therapy begins.

Early after menopause, when arteries are relatively healthy, estrogen appears to support vascular function through:

• improved endothelial function

• reduced LDL oxidation

• improved vasodilation

• reduced inflammation

But once atherosclerosis is established, estrogen may behave differently.

Experimental work suggests estrogen can increase matrix metalloproteinases such as MMP-9, enzymes involved in plaque instability.

In other words, estrogen may help prevent early vascular disease, but may not help—and could theoretically worsen—advanced disease.

Evidence for Timing

The ELITE trial (Early vs Late Intervention Trial with Estradiol) directly tested this hypothesis.

Women were randomized to estradiol or placebo and stratified according to time since menopause.

Women who began estradiol within six years of menopause showed slower progression of carotid atherosclerosis.

Women who began therapy more than ten years after menopause showed no benefit.

Figure. Effect of estradiol therapy on progression of carotid intima–media thickness (CIMT) according to time since menopause (ELITE Trial).
Mean carotid intima–media thickness (CIMT) as a measure of atherosclerosis measured over six years in women randomized to oral estradiol or placebo, stratified by time since menopause. In women in early postmenopause (<6 years since menopause), estradiol significantly slowed the progression of CIMT compared with placebo. In women in late postmenopause (≥10 years since menopause), estradiol did not reduce CIMT progression compared with placebo. These findings support the timing hypothesis, suggesting that the vascular effects of estrogen depend on when therapy is initiated relative to menopause. Data adapted from the Early vs Late Intervention Trial with Estradiol (ELITE)

Cardiovascular Outcomes

Meta-analyses of randomized trials have examined clinical outcomes.

Among women who started hormone therapy:

• before age 60, or

• within 10 years of menopause

studies show approximately:

• 30–40% reduction in coronary heart disease events

• ~30% reduction in all-cause mortality

A Danish randomized trial similarly found reduced cardiovascular events in recently postmenopausal women receiving hormone therapy for up to 16 years.

Hormone Therapy and the Brain

While much research has focused on cardiovascular disease, patients are often most concerned about brain health.

Estrogen influences several biological processes relevant to cognition:

• synaptic plasticity

• mitochondrial function

• cerebral blood flow

• inflammation

• neuronal metabolism

Laboratory studies suggest estrogen may support neuronal resilience and synaptic function.

This biological rationale led many researchers to believe hormone therapy might help prevent Alzheimer’s disease.

However, clinical trials have not confirmed that expectation.

Hormone Therapy and Dementia Prevention

The most important trial examining this question was the Women’s Health Initiative Memory Study (WHIMS).

WHIMS enrolled more than 7,000 women aged 65 and older to test whether hormone therapy could prevent dementia.

The results were unexpected.

Women receiving combined estrogen-progestin therapy had approximately twice the risk of dementia compared with placebo when therapy was started after age 65.

Importantly, this finding does not take into account the role of timing.

Later studies suggest that hormone therapy begun earlier in life does not increase dementia risk, but it also has not convincingly reduced it.

At present, the conclusion is straightforward:

There is no strong randomized evidence that hormone therapy prevents dementia.

APOE4 and Brain Vulnerability

The picture becomes more complex when genetics are considered.

The APOE4 allele is the strongest common genetic risk factor for Alzheimer’s disease.

APOE4 carriers often show:

• earlier amyloid deposition

• greater vascular dysfunction

• increased blood–brain barrier fragility

Importantly, not all APOE4 carriers are the same.

A cognitively normal APOE4 carrier may still have significant neural reserve.

But once someone develops mild cognitive impairment or dementia, the brain becomes far less resilient.

Estrogen, MMP-9, and Neurovascular Biology

One pathway linking estrogen to both cardiovascular and neurological disease involves matrix metalloproteinase-9 (MMP-9).

MMP-9 regulates:

• extracellular matrix remodeling

• vascular stability

• blood–brain barrier permeability

Elevated MMP-9 activity has been associated with:

• plaque rupture in cardiovascular disease

• blood–brain barrier breakdown

• neuroinflammation

Estrogen signaling can influence MMP-9 activity, suggesting that estrogen’s effects may differ depending on the stage of vascular or neurodegenerative disease.

The Problem of Uncertainty

Despite decades of research, hormone therapy remains one of the most debated topics in medicine.

Several factors contribute to this uncertainty.

Different studies examine different populations. Many randomized trials studied women who began therapy long after menopause, while clinical practice typically begins therapy earlier.

Hormone formulations also differ. Earlier trials studied oral conjugated estrogens and synthetic progestins, whereas modern regimens often use transdermal estradiol and micronized progesterone.

Most hormone trials were designed to study cardiovascular disease and fractures, not dementia.

And despite the major role of APOE genetics in Alzheimer’s disease, very few studies have stratified hormone therapy outcomes by genotype.

Current evidence on hormone therapy and dementia has important gaps, particularly for APOE4 carriers. Most randomized trials were not designed to study genetic subgroups and rarely stratified participants by APOE genotype. In addition, many trials initiated hormone therapy years after menopause, limiting their ability to test the timing hypothesis in the brain.

As a result, we still lack trials that start hormone therapy near menopause, follow women long-term, and specifically evaluate cognitive outcomes in APOE4 carriers. Studies using modern hormone formulations and neuroimaging or biomarker endpoints are also limited. These gaps mean that the effects of hormone therapy on dementia risk, especially in genetically vulnerable populations, remain uncertain.

Taken together, these limitations mean that hormone therapy decisions still require clinical judgment rather than simple rules.

Returning to the Patient

After discussing the science, the question comes back to the woman who started this conversation.

Like many medical interventions, the value of hormone therapy depends on several factors:

• timing

• biology

• individual risk factors

• patient goals

For my patient, the answer is not straightforward.

Hormone therapy likely helped her menopausal symptoms, and, given that she started treatment near menopause and has tolerated it well, it may still be reasonable to continue.

But when it comes to protecting the brain from dementia, science has not yet provided a definitive answer.

New memory concerns should prompt a formal cognitive assessment and a thoughtful discussion about whether continuing hormone therapy remains appropriate.

Take-Home Messages

Hormone therapy remains the most effective treatment for menopausal symptoms.

• Timing matters. Starting hormone therapy near the menopausal transition appears biologically different from starting it decades later. Much of the risk seen in earlier trials occurred in women who initiated therapy long after menopause, highlighting the importance of timing.

• Cardiovascular effects depend on vascular health. Estrogen may support vascular function in relatively healthy arteries, but its effects may differ once atherosclerosis is established, potentially altering plaque biology.

• Hormone therapy is primarily a treatment for menopausal symptoms. Its strongest evidence supports relief of vasomotor symptoms and prevention of bone loss. Current evidence does not support using HRT as a general longevity or dementia-prevention therapy.

• Cognitive symptoms warrant reassessment. When mild cognitive impairment or dementia emerges, there is less brain resilience, which may alter the risk–benefit balance, and continued therapy should be reassessed with a clinician.

• Genetics may modify risk. Factors such as the APOE4 genotype, along with vascular health and baseline cognitive status, may influence how hormone therapy affects the brain, though this area remains incompletely studied.

• Ultimately, hormone therapy should not be viewed as either a miracle therapy or a dangerous drug.

Until the science becomes clearer, the most important step is not a universal rule, but careful conversations between patients and their physicians, weighing symptoms, risks, and individual goals.

What brought him in was a lab value that did not fit his lifestyle: LDL cholesterol 175 mg/dL. He had read conflicting messages, including claims that statins might worsen memory. He wanted to understand whether he should do something about his LDL, and how to think about that decision in the context of APOE4/4 and dementia risk.

So the question became:

If an APOE4/4 carrier has elevated LDL but no dementia, does lowering LDL with a statin meaningfully help brain health, and is there evidence that statins harm cognition?

This post is not medical advice. It is a way to read the evidence with the patient’s real-world decision in mind.

1) APOE4, high cholesterol, and ischemic heart disease: the “why” behind the lab

APOE is not just an “Alzheimer’s gene.” It is also a lipid transport gene. One practical consequence is that APOE4, especially APOE4/4, shifts lipid handling in ways that can raise LDL, even in people who eat well and exercise consistently.

Mechanistically, APOE sits on lipoprotein particles and helps them interact with hepatic receptors involved in clearance. In a randomized human study using a surface plasmon resonance approach plus hepatocyte uptake assays led by Anne Marie Mihihane and her team, APOE4 carriers showed altered lipoprotein–LDL receptor binding and downstream handling consistent with a propensity toward higher LDL under certain dietary fat conditions. This is one concrete example of how genotype can constrain physiology even when behavior is optimal.

The next step in the logic is vascular risk. Large population data support that APOE genotypes associate not only with dementia risk but also with ischemic vascular disease. For example, in UK Biobank (about 391,992 white British participants), APOE genotypes were associated with ischemic heart disease and relevant vascular risk factors, with effects that vary by genotype, age, and sex.

That matters for brain health because vascular injury, clinical stroke and “silent” small vessel disease, can lower cognitive reserve and amplify neurodegenerative trajectories. If someone is APOE4/4 and carrying a high LDL burden over time, it is reasonable to ask whether LDL lowering could reduce downstream vascular contributions to cognitive risk, even if it does not directly target Alzheimer pathology.

This is the first frame shift for the patient: his LDL cholesterol level may be partially genetic, and the brain relevance may be vascular as much as, or more than, direct Alzheimer prevention.

2) Genetic epidemiology signals: direction-of-effect, not proof

When randomized prevention trials are difficult, researchers often turn to genetic epidemiology to test whether a risk factor plausibly sits upstream of disease.

One example used ADNI data (N = 1,534 across cognitively normal, early MCI, late MCI, and AD) and performed a Mendelian randomization (MR) analysis using APOE as a genetic instrument to examine whether higher total cholesterol might contribute to risk along the clinical spectrum. They reported that higher total cholesterol was associated with higher odds of MCI and AD diagnoses in APOE4-positive versus APOE3 carriers in their MR framework.

How should we treat this?

• It is not a statin trial.

• MR is best read as a direction-of-effect argument: lipid biology is plausibly upstream of risk, particularly in APOE4.

• APOE is biologically pleiotropic, so MR assumptions can be strained. The takeaway is plausibility, not certainty.

Next comes the observational pharmaco-epidemiology signal (association, not proof): In the Chicago Health and Aging Project (CHAP; N = 4,807), statin initiation was associated with a lower hazard of incident clinical Alzheimer’s disease overall, and the association appeared stronger in APOE ε4 carriers (HR about 0.60 in ε4 carriers vs about 0.96 in non-carriers; interaction reported).

The figure above shows the covariate-adjusted cumulative incidence of AD Dementia, by statin initiation and the APOE e4 Allele

This type of result motivates clinicians and patients while also raising methodological caution, because healthy-user bias, confounding by indication, and time-varying treatment patterns are hard to fully eliminate.

So the honest interpretation is: there are credible signals suggesting subgroup benefit (notably in APOE4), but they are not definitive.

3) Why so many clinical trials are null, and why that may not settle prevention

If you only looked at randomized trials in people with established Alzheimer’s disease, you might walk away thinking the case is closed: statins do not help.

Two large symptomatic AD trials illustrate the point:

• LEADe randomized 640 patients with mild-to-moderate AD to atorvastatin 80 mg/day vs placebo for 72 weeks and found no significant benefit on cognition (ADAS-Cog) or global function (ADCS-CGIC).

• A separate randomized trial in 406 patients with mild-to-moderate AD using simvastatin vs placebo similarly reported no meaningful differences in cognitive or functional decline over 18 months.

These are important results, but they answer a treatment question (does this help after diagnosis) more than a prevention question (does decades of lower LDL reduce the probability of reaching symptomatic disease).

Why prevention is hard to prove in standard randomized clinical trials:

• Dementia unfolds over years to decades, so trials need long follow-up and large samples.

• People may cross over: they start and stop statins, and the cognitive risk benefit may change if the change diets, change blood pressure meds.

• Cognitive endpoints can be relatively insensitive over short windows, especially in healthy or mildly impaired individuals.

• If a therapy primarily reduces vascular events, the cognitive signal may be indirect and diluted, especially if neurodegeneration is already advanced.

So the null symptomatic trials are informative, but they do not fully answer what our patient cares about: risk modification earlier in life. One important finding from these trials is that even in patients with AD, statins do not worsen memory (more on that below). Newer trials for brain outcomes using statins should consider more brain biomarkers than cognition during the predementia phases, and especially those that reflect the effects of statins on the brain.

4) Debunking the idea that statins “worsen memory”

Patients commonly report cognitive symptoms while taking statins, but the key scientific question is whether statins cause clinically meaningful cognitive decline in controlled data.

A useful anchor here is that large randomized trials that included cognitive testing have generally not shown a consistent cognitive harm signal. For example, in PROSPER (5,804 participants aged 70 to 82 randomized to pravastatin vs placebo), detailed cognitive outcomes were assessed repeatedly and did not support a clinically meaningful adverse effect on cognition attributable to pravastatin.

A practical way to say this in clinic is: the best available evidence does not support the claim that statins generally worsen memory. If a specific patient experiences cognitive symptoms temporally associated with a medication, that should be evaluated carefully, but it should not be assumed to be the expected or typical effect.

5) Lipophilic and hydrophilic statins: why the distinction persists

Statins differ in chemical properties that influence distribution. Lipophilic statins are often discussed as having greater potential CNS penetration, while hydrophilic statins are generally more hepatoselective and do not enter the brain.

Does this translate into meaningfully different dementia outcomes? The evidence is not definitive, but large observational datasets have explored the question.

One widely cited example is a retrospective Medicare cohort of 694,672 beneficiaries that compared dementia risk across combinations of statins and antihypertensive classes. The authors reported that combinations involving pravastatin or rosuvastatin (hydrophilic statins) with renin-angiotensin system acting antihypertensives, particularly ARBs, were associated with lower dementia risk compared with some other combinations.

This is not causal proof, but it supports a reasonable scientific posture: drug class and combinations are plausible modifiers, and the question deserves prospective testing.

6) Uncertainties that remain, especially once Alzheimer’s disease is diagnosed

Two ideas should be kept separate:

• Risk modification: lowering LDL and reducing vascular events, which plausibly supports brain resilience.

• Disease modification: changing core Alzheimer’s pathology trajectories (amyloid, tau, neurodegeneration).

The large symptomatic AD trials above were largely null on cognition, which argues against presenting statins as established disease-modifying Alzheimer therapies once dementia is present.

For an APOE4/4 carrier without dementia, the strongest rationale remains vascular risk reduction. Whether LDL-lowering meaningfully changes dementia incidence is still uncertain, in part because it is difficult to run long, well-powered prevention trials for a peripheral target. The implication of this analysis makes us question APOE4 carriers with low LDL levels. Would they benefit from statin treatment if they had a lower cardiovascular risk profile?

Back to the case: risk-benefit framing

For this 65-year-old APOE4/4 man with LDL 175 mg/dL and no dementia, the most evidence-based framing is vascular.

• APOE4/4 is associated with higher ischemic heart disease risk in large population data.

• Elevated LDL is a modifiable vascular risk factor, and vascular events are relevant to brain health.

• The best controlled evidence does not support a general claim that statins worsen cognition.

So, should he take a statin?

What can be said responsibly, based on the evidence reviewed, is that an LDL of 175 mg/dL at age 65 commonly triggers a clinician-patient discussion about lipid-lowering for vascular risk reduction. APOE4/4 and family history make the prevention context more salient, but they do not turn statins into a proven dementia-prevention drug.

The decision belongs in a discussion with his clinician that incorporates his overall cardiovascular risk profile, family history, preferences, and tolerance, while keeping expectations calibrated: the clearest benefit is vascular, the long-term dementia prevention-related benefit is plausible but not proven.

Take-home messages

• APOE4/4 can raise LDL through lipid handling biology, even when lifestyle is excellent.

• APOE genotypes, including ε4ε4, are associated with ischemic heart disease risk in large population data.

• Genetic and observational studies provide plausible signals that lipid biology and statin exposure may matter more in APOE4, but they are not definitive prevention proof.

• Large symptomatic Alzheimer’s trials of statins have been largely null, which does not settle prevention questions.

• The best controlled evidence does not support the claim that statins generally worsen memory.

• Whether to start a statin should be decided in discussion with a clinician, weighing vascular risk, LDL level, patient values, and tolerance, without assuming statins are a proven dementia-prevention therapy.

• The benefit of statin initiation in those with low cardiovascular risk or low LDL levels for AD is uncertain.

Repeatedly, one enzyme emerged as central to that biology: calcium-dependent phospholipase A2 (cPLA2).

The remaining question was both anatomical and clinical:

Is cPLA2 activated at human synapses—the structures most closely linked to cognition—and is that activation associated with impairment?

Our recent study was designed to address that question directly. Dr. Qiulan Ma led this study at USC over the past 3 years.

What Is a Synaptosome?

Synapses are the specialized junctions where neurons communicate. Synaptic density and integrity are among the strongest pathological correlates of cognitive function in Alzheimer’s disease.

Because living human synapses cannot be directly studied, we isolate synaptosomes from postmortem brain tissue. Synaptosomes are subcellular particles enriched in intact presynaptic and postsynaptic components. They preserve synaptic membranes, receptors, scaffold proteins, and signaling enzymes.

Figure 1. Synaptosome markers and corresponding human synaptic ultrastructure.
Left: Simplified schematic of a human synaptosome illustrating preserved presynaptic and postsynaptic components. The presynaptic membrane (upper thick dark line) contains SVs (synaptic vesicles) and synaptic proteins including synapsin, as well as mitochondria that support neurotransmission. The synaptic cleft is the extracellular space between the pre- and postsynaptic membranes. The postsynaptic membrane (lower thick dark line) contains key excitatory synaptic markers including NMDARs (N-methyl-D-aspartate receptors), AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors), PSD-95 (postsynaptic density protein 95), and CaMKIIα (calcium/calmodulin-dependent protein kinase II alpha), which are central to synaptic signaling and plasticity.

Right: Representative transmission electron microscopy images of isolated human synapses from brains with low and high Alzheimer’s disease neuropathologic change (ADNC). Labeled structures include Mito (mitochondria), SVs (synaptic vesicles), PSD (postsynaptic density), presynaptic membrane, postsynaptic membrane, and the synaptic cleft. Scale bar = 0.5 μm.Although not complete neurons, they retain the biochemical machinery of synapses and allow direct measurement of synaptic protein levels and lipid mediators.

Using synaptosomes from participants in a longitudinal aging cohort with detailed cognitive assessments prior to death (Religous Order Study), we examined cPLA2 levels, downstream lipid signaling, and their relationship to cognition.

Selective Synaptic Vulnerability

Synaptosome yield was significantly reduced in individuals with mild cognitive impairment (MCI) and Alzheimer’s dementia compared with cognitively normal controls. In contrast, glial- and myelin-enriched fractions were not similarly reduced.

Fig. 2 Reduction of synaptosome yield in MCI and AD cases.

This finding supports selective synaptic vulnerability during disease progression and confirms that synaptic loss is detectable even at the MCI stage.

Elevated cPLA2 at Human Synapses

We measured two isoforms: cPLA2α and cPLA2β.

Both were elevated in synaptosomes from Alzheimer’s dementia cases. Notably, cPLA2β was already elevated in MCI.

Fig. 3 Elevation of cPLA2 in synaptosomes of AD.

This suggests that synaptic cPLA2 activation is not restricted to advanced disease and may emerge during earlier clinical phases.

Association With Cognitive Performance

Higher synaptosomal cPLA2β levels were associated with worse global cognition and episodic memory after adjusting for age, sex, and education. These associations were particularly strong in male participants.

Fig. 4 Correlation between synaptosomal cPLA2 levels and cognitive dysfunction. a. p-cPLA2a (all). b. p-cPLA2a (male participants). c. cPLA2b (all). d. cPLA2b (male participants). Residuals were calculated from linear regression models in which cognitive function was regressed on age at last visit, sex and education. For sex-based analyses, residuals were calculated from models regressing cognitive function on age at last visit and education. *P < 0.05, **P < 0.01. ****P < 0.0001. ROS Cohort.

These findings are correlational and do not establish causation. However, they demonstrate that synaptic cPLA2 levels closely align with clinical impairment in humans.

Biochemical Evidence of Pathway Activation

cPLA2 hydrolyzes membrane phospholipids to release arachidonic acid (AA), which is then converted into eicosanoids—prostaglandins that regulate inflammatory signaling.

In Alzheimer’s synaptosomes, we observed:

• Increased arachidonic acid

• Increased AA-derived eicosanoids

• Strong correlations between cPLA2 levels and AA metabolites

Other lipid pathways, including cholesterol metabolism, were not similarly altered. This supports the specificity of the cPLA2–arachidonic acid pathway.

Fig 5. Alterations of AA and AA metabolites but not cholesterol and oxysterols in AD synaptosomes. a, b. Heatmap generated from lipidomic analysis of PUFAs and PUFAs’ metabolites in synaptosomes comparing AD vs. NCI by Wilcox rank sum test. The color represents the Wilcox test estimate, where redness indicated the increased lipid species in AD, and vice versa. Overall, relative to NCI, AD showed high arachidonic acid (AA) and AA metabolites, including increased TXB2 and PGF2a, which were highly corelated with cPLA2a (c). AA, PGD2, PGE2, and adrenic acid were corelated with both cPLA2a (c) and cPLA2b (d). Cholesterol and oxysterols, including 7-dehydrocholesterol (7-HC), 25-hydroxycholesterol (25-HC), and 7a, 25-hydroxychlesterol (7a, 25-HC), were not changed (e). f. A diagram of cPLA2 activation involved AA metabolic pathway. c-d Graphs show Pearson correlation between two variables, as described on the axis, *P < 0.05, **P < 0.01, ****P < 0.0001. ROS cohort.

These findings indicate that synaptic cPLA2 is not only elevated but enzymatically active.

Excitotoxicity and Postsynaptic Localization

Excitotoxicity refers to neuronal injury resulting from sustained activation of excitatory glutamate receptors and excessive calcium influx. Elevated intracellular calcium activates downstream enzymes that destabilize synaptic structure.

cPLA2 is calcium-dependent.

In human iPSC-derived neurons, amyloid-β oligomers increased phosphorylation of cPLA2 and induced its redistribution to dendritic membranes. Activated cPLA2 colocalized with PSD-95 and CaMKIIα—proteins central to postsynaptic organization and synaptic plasticity.

Inhibition of cPLA2 suppressed amyloid-induced synaptic alterations in these models.

These observations support a mechanistic framework in which pathological calcium signaling activates cPLA2 at postsynaptic sites, leading to localized inflammatory lipid release and synaptic destabilization.

Interpretation and Uncertainty

Several limitations are essential to acknowledge:

Correlation does not establish causation.
Elevated synaptic cPLA2 may contribute to dysfunction, but it may also represent a downstream response to amyloid, tau, or other pathological processes.

Cross-sectional human data cannot determine temporal sequence.
We cannot establish whether synaptic cPLA2 activation precedes cognitive decline or follows it.

Experimental models simplify disease biology.
Cell-based systems allow mechanistic interrogation but do not replicate the full complexity of aging human brain networks.

Physiological roles of cPLA2 must be preserved.
cPLA2 participates in normal membrane remodeling and signaling. Excessive inhibition could disrupt essential processes.

These uncertainties require that translational claims remain cautious.

Why These Findings Support Testing a Disease-Modifying Hypothesis

A disease-modifying therapy alters the biological trajectory of a disease rather than temporarily improving symptoms.

The present study demonstrates that:

• cPLA2 activation occurs directly at human synapses

• Synaptic cPLA2 levels are associated with cognitive impairment

• The arachidonic acid inflammatory pathway is upregulated at those sites

• Amyloid-induced cPLA2 activation and synaptic alterations can be pharmacologically suppressed in human neurons

In our prior inhibitor study, selective brain-penetrant cPLA2 inhibition reduced amyloid-induced tau hyperphosphorylation and preserved synaptic markers in human neuronal systems. Those findings established that this pathway is modifiable and that its modulation affects downstream tau and synaptic biology.

Taken together, the data support a specific mechanistic proposition:

Pathological activation of cPLA2 may represent a convergence point linking lipid dysregulation, excitotoxic signaling, tau phosphorylation, and synaptic loss.

If correct, then selective modulation of cPLA2 activity—particularly during early clinical stages—could alter the rate of synaptic deterioration. That possibility meets the conceptual definition of a disease-modifying strategy.

This hypothesis has not yet been tested in clinical trials. It requires rigorous evaluation of safety, timing, and long-term impact.

However, the convergence of human synaptic data and pharmacologic modulation provides a biologically coherent framework for such testing.

Conclusion

This study establishes that cPLA2 activation occurs at human synapses in Alzheimer’s disease and is associated with cognitive impairment.

It connects earlier observations of lipid imbalance to a defined synaptic mechanism and links that mechanism to tau and excitatory signaling pathways known to drive neurodegeneration.

These findings do not establish therapeutic efficacy. They provide mechanistic support for evaluating whether selective, brain-penetrant modulation of cPLA2 can slow synaptic decline and modify disease progression.

The next step is careful translational testing.

Reference:

Ma, QL., Ebright, B., Li, B. et al. Evidence for cPLA2 activation in Alzheimer’s disease synaptic pathology. acta neuropathol commun (2026). https://doi.org/10.1186/s40478-025-02214-6

Funding:

This work was support by grants from by the National Institute on Aging. R01AG076124 (HNY, ZA), P30AG066530 to HNY; P30AG066530 subaward (QLM); R21AG089611(QLM) P30AG066530 to Neuropathology Core, R01AG070255 (AL), ROS is supported by P30AG10161, P30AG72975, and R01AG15819, and U01AG094622 to HNY and SL.

ROS resources can be requested at

https://www.radc.rush.edu

and www.synpase.org.

He was worried for understandable reasons. Both of his parents developed dementia in their 80s. He had also undergone neuropsychological testing because he noticed cognitive changes. The testing showed objective mild cognitive impairment (MCI). Genetic testing showed one copy of APOE ε4.

After that evaluation, he started a ketogenic protocol that was presented to him as a way to prevent dementia. He followed it consistently for a full year.

Over that year, he lost ~25 pounds, and his BMI is now ~19.

His question was straightforward:

“Given my genetics and MCI, is staying in ketosis helping my brain—or am I pushing my body into a state that could backfire?”

This is the central tension: ketosis is often discussed as a brain-fuel strategy, but in real life it frequently comes bundled with weight loss, and weight loss can be biologically meaningful in older adults—especially those already symptomatic.

What ketosis is actually trying to accomplish

The ketogenic argument for brain health rests on a plausible idea: the brain can use ketones, and in Alzheimer’s disease brain glucose metabolism is impaired. Raising ketones might provide alternative substrate support.

The clinical question is not whether ketones can be used. It is whether raising ketones translates into meaningful, durable benefit in the population in front of us—older, symptomatic, and APOE ε4-positive—and whether the cost of maintaining ketosis (often weight loss and physiologic stress) is acceptable.

A second constraint matters in APOE ε4 and later-stage disease: there is evidence and mechanistic concern that ketone delivery and/or utilization in the brain may be impaired due to blood–brain barrier changes, transporter limitations, and mitochondrial dysfunction.

What human intervention studies suggest (focusing on larger samples)

Ketone-raising interventions in Alzheimer’s dementia: inconsistent efficacy, genotype signal

A randomized trial in 152 patients with mild-to-moderate Alzheimer’s disease tested a ketone-raising compound (AC-1202). The cognitive signal was reported primarily in APOE ε4–negative participants, with less evidence of benefit in ε4 carriers despite ketone elevation.

The figure above shows the mean change from baseline in ADAS-Cog score (which measures the severity of memory, language, and thinking problems in people with dementia, with a higher score indicating worse performance) over 90 days in participants randomized to AC-1202 (red) or placebo (blue). Assessments were performed at baseline (Day 0), Day 45, and Day 90. Panel A: all genotypes combined. Panel B: APOE ε4 non-carriers (APOE4−). Panel C: APOE ε4 carriers (APOE4+). Values represent mean ± error bars (as reported in the original study). The y-axis is oriented so that movement upward (more negative change) reflects clinical improvement (lower ADAS-Cog score), and downward reflects worsening. Asterisks indicate statistically significant differences between groups at the specified time point (typically p < 0.05).

A later multi-site trial using a related formulation (AC-1204) in 413 patients did not show overall cognitive benefit, with practical issues such as attrition and formulation/bioavailability discussed as limiting factors.

A careful, clinically honest read of this literature is: ketone-raising strategies can produce symptomatic signals in some settings, but the evidence is not consistent enough to treat ketosis as a broadly effective therapy for established dementia—and APOE genotype likely influences response.

Ketone-based intervention in MCI: a more plausible window, still not definitive

In MCI, ketone interventions may have a more plausible biologic window. A 6-month randomized trial in 82 participants with MCI using a ketogenic medium-chain triglyceride intervention reported cognitive benefits alongside evidence of increased ketone availability.

This matters for the case because the patient has MCI, not dementia. But it does not settle the question of long-term outcomes, and it does not answer whether sustained nutritional ketosis is required (or safe) in an older, lean APOE ε4 carrier.

The part that changes the risk–benefit analysis in this case: catabolic vulnerability

This case is not “ketosis in the abstract.” It is ketosis plus substantial weight loss in a 70-year-old with MCI.

In older adults, significant weight loss can reflect or contribute to:

• lower physiologic reserve,

• loss of lean mass and strength,

• vulnerability to illness and stressors,

• and (in some cases) a prodromal neurodegenerative trajectory.

Several large human datasets link late-life weight loss with higher dementia risk, and APOE ε4 can modify those relationships. For example, a long-term cohort of 1,462 women reported that APOE ε4 carriers with greater late-life weight loss had higher dementia risk.

Interventional data add nuance. In Look AHEAD (5,145 adults with type 2 diabetes and overweight/obesity), subgroup analyses suggest that cognitive effects of intensive lifestyle weight loss are not uniform across groups, and have been interpreted in the literature as consistent with the idea that weight loss may deprive some APOE ε4 brains of a relevant energy buffer.

None of this proves that weight loss causes dementia. But it supports a practical clinical posture:

In an older APOE ε4 carrier who is already symptomatic, substantial weight loss—especially to low BMI—should not be assumed to be beneficial for brain health.

Mechanisms: why APOE ε4 may increase sensitivity to catabolism

The mechanistic concern is not “thin is bad.” It is that APOE ε4 may be associated with differences in metabolic handling and adipose biology that reduce buffering capacity during stress. One mechanism includes the blunted PPARγ-related responses and adipose remodeling differences in APOE ε4 contexts.

Add one more layer: if later-stage disease limits brain ketone uptake/oxidation (BBB/transport/mitochondria),

then a patient may incur the systemic costs of restriction and weight loss while receiving less of the intended energetic benefit.

That is the catabolic vulnerability problem in one sentence.

Chronic ketosis can be physiologically stressful (especially in lean older adults)

Ketosis is not inherently harmful, but chronic nutritional ketosis is an active physiologic state with predictable stress points:

• early diuresis (water/sodium shifts),

• electrolyte needs,

• and potential for muscle loss if protein and total energy intake are not adequate.

Early weight loss contributions include glycogen-linked water loss and ketone-associated natriuresis/diuresis, with clinical concerns such as dehydration and muscle loss risk with ketogenic dieting—along with mitigation strategies.

There is also evidence framed as a biphasic oxidative stress response (initial rise in oxidative stress markers with later adaptive signaling), consistent with a hormetic model.

Clinically, the relevance is straightforward: a physiologic stressor can be adaptive in one person (younger, metabolically impaired, high reserve) and costly in another (older, low BMI, already cognitively vulnerable).

Long-term feasibility and the LDL question in APOE ε4

Even if ketosis were metabolically helpful short term, long-term lifestyle ketosis raises two practical issues: adherence and cardiometabolic tradeoffs.

A 12-month randomized trial (n=118) comparing very-low-carbohydrate versus low-fat diets illustrates lipid tradeoffs over longer duration.

Across longer-duration comparisons, LDL-C can rise on very-low-carbohydrate ketogenic patterns in aggregate (with large meta-analytic datasets reporting LDL increases).

For APOE ε4 carriers, LDL is not a side detail. APOE ε4 is associated with higher LDL levels with diet-response considerations relevant to saturated fat intake and lipid handling.

So, even if a patient experiences some symptomatic benefit, a long-term pattern that worsens LDL may introduce competing vascular risk—highly relevant to brain aging.

Symptomatic benefit vs disease modification

This distinction should be explicit.

Most ketosis/ketone intervention studies are designed to test symptomatic outcomes (cognitive scales, function) over months.

A disease-modifying claim would require evidence that an intervention changes core pathobiology trajectories. At present, it is fair to say we do not have strong evidence that nutritional ketosis reduces phosphorylated tau or amyloid levels in humans or clearly modifies Alzheimer’s disease course over long horizons.

That does not rule out benefit. It simply sets the appropriate scientific boundary for “prevention” claims.

Who may benefit from ketosis—and who should be cautious?

This is where the discussion should land: matching the tool to the patient.

More plausible benefit profile

Ketosis (or other structured carbohydrate restriction) is most defensible when the primary target is a metabolic disorder:

• obesity,

• insulin resistance,

• type 2 diabetes,

• hypertriglyceridemia/metabolic syndrome.

In that setting, short-term metabolic improvements are consistently reported, while longer-term differences often attenuate and require careful attention to adherence and lipid response.

If a patient is younger, metabolically at risk, and not yet demented, the risk–benefit balance can be favorable—especially if weight loss is therapeutic rather than destabilizing.

Higher caution profile

For an older adult with established cognitive impairment and low BMI or ongoing weight loss, particularly with APOE ε4:

• the downside of catabolism is higher,

• the uncertainty around brain ketone utilization is greater,

• and long-term lipid tradeoffs matter more.

Take-home messages

• Ketosis can be helpful for some metabolically at-risk people—but it is not yet a proven disease-modifying tool for Alzheimer’s pathology.

• In older adults with MCI, low BMI should be treated as a clinical risk signal, and the cost-benefit from ketosis should be discussed with a clinician.

• APOE ε4 may shift the cost–benefit balance because of metabolic buffering differences and because ketone utilization in later-stage disease may be constrained.

• Chronic ketosis can be physiologically stressful (fluid/electrolyte shifts, potential muscle loss), which matters more in lean older adults.

• Long-term ketosis requires metabolic vigilance—especially monitoring muscle mass, metabolic stress signals and LDL cholesterol levels.

Over the past year, he has had increasing difficulty remembering recent events. He no longer drives. His family notices that conversations repeat. These changes didn’t happen suddenly, but they are now affecting his daily life.

He has had high blood pressure for many years, and over the past 10 years, he started taking blood pressure medication consistently. At today’s visit, his blood pressure was 110/70, well within standard treatment guidelines.

His brain MRI, however, showed something important: moderate to severe white matter hyperintensities.

In this post, I will help explain why the relationship between blood pressure and brain health is more nuanced than a single number.

What are white matter hyperintensities?

White matter is the brain’s communication system—the wiring that allows different regions of the brain to talk to each other.

On certain MRI scans, areas of injury in this wiring appear bright. These are called white matter hyperintensities.

White matter hyperintensities are so named because they appear as bright areas in the brain’s white matter on water-sensitive MRI sequences (such as T2-weighted and FLAIR images, in the image below), reflecting increased tissue water from chronic small-vessel injury.

In plain language, white matter hyperintensities are signs of long-standing injury to the brain’s small blood vessels. High blood pressure is one of the most common contributors. Over many years, elevated or unstable blood pressure can stiffen and damage tiny vessels, making it harder for the brain to regulate blood flow smoothly.

White matter hyperintensities don’t appear overnight. They usually build up slowly, often beginning in midlife. When they become extensive, they can be associated with:

• slower thinking and memory,

• difficulty with balance and walking,

• higher risk of stroke,

• and higher risk of dementia.

They represent the brain’s vascular history written into its structure.

Genetics adds vulnerability: APOE ε4

This patient also carries one copy of APOE ε4, the strongest known genetic risk factor for late-onset Alzheimer’s disease.

APOE ε4 does not mean someone is destined to develop dementia. Many carriers never do. What it does mean is that the brain is more vulnerable to injury, particularly injury related to blood vessels.

In people with APOE ε4:

• the same blood pressure exposure can lead to more white matter damage,

• cognitive effects may appear earlier,

• and vascular risk factors play a larger role in shaping long-term brain health.

This makes prevention—especially earlier in life—particularly important.

What the science tells us about blood pressure control and dementia

One of the most consistent findings in brain health research is this:

High blood pressure in midlife is strongly linked to dementia risk later in life.

This relationship is especially pronounced in people who carry APOE ε4.

Large long-term studies show that:

• elevated blood pressure in midlife predicts worse memory decades later,

• persistent hypertension over many years increases dementia risk,

• and much of the brain injury occurs silently, long before symptoms appear.

This is why blood pressure control in midlife is one of the most powerful tools we have for protecting long-term brain health, particularly for those with genetic vulnerability.

What did we learn from SPRINT MIND?

The Systolic Blood Pressure Intervention Trial (SPRINT) was a large, landmark study designed to answer a simple but important question: How low should blood pressure be treated to reduce cardiovascular risk? More than 9,000 adults with hypertension and elevated cardiovascular risk were randomly assigned to either standard blood pressure treatment (target systolic blood pressure <140 mm Hg) or more intensive treatment (target <120 mm Hg).

SPRINT showed that targeting lower systolic blood pressure significantly reduced rates of heart attack, heart failure, and cardiovascular death. These cardiovascular benefits prompted a fundamental shift in how clinicians think about blood pressure targets—and raised the natural next question: could the same approach also protect the brain?

The SPRINT MIND trial tested whether aiming for lower blood pressure could protect the brain.

Adults over age 50 with hypertension were assigned to either:

• standard blood pressure control, or

• more intensive control with lower targets.

The results were important—but nuanced:

• People in the intensive treatment group developed mild cognitive impairment less often.

• Brain imaging showed slower progression of white matter injury.

• The overall trend favored intensive treatment, although the study ended early and was not powered to definitively prove a reduction in dementia.

When researchers looked more closely, a clear pattern emerged:

• The cognitive benefit was strongest in participants under age 75.

• Benefits were less clear in the oldest participants.

• Benefits were more apparent in people without advanced cardiovascular or kidney disease.

SPRINT MIND supports a central idea:
lower and stable blood pressure earlier in adulthood helps protect the brain.

It was a prevention trial—not a treatment for established brain disease.

Importantly, we still have gaps: we know that high blood pressure in midlife damages the brain, that APOE ε4 carriers are especially vulnerable, and that earlier, steadier blood pressure control appears protective—but we still lack a clinical trial designed to directly test blood pressure targeting in midlife APOE ε4 carriers. A pragmatic study is needed to determine when, how tightly, and for whom blood pressure control can most effectively protect long-term brain health using surrogate targets based on advanced imaging techniques of brain vessels and blood flow, before the onset of clinical dementia.

Where APOE ε4 fits

SPRINT MIND did not test genetic risk directly. But its findings align closely with what we know about APOE ε4.

APOE ε4 carriers:

• accumulate vascular brain injury earlier,

• show cognitive effects of blood pressure at lower thresholds,

• and are more sensitive to long-term vascular stress.

Taken together, the evidence suggests that early, sustained, and stable blood pressure control may be especially protective for APOE ε4 carriers, before white matter injury becomes extensive.

Blood pressure is more than a number: stability matters

Blood pressure is not just about the average reading—it’s also about how much it fluctuates.

Dan Nation and his team have shown that large swings in blood pressure, known as blood pressure variability, place repeated stress on small blood vessels in the brain.

Higher variability has been associated with:

• greater white matter injury,

• faster cognitive decline,

• and stronger effects in people with APOE ε4.

For brain health, steady control may matter as much as how low the number goes.

Why the message changes later in life

High blood pressure remains a major risk factor for stroke, heart disease, and vascular dementia at any age. That does not change.

What does change with advanced age is how the brain responds to blood pressure lowering.

In very old adults—especially those with:

• cognitive symptoms,

• significant white matter injury,

• or long-standing vascular disease—

research suggests that lower blood pressure is not always more protective for the brain. In some cases, very low blood pressure in late life has been associated with worse cognitive outcomes.

There are several possible reasons:

• the aging brain may have a reduced ability to regulate its own blood flow,

• damaged small vessels may require higher pressure to maintain adequate perfusion,

• and falling blood pressure can sometimes be a sign of evolving brain or systemic illness rather than protection.

This does not mean very high blood pressure should be ignored or left untreated in older adults. Rather, it means that aggressive blood pressure lowering is not automatically better for everyone, especially when cognitive impairment or extensive brain injury is already present.

In later life, the goal often shifts from “pushing numbers lower” to finding a blood pressure range that:

• reduces stroke and cardiovascular risk,

• avoids dizziness or falls,

• minimizes large fluctuations,

• and supports adequate blood flow to an already vulnerable brain.

These decisions should be individualized and discussed with a clinician—not made by patients on their own.

Bringing it back to the patient

In my 85-year-old patient, the MRI findings likely reflect decades of vascular stress, influenced by genetics.

At this stage, the question isn’t whether blood pressure matters—it does.

The question is what blood pressure range best balances brain perfusion, stability, and vascular protection for him now. That question is very different at 85 than it would have been at 55.

The broader lesson is that while blood pressure targets may need to be reconsidered and individualized later in life, hypertension should be identified and treated much earlier, when the brain is more resilient and long-term damage is still preventable.

Take-home messages

1. Blood pressure control is an essential component of dementia prevention.

2. The strongest opportunity for dementia prevention is in midlife, especially for APOE ε4 carriers.

3. Earlier, steadier blood pressure control appears to protect the brain later.

4. In older age, aggressive blood pressure control is not always more protective, and goals may need to be individualized.

5. Age-specific blood pressure targets should be discussed with a clinician, balancing stroke prevention, stability, and brain perfusion.

6. Pragmatic trials in mid-life with surrogate biomarkers ( e. g., advanced brain imaging of blood vessels) can help us better define these blood pressure targets in high-risk groups.

When it comes to brain health, timing, stability, and personalization matter—not just the number on the cuff.

She has no memory complaints. She remains professionally active and fully independent. She found out using 23&me that she carries two copies of the APOE4 allele, a variant of the APOE gene associated with increased risk for Alzheimer’s disease. Her mother developed dementia in her mid sixties.

She has lived with the consequences of this disease.

When she reads that blood tests for Alzheimer’s disease are now available, she does not ask for a prescription or reassurance. She asks a more fundamental question:

“What do these new Alzheimer’s blood tests actually tell me?”

That question captures where the field stands today—between a genuine scientific advance and persistent uncertainty about prediction, interpretation, and ethics.

The central scientific advance: Alzheimer’s biology from blood

For decades, identifying amyloid plaques and tau pathology required amyloid PET imaging or cerebrospinal fluid (CSF) testing—procedures that are invasive, expensive, and unevenly accessible. Over the past several years, plasma biomarkers, particularly phosphorylated tau species such as p-tau217, have demonstrated strong biological validity across multiple independent cohorts.

Across studies comparing plasma p-tau217 with amyloid PET or CSF reference standards, discrimination is consistently high. These findings have been replicated across memory-clinic populations and research cohorts using different analytical platforms.

This represents a meaningful shift: Alzheimer’s disease biology can now be assessed through blood with high fidelity.

FDA clearance of a specific assay (for example, Lumipulse) matters because it indicates that at least one platform meets standards for analytical performance and biological correlation. But the deeper change is conceptual: Alzheimer’s disease biology has become scalable.

Alzheimer’s biology is not Alzheimer’s dementia

Blood biomarkers bring renewed attention to a distinction that has always existed.

• Alzheimer’s disease biology refers to amyloid plaques, tau pathology, and downstream neurodegenerative processes.

• Alzheimer’s dementia is a clinical syndrome defined by cognitive decline and functional impairment that interfere with daily life.

The two are related, but not interchangeable.

Autopsy and imaging studies consistently show that many older adults harbor amyloid pathology without dementia. Conversely, many individuals who develop dementia do so with mixed pathology, including vascular injury, Lewy body pathology, neuroinflammation, and synaptic loss.

Blood biomarkers such as p-tau217 are strongest as biological indicators. They are inherently less precise as predictors of clinical trajectories, because dementia is not driven by amyloid alone.

What p-tau217 does exceptionally well

When the question is whether Alzheimer’s-type pathology is present, plasma p-tau217 performs extremely well. Studies comparing p-tau217 with PET and CSF biomarkers consistently report with Area Under the ROC Curve (AUC) values above 0.90, often exceeding 0.95, for identifying amyloid positivity and tau pathology.

In this context, p-tau217 functions as a biological classifier.

This does not mean p-tau217 diagnoses dementia. It means it can often identify whether the molecular hallmarks of Alzheimer’s disease are present.

Why predicting dementia is more difficult

The woman in front of me is not only asking whether amyloid or tau biology is detectable. She is asking what it means for her future:

Will she develop dementia?
When might symptoms appear?
How likely is progression?

These are substantially harder questions.

Dementia is a complex clinical outcome shaped by:

• multiple pathologies beyond amyloid and tau

• cognitive reserve and resilience

• vascular and metabolic disease

• inflammation and other neurologic processes

• the time horizon being considered (five years versus fifteen)

Predicting dementia requires not only detecting pathology, but anticipating whether and when that pathology will become clinically expressed in a particular person.

Understanding AUC, PPV, and NPV

Biomarker studies frequently report AUC, positive predictive value (PPV), and negative predictive value (NPV). Each addresses a different aspect of performance.

AUC (Area Under the ROC Curve)

AUC is a measure of discrimination.

A practical interpretation is:

If you randomly select one person who will develop the outcome and one who will not, AUC is the probability that the test assigns a higher (“more abnormal”) value to the person who will develop the outcome.

• AUC = 0.50 indicates no discrimination, coin flip

• AUC ≈ 0.70–0.75 indicates modest discrimination with substantial overlap

• AUC ≥ 0.90 indicates strong discrimination with limited overlap

AUC describes group-level separation across all possible thresholds. It does not indicate how many individuals will be misclassified at a specific cutoff.

PPV and NPV

• PPV is the probability that a person with a positive test truly has—or will develop—the outcome.

• NPV is the probability that a person with a negative test truly does not have—or will not develop—the outcome.

Unlike AUC, PPV and NPV depend strongly on baseline risk in the population being tested.

p-tau217 and dementia prediction: what an AUC between 0.7-0.8 implies

When plasma biomarkers are evaluated for future cognitive outcomes rather than current pathology, performance is more modest.

In population-based cohorts and prevention studies—often composed largely of cognitively unimpaired individuals—models incorporating p-tau217 (typically alongside age and baseline cognition) commonly yield AUC values in the low 0.70 range for predicting incident mild cognitive impairment or dementia over several years. One example is a large prospective study of 2,766 cognitively unimpaired women aged ≥ 65 years at baseline, where plasma p-tau217 measured with an ALZpath Simoa assay, was associated with future MCI and dementia over up to 25 years of follow-up. When combined with age, p-tau217 provided discriminative accuracy for incident MCI/dementia with an AUC of ~72 % in White women and ~70 % in Black women, showing similar performance across these groups (AUC ≈0.72).

This indicates a real signal, but also substantial overlap between those who will and will not progress over the observed timeframe.

Translating statistics into people: two illustrative scenarios

AUC alone does not uniquely determine misclassification; that depends on the chosen operating threshold. The following scenarios use a plausible operating point for illustration.

Scenario 1: the asymptomatic 55-year-old

Imagine 1,000 cognitively normal 55-year-olds, followed for ten years. Approximately 2% (20 people) develop dementia.

Using a test with 70% sensitivity and 70% specificity:

• 14 are correctly flagged and later develop dementia

• 6 are missed

• 294 are falsely labeled “higher risk”

• 686 are correctly labeled “lower risk”

Among those with a positive test, PPV is approximately 4–5%. Most positive results are false alarms.

Scenario 2: Adults aged 70–80 with objective cognitive impairment

Now consider 1,000 adults aged 70–80 with measurable cognitive impairment. Over several years, ~30% (300 people) progress to dementia.

Using the same test:

• 210 are correctly flagged

• 90 are missed

• 210 are falsely flagged

• 490 are correctly labeled lower risk

Here, PPV is approximately 50%.

The biomarker did not change. Context did.

False positives carry very different ethical weight in asymptomatic individuals than in people already experiencing objective cognitive decline.

Color legend

• 🟥 True positives
  Individuals who test positive and go on to develop MCI or dementia during follow-up.

• 🟦 False positives
  Individuals who test positive but do not develop MCI or dementia during follow-up.

• 🟩 True negatives
  Individuals who test negative and do not develop MCI or dementia during follow-up.

• 🟨 False negatives
  Individuals who test negative but do go on to develop MCI or dementia during follow-up.

Familial hypercholesterolemia, APOE4, and limits of analogy

Cholesterol is often invoked as an analogy. The most appropriate comparison is familial hypercholesterolemia (FH).

FH is characterized by:

1. a well-defined biological abnormality, LDL-cholesterol > 190 mg/dL with a family history of premature heart disease

2. stable, standardized measurement

3. a strong and consistent link to clinical outcomes

4. interventions—such as statins—that clearly reduce morbidity and mortality

This alignment justifies measuring LDL cholesterol with an early diagnosis in people who feel well.

APOE4 homozygosity can feel similar emotionally. But important differences remain:

• APOE4 increases risk but does not determine individual destiny

• Amyloid positivity does not guarantee progression to dementia

• Dementia is frequently multifactorial

• Anti-amyloid therapies carry non-trivial risks, including brain swellings such as ARIA

• ARIA risk is higher in APOE4 carriers

• Preventive benefit in asymptomatic individuals has not been established

Unlike FH, Alzheimer’s pathology currently lacks a clearly effective, low-risk preventive intervention.

Biomarkers that became actionable: instructive contrasts

Some biomarkers transformed care because prediction and intervention aligned.

High-sensitivity troponin achieved very high discrimination for myocardial infarction, enabling rapid diagnostic pathways and immediate therapeutic decisions.

BRCA1/2 testing identifies individuals with markedly elevated lifetime cancer risk and offers actionable options such as enhanced surveillance or risk-reducing surgery, supported by outcome data.

In each case, strong discrimination was paired with interventions that changed outcomes and carried acceptable risk.

Looking ahead: when tests may become more actionable

Current limitations should not be viewed as permanent.

If future therapies demonstrate:

• clear efficacy in delaying or preventing cognitive decline

• favorable safety profiles suitable for long-term use

• predictable benefit across biological risk strata

then the meaning of a positive Alzheimer’s blood biomarker could change substantially.

Just as cholesterol testing became actionable after the development of statins—therapies that were both effective and safe for people who felt well—a similar shift could occur in Alzheimer’s disease prevention and treatment.

In parallel, combining biomarkers such as p-tau217, with promising biomarkers such as neurofilament light, and GFAP with age and longitudinal cognitive change may improve predictive accuracy toward AUC values in the 0.8 range or higher in defined populations. Higher discrimination would reduce false positives, but actionability would still depend on the availability of safe, effective interventions.

The ethical tension remains

Blood biomarkers sharpen a fundamental dilemma:

What does it mean to diagnose a biological condition that may never become a clinical syndrome?

Potential benefits include improved understanding, better research, and earlier identification of risk. Potential harms include anxiety, stigma, and pressure toward interventions with uncertain benefit or real risk.

The challenge is not whether these biomarkers are scientifically valuable—they are. The challenge is how to use biological information responsibly when prognosis is uncertain.

Take-home messages

• Blood-based biomarkers, particularly plasma p-tau217, represent a major advance in detecting Alzheimer’s disease biology.

• These biomarkers perform exceptionally well for identifying amyloid and tau pathology.

• Predicting future dementia is a harder problem; in general populations, AUC values around 0.7 imply substantial uncertainty.

• AUC describes group-level discrimination; PPV and NPV depend strongly on baseline risk.

• Context—age, cognition, and comorbid pathology—fundamentally alters interpretation.

• Familial hypercholesterolemia is a useful comparison, but APOE4-associated amyloid does not yet have a comparable low-risk preventive intervention.

• The actionability of these tests is likely to evolve alongside safer and more effective therapies.

Blood-based biomarkers provide an unprecedented window into Alzheimer’s disease biology. A clearer view of biology does not yet offer a clear forecast—but it accelerates the work needed to eventually change outcomes.

For decades, Americans were told to focus on nutrients: calories, fat percentages, carbohydrates, cholesterol. Meanwhile, rates of obesity, diabetes, and cognitive decline continued to rise. This wasn’t because people lacked discipline or information—it was because the food environment changed in ways our guidelines failed to confront.

The new food pyramid represents an important course correction. For the first time, food processing—not just nutrients—moves to the center of dietary advice. Whole, minimally processed foods form the foundation. Ultra-processed foods are no longer treated as neutral choices to be “managed,” but as products that should be actively displaced.

That shift matters for weight, for metabolism, and profoundly for the brain.

What Earlier Guidelines Missed

To be clear: earlier dietary guidelines didn’t create ultra-processed foods. Industry did.

Food manufacturers engineered products to be hyper-palatable, easy to overconsume, shelf-stable, and highly profitable—all reinforced by aggressive marketing. They accomplished this through refining, additives, emulsifiers, texture engineering, and flavor manipulation.

What earlier guidelines failed to do was name processing itself as a biological problem.

Ultra-processed foods were treated as ordinary foods that simply required moderation. But these products aren’t neutral. They’re designed to bypass normal appetite regulation.

For years, this was suspected. Then it was tested.

What Happens When You Isolate Processing Itself

In a landmark NIH-led randomized trial led by Kevin Hall, researchers asked a simple question: Does food processing itself cause people to eat more?

Participants lived in a metabolic ward and were fed two diets—one composed largely of ultra-processed foods, one composed of minimally processed whole foods. The diets were matched for calories offered, sugar, fat, fiber, and macronutrient composition. Participants could eat as much or as little as they wanted.

The results were striking.

On the ultra-processed diet, people ate about 500 extra calories per day, ate faster, and gained weight—without feeling satiated or more satisfied. On the whole-food diet, they spontaneously ate less and lost weight.

Nothing about willpower changed. Nothing about nutrients changed. Only processing changed.

This study provided causal evidence that ultra-processed foods promote overeating by disrupting satiety—something older dietary guidelines never adequately addressed.

Why Whole Foods Support Weight Control

Whole foods—whether animal-based or plant-based—retain their natural structure. They require chewing, digestion, and metabolic work. They slow eating, activate fullness hormones, and signal the brain before overeating occurs. This is why diets built around whole foods often lead to weight control without constant restraint.

This matters because midlife obesity, insulin resistance, and hypertension are among the strongest predictors of cognitive decline decades later. Weight regulation isn’t just about appearance or longevity—it’s upstream of brain health.

Red Meat Is Not the Same as Processed Red Meat

Much of the nutrition debate collapses when very different foods are lumped together.

Processed red meat—bacon, sausages, hot dogs, deli meats—is consistently associated with worse health outcomes. These foods are typically ultra-processed, high in sodium, nitrites, and additives, and easy to overconsume.

Whole, unprocessed red meat is a different food entirely. When consumed as part of a balanced, minimally processed diet, whole cuts of meat provide high-quality protein, iron, zinc, B vitamins, and choline—nutrients that support muscle mass, satiety, and metabolic health.

The issue isn’t meat. The issue is processing.

Protein-rich whole foods—animal or plant—help regulate appetite by signaling fullness early and durably.

It Doesn’t Have to Be Meat

None of this means meat is required for health.

Well-designed plant-based diets can be equally supportive—when they’re diverse, protein-adequate, and minimally processed. Traditional plant-forward dietary patterns associated with better metabolic and cognitive outcomes share common features: vegetables and fruits, legumes, nuts and seeds, whole grains, and healthy fats.

What matters is diversity and structure, not dietary identity.

A plant-based diet built on lentils, beans, vegetables, nuts, seeds, and whole grains behaves very differently from one dominated by refined flours, sugary beverages, and packaged substitutes. The brain responds to food quality—not labels.

Why Brain Health Depends on Starting Early

Here’s where the science becomes both clearer and more urgent.

Brain changes associated with dementia begin decades before symptoms appear. Long before memory loss, subtle shifts occur in brain energy metabolism, vascular function, and inflammation. Diet influences all of these systems, but the timing of that influence matters.

Nutrition plays a role at every stage of life. Even in people living with cognitive impairment or dementia, good nutrition supports overall health, reduces frailty, preserves muscle mass, and improves quality of life.

But its preventive power is strongest earlier, when the brain is still metabolically flexible, and damage isn’t yet entrenched. In later stages of disease, nutrition becomes more supportive than transformative. In midlife—or earlier—it may meaningfully shape the trajectory of brain aging.

APOE ε4 and the Case for Personalized Nutrition

This timing issue is especially important for individuals who carry the APOE ε4 gene copy, the strongest genetic risk factor for late-onset Alzheimer’s disease.

APOE ε4 affects the brain in ways that make it more vulnerable to metabolic stress: less efficient lipid transport and repair, greater susceptibility to insulin resistance, increased inflammation, and earlier disruption of the blood–brain barrier. These changes develop gradually, often beginning in midlife—long before any symptoms appear.

For APOE ε4 carriers, this has two important implications.

First, diet quality may matter more, earlier. Diets dominated by ultra-processed foods, refined carbohydrates, and excess energy appear especially mismatched to the biology of the APOE ε4 brain.

Second, by the time cognitive symptoms emerge, the brain’s ability to respond to nutritional interventions may already be constrained. Changes in nutrient transport, mitochondrial efficiency, and vascular integrity limit how much benefit late interventions can provide. The figure below illustrates why interventions during the cognitively unimpaired stage are likely to be more effective than when dementia is diagnosed.

This helps explain why nutrition trials often show limited effects in older APOE ε4 carriers—and why this shouldn’t be interpreted as evidence that nutrition doesn’t matter for them. Rather, it underscores the importance of starting earlier.

Where Supplements and Personalization Fit

This perspective also clarifies the role of supplements.

Supplements aren’t a substitute for food quality. When used broadly, without regard to diet or individual biology, they rarely prevent cognitive decline.

At the same time, supplements aren’t irrelevant. There are situations where targeted supplementation may be appropriate—such as in individuals with documented deficiencies, restricted diets, impaired absorption, or age-related metabolic changes. In these contexts, supplements can help fill gaps, particularly when layered on top of a high-quality dietary pattern.

This is where personalized nutrition becomes important.

Personalized medicine doesn’t mean chasing pills or extreme diets. It means recognizing that risk isn’t evenly distributed, and that some individuals—such as APOE ε4 carriers—may benefit from earlier, more intentional attention to metabolic and dietary health.

Food quality does the heavy lifting. Personalization helps fine-tune the approach.

Why the New Food Pyramid Is a Step Forward

The new food pyramid reflects these biological realities.

It doesn’t prescribe a single ideology. It allows for animal-based diets, plant-based diets, and everything in between. What matters is food quality.

By prioritizing whole, minimally processed foods, the pyramid aligns guidelines with how appetite, metabolism, and brain health actually work over time. Weight regulation becomes a byproduct of satiety. Brain protection becomes a downstream effect of metabolic health.

The pyramid isn’t a solution by itself. But it finally names the central problem: a food environment dominated by ultra-processed products is incompatible with long-term metabolic and brain health.

The Takeaway

Brain health is built slowly, quietly, and early.

It’s shaped not by a single superfood, supplement, or diet trend, but by daily patterns repeated over years. Diets dominated by ultra-processed foods make it harder for the body to regulate appetite, harder to maintain metabolic health, and harder for the brain to meet its energy demands with age.

The solution doesn’t require perfection or ideology.

For most people, there is no need to eliminate entire food groups. No need for supplements to compensate for a broken food environment.

You need food that still looks like food—and you need to start early.

Whether your diet includes animal foods, is mostly plant-based, or falls somewhere in between, the principle is the same: prioritize whole, minimally processed foods chosen for diversity, nourishment, and satiety. Over time, the body regulates itself more easily, and the brain is better protected. And for APOE ε4 carriers, this is more urgent and personalized. Nutrition trials are evolving, and we are on the right track.

Around 2015, I was trying to understand why omega-3 fatty acids—especially DHA—were not delivering the benefits we expected in Alzheimer’s disease. The rationale seemed sound. DHA is a major component of the brain, supports synaptic function, and gives rise to lipid mediators that help resolve inflammation. Observational studies consistently linked higher omega-3 levels to lower dementia risk.

Yet clinical trials were largely disappointing.

When we looked more closely, the lack of benefit was not evenly distributed. People who carried the APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer’s disease, appeared to benefit the least. Their blood DHA levels increased with supplementation, but markers of brain delivery rose much less—especially in those with amyloid pathology.

At first, we assumed the explanation would be simple: impaired transport into the brain, or perhaps insufficient dose. But even higher doses failed to normalize the response in APOE4 carriers. That was the first sign that this was not just a nutrition problem.

From levels to dynamics

To move forward, we had to rethink the question. Instead of asking how much DHA was present, we began asking how the brain handles lipids over time.

Imaging and tracer studies suggested something unexpected: cognitively normal APOE4 carriers sometimes showed higher rates of DHA uptake into certain brain regions. Over time, we came to see this not as a sign of sufficiency, but of compensation—the brain pulling in DHA to replace what it was losing or breaking down more rapidly.

This interpretation fit with metabolic studies showing faster DHA turnover in APOE4. It shifted our thinking away from deficiency and toward altered lipid handling inside brain cells.

Why balance mattered more than abundance

As we expanded our analyses, another pattern became hard to ignore. Across blood, cerebrospinal fluid, and eventually brain tissue, APOE4 carriers tended to have lower omega-3–to–omega-6 ratios, particularly DHA relative to arachidonic acid.

That balance matters. Omega-3 and omega-6 fats feed into competing signaling systems. Omega-3–derived mediators generally help resolve inflammation. Arachidonic acid, an omega-6 fat, is the precursor for many inflammatory molecules.

What stood out was that increasing DHA intake did not reliably correct this imbalance in APOE4 carriers. Even when omega-3 levels rose, inflammatory lipid signaling often remained elevated.

This raised a more uncomfortable possibility: APOE4 may actively bias the brain toward inflammation, rather than simply limiting access to protective fats.

Seeing the problem directly in human brains

For years, much of this work relied on indirect measures. A turning point came when we examined human post-mortem brain tissue.

In a study led by Brandon Ebright and colleagues, we analyzed inflammatory and pro-resolving lipid mediators in brains from people with and without Alzheimer’s dementia, stratified by APOE genotype. The findings were sobering.

Alzheimer’s brains showed:

• lower omega-3–to–omega-6 ratios

• markedly reduced levels of neuroprotectin D1, a DHA-derived molecule linked to neuronal survival

• elevated levels of arachidonic-acid–derived inflammatory lipids

What mattered most was how APOE4 modified this picture. In APOE4 carriers with dementia, both inflammatory and pro-resolving mediators were elevated. This pattern is consistent with chronic unresolved inflammation—the system is trying to restore balance, but not succeeding.

Importantly, these lipid signatures correlated with cognitive performance and pathological burden, especially in APOE4 carriers. At that point, lipid dysregulation no longer looked like a bystander. It looked intertwined with the disease process itself.

Why one enzyme kept reappearing

Once we had human brain data, the question narrowed: what controls the release of these lipids?

Again and again, the same enzyme emerged: calcium-dependent phospholipase A2 (cPLA2). When activated, cPLA2 releases arachidonic acid from cell membranes, feeding inflammatory signaling pathways.

Earlier work in our lab, led in large part by Shaowei Wang, showed that APOE4 is associated with persistent activation of cPLA2 in astrocytes, animal models, and human brain tissue. The lipidomics data reinforced this finding.

What became clear was that the problem was not constant triggering, but a failure to turn activation off.

Why this was not an obvious therapeutic path

Even with strong evidence, we were cautious.

cPLA2 is essential for normal brain function. Completely inhibiting it would almost certainly cause harm. And historically, efforts to target cPLA2 failed because available compounds were not selective, did not cross the blood–brain barrier, or worked only in artificial assays.

For a long time, it was not clear that this pathway could be modulated safely in the brain.

The study that tested whether this was even possible

The recent paper grew out of that uncertainty.

Anastasiia Sadybekov and Marlon Vincent Duro led an effort that began not with existing inhibitors, but with chemical space itself. Using large-scale computational screening, they evaluated billions of potential molecules, prioritizing those predicted to be selective, brain-penetrant, and active under biologically relevant conditions. Anastasiia, under the supervision of Seva Katritch, designed the compounds, and Marlon tested them in the lab. Once we identified the top hits, Stan Louie’s team helped formulate them for administration in animal models.

The figure above shows a first-generation cPLA2 inhibitor that successfully reduced cPLA2 activity in the lab. After multiple rounds of refinement and testing over 3 years, the team identified a compound that reduced pathological cPLA2 activation in brain-relevant cells exposed to Alzheimer’s-related stressors. In mice, the compound reached the brain and shifted lipid signaling away from excessive inflammatory pathways.

These experiments were intentionally narrow. They were designed to answer a single question:

Can pathological cPLA2 activity be modulated in a living brain?

They do not show disease prevention, cognitive benefit, or long-term safety.

What this does—and does not—mean

It would be easy to overinterpret these findings. We try not to.

Alzheimer’s disease is complex. Lipid dysregulation is one part of a much larger system involving protein aggregation, vascular health, metabolism, and aging. Modulating cPLA2 may help in some contexts and not others. Timing, genetics, and duration all matter, and many of those questions remain unanswered.

What this work provides is something more modest, but essential: a way to directly test a mechanism that years of human and experimental data have pointed toward.

Where we go next

Building on nearly a decade of work, our team has now secured NIH support to translate these discoveries into a brain-penetrant, selective inhibitor of cPLA2, with the goal of testing whether targeting inflammation can alter Alzheimer’s risk—particularly in APOE4 carriers. This next phase focuses not on promises, but on carefully determining whether modulating this pathway is safe, feasible, and ultimately meaningful for human disease.

Science moves forward this way more often than not: incrementally, collaboratively, and with humility about what we still don’t know.

For now, that is where we are.

Sadybekov, A.V., Duro, M.V., Wang, S. et al. Development of potent, selective cPLA₂ inhibitors for targeting neuroinflammation in Alzheimer’s disease and other neurodegenerative disorders. npj Drug Discov. 3, 2 (2026). https://doi.org/10.1038/s44386-025-00035-0

Acknowledgment and disclosures: This work is the result of a close collaboration between the Katritch Lab, the Louie Lab, and the Yassine Lab, and was supported by the National Institute on Aging under grant U01AG094622. I am deeply grateful to all of the authors whose tireless work made this research possible: Anastasiia V. Sadybekov, Marlon Vincent Duro, Shaowei Wang, Brandon Ebright, Dante Dikeman, Cristelle Hugo, Bilal Ersen Kerman, Qiu-Lan Ma, Antonina L. Nazarova, Arman A. Sadybekov, and Isaac Asante. I also want to acknowledge PebRx, a company developing cPLA2 inhibitors, which I founded to help translate this research beyond the laboratory.

I start this post with a well-characterized study population, because it provides informative data on how APOE ε4 affects cognitive functions.

The Religious Orders Study (ROS) is a long-running collaboration between Rush University and partner U.S. medical centers, under the leadership of David Bennet. It follows older religious clergy—nuns, priests, and brothers—who agree to two things that rarely come together at scale: annual medical and cognitive evaluations during life, and brain donation after death. That design lets researchers do something powerful: connect a person’s performance on cognitive testing over many years with what was actually happening in the brain.

When you have repeated cognitive testing over a long window—often 10 to 20 years—you can see that cognitive change doesn’t always look like one smooth, steady slide. In these data, it often looks like two different “speeds,” with a bend between them.

Dementia is cognitive impairment that is severe enough to interfere with everyday independence, meaning it causes disability in daily activities. It is different from mild cognitive impairment (MCI), where changes are measurable but a person can still function independently.

In the above spaghetti plots (credit to Xinhui Wang for the graphs), each thin line represents one person’s performance on cognitive testing tracked repeatedly over time, aligned by years before death. The most important thing to notice isn’t the year-to-year wiggle—scores naturally bounce with attention, sleep, mood, illness, and measurement noise—but the overall shape of the trajectory. Across both panels, dementia status dominates the picture: the no-dementia trajectories (teal) tend to cluster higher and often look relatively steady or only gently declining across the long stretch (about 10–20 years), whereas the dementia trajectories (red) more often show a stronger downward tilt and a visible acceleration closer to death. That acceleration is where the “terminal decline” window shows up visually: in the final ~3 years, many dementia trajectories bend into a steeper drop, while most no-dementia trajectories do not.

Preterminal decline is the long stretch—think the 10–20 years leading up to the final few years of life—when performance on cognitive testing may be stable for some people and gradually drifting downward for others. The key idea is that changes in this period are often slow enough to be subtle from one year to the next, even if they add up over time.

Terminal decline refers to a later window—roughly the last ~3 years of life in this dataset—when the average trajectory becomes noticeably steeper. Not everyone shows this in the same way, but when the pattern is present, it looks like a shift from a gentle slope to a sharper drop.

The bend (sometimes called a “change point”) is simply the transition between those two phases: the point where the preterminal slope accelerates into the terminal slope. It’s not a single dramatic day; it’s the place on the trajectory where the overall rate of change increases.

APOE ε4 doesn’t change cognition in just one way in this study. It shifts three parts of the “two-speed” pattern we’ve been talking about:

1) The long, slow stretch before the final years (preterminal decline).
Compared with non-carriers, people with APOE ε4 show a slightly faster slow decline during the long stretch leading up to the end. Think of it as a gentle downhill that’s a bit steeper.

2) The point where the line “bends” into a faster drop (the change point).
For non-carriers, the faster phase typically begins about 3.2 years before death. For APOE ε4 carriers, that bend happens earlier by about 9 months. In plain terms: the period of faster decline starts sooner.

3) The final fast-drop period (terminal decline).
Once the faster phase begins, APOE ε4 carriers also tend to decline more quickly than non-carriers in those last years. So the steep part of the slope is steeper.

One important nuance we learned from this ROS study: when researchers account for how much Alzheimer’s-related brain change (plaques and tangles) is present, most of these APOE ε4 differences get much smaller or disappear. That pattern strongly suggests the gene is linked to a worse trajectory mainly because it’s linked to more Alzheimer’s pathology, rather than acting independently on cognition.

ROS is powerful precisely because it isn’t a slice of the general population. In the ROS subset here (sample size = 411), participants lived to very advanced ages: the average age at death was 88.4 years (with a typical spread of about ±6 years). Importantly, longevity was similar in both genetic groups—APOE ε4 carriers died at about 88.0 on average, and non-carriers at 88.5. Education was also high in both groups (about 16–17 years on average). That combination—very old age plus high education—matters because it tends to be associated with what researchers sometimes call “reserve”: people can maintain day-to-day function longer even if brain changes are building underneath.

In ROS, you still see a clear difference in clinical outcomes by APOE status: 55.6% of ε4 carriers had Alzheimer’s dementia at death versus 32.0% of non-carriers. Put simply, in this ROS sample, about 56 out of 100 carriers ended life with Alzheimer’s dementia compared with about 32 out of 100 non-carriers. That’s a big gap—but it can still make genetic risk look smaller than it does in more diverse, population-based cohorts. That corresponds to roughly a 1.7-fold higher likelihood of dementia in ε4 carriers versus non-carriers.

Now contrast that with the UK Biobank, which is far closer to “big population data.” In that study, researchers tracked dementia risk over time and reported it as a hazard ratio, which you can think of as “how much more likely someone is to be diagnosed during follow-up.” Compared with people who had no ε4 alleles, those with one ε4 allele had about a 2.74× higher dementia risk. Those with two ε4 alleles had about an 8.66× higher risk. In everyday terms: one ε4 roughly tripled risk, and two ε4 copies increased risk by almost nine-fold in that population sample. UK Biobank also showed something that helps explain why ROS might look different: education changed how strongly APOE ε4 translated into dementia. Among people with one ε4, the risk estimate was lower in the high-education group (2.32×) than in the low-education group (3.61×). Among people with two ε4 copies, it was 6.63× in high education versus 12.15× in low education. That pattern fits the idea that education—and the life experiences that often come with it—can delay or reduce the chance that underlying brain changes become disabling dementia.

So what do we learn from ROS for prevention? Not that everyone needs to live like clergy, but that the “distance” between brain pathology and daily-life disability can be widened. ROS participants tend to have unusually consistent routines, stable social structure, and reliable access to care—conditions that likely support sleep, stress regulation, and management of vascular risks. Combined with high education, those factors may help people function well longer, even when Alzheimer’s pathology is present.

These features make ROS a kind of natural experiment in dementia resilience. The participants are not immune to Alzheimer’s disease—autopsies show plaques and tangles are common—but their lifestyles illustrate how much can be done to buffer risk, even in people with genetic susceptibility like APOE ε4. Lessons from ROS point toward prevention strategies that anyone can apply: maintain vascular health through regular exercise and blood pressure control, healthy dietary patterns, stay socially and mentally active, engage in lifelong learning, and cultivate consistent routines that reduce stress and support restorative sleep. The ROS experience reminds us that genes load the gun, but environment and habits often decide when—or whether—the trigger is pulled.

My perspective on this topic comes from more than a decade of work in our lab studying DHA, brain aging, and Alzheimer’s disease, with a particular focus on APOE4 carriers, who are at higher risk for dementia and appear to handle lipids differently across the lifespan. Over this time, the field has evolved from epidemiologic observations to mechanistic discoveries and large clinical trials. Some of the enthusiasm around omega-3s—including phospholipid forms highlighted in krill oil—is grounded in real biology. At the same time, parts of the narrative have moved faster than the clinical evidence. In this post, I want to take a measured look at what recent scientific studies support, especially for APOE4 carriers, and where important caveats remain.

Much of the phospholipid DHA story traces back to fundamental discoveries about how DHA enters the brain. The identification of the transporter MFSD2A showed that early in life, DHA that crosses the blood–brain barrier in the form of lysophosphatidylcholine (LPC-DHA) is essential for brain development. These findings were later extended—speculatively—to aging and Alzheimer’s disease, particularly in APOE4 carriers, who may have altered blood–brain barrier integrity and lower omega-3 brain transport. A second assumption reinforced this extension: epidemiologic studies often suggest that fatty fish consumption is associated with better cognitive outcomes than omega-3 supplements. But fatty fish intake is also a marker of broader dietary patterns and lifestyle factors, and fish contain many bioactive components beyond DHA in phospholipid form. These observations do not isolate phospholipid DHA as the causal factor, nor do they show that supplementing a single molecular form reproduces the benefits of a healthy diet.

When we look closely at what happens to DHA after ingestion, the picture becomes more nuanced. Regardless of whether DHA is consumed as triglyceride, ethyl ester, or phospholipid, it is digested, absorbed, and extensively repackaged before entering circulation. DHA continuously cycles among triglyceride, phospholipid, and cholesteryl ester pools through lipoprotein metabolism and tissue exchange. We have shown that ingesting triglyceride DHA increases phospholipid DHA in plasma and cerebrospinal fluid (Figure 1), consistent with equilibration across different lipid pools, arguing against a preference for one particular form of DHA. In the figure, CE stands for cholesterol ester, PC stands for phosphatidyl choline, which are lipid components of lipoprotein particles. The numbers refer to specific fatty acids; in this case containing DHA. By the way, krill oil is made of DHA and EPA bound to phosphatidyl choline.

Some initial studies suggested that phospholipid DHA formulations are more effective in reaching the brain. But a recent replication study by the Bazinet group in mice found that changing DHA formulation—including phospholipid and LPC forms—did not increase total brain DHA compared with other forms, despite clear systemic absorption. Together, these findings challenge the idea that consuming phospholipid DHA uniquely determines how much DHA ultimately reaches the brain.

The most important question, however, is whether these biological changes translate into clinical benefit, particularly for APOE4 carriers. Across randomized trials, omega-3 supplementation has produced mostly null cognitive results, including in older adults and Alzheimer’s disease. This does not mean omega-3s are irrelevant—especially for APOE4 carriers, who may be more sensitive to lipid imbalance and chronic inflammation. Evidence increasingly suggests that omega-3s may be most helpful when they are part of a broader, healthy dietary context.

APOE4 carriers consuming Western dietary patterns—high in saturated fat and low in fiber—are more likely to develop gut dysbiosis and systemic inflammation that may blunt the effects of supplementation. In contrast, fiber-rich, plant-forward diets that support a healthy gut microbiome and lower inflammatory tone may create the conditions under which omega-3s, including DHA, can exert meaningful biological effects. From this perspective, the expanding supplement aisle reflects genuine scientific interest—but the science itself points toward a more holistic conclusion: for APOE4 carriers, more omega-3s may be beneficial, but only when layered onto an overall healthy diet and lifestyle, not as a substitute for one. Converging kinetic, imaging, and epidemiologic evidence suggests that APOE4 carriers are uniquely vulnerable to dietary omega-3 deficiency and are most likely to benefit from sustained, long-term intake of DHA as part of an omega-3–rich dietary pattern—initiated earlier in life and supported by a healthy metabolic and less inflammatory milieu—rather than from short-term supplementation alone.

What this means for APOE4 carriers

• Omega-3s still matter. APOE4 carriers tend to have altered lipid handling and may be more vulnerable to DHA insufficiency and inflammation. Adequate omega-3 intake remains biologically relevant.

• Form is probably less important than context. Current evidence does not show that phospholipid DHA (e.g., krill oil) is clinically superior to other DHA forms for brain outcomes. After ingestion, DHA is extensively redistributed across lipid pools.

• Dietary pattern sets the stage. Omega-3s are most plausible as part of an anti-inflammatory dietary pattern—rich in fiber, plant foods, and unsaturated fats—rather than layered onto a Western diet.

• Gut health may be a key modifier. A diverse, resilient gut microbiome may be necessary for omega-3s to translate into downstream benefits, particularly in APOE4 carriers.

• Supplements are not a shortcut. For APOE4 carriers, omega-3s should be viewed as a supportive component of a broader lifestyle strategy, not a stand-alone solution.

A Stanford team led by Pascal Geldsetzer and colleagues reported important advances on zoster vaccination and dementia incidence. Two recent natural experiments—accidental but scientifically powerful—suggest the answer may be yes. In Wales, a quirk in the shingles vaccine rollout created two nearly identical groups who differed only in vaccine eligibility. Individuals who received the vaccine were about 20 percent less likely to develop dementia over the next seven years.

Figure 1 shows a natural experiment created by Wales’ date-of-birth rule for shingles vaccine eligibility: people born just after September 2, 1933 were eligible, while those born just before were not, even though the groups differ in age by only days. By plotting dementia incidence against week of birth, the graph reveals a clear downward “jump” at the eligibility cutoff, indicating that those who could receive the vaccine developed significantly fewer dementia diagnoses over the seven-year follow-up. The estimated effect of eligibility is a 1.3 percentage-point reduction in dementia risk.

A few years later, Australia unknowingly created a near-clone of this design when it offered the vaccine only to those who turned 80 after a specific date. Again, two nearly matched cohorts—one eligible for vaccination, one not—and again, a significant drop in dementia diagnoses: 1.8 percentage points over 7.4 years.

A third study deepens the story by showing that shingles vaccination is associated not only with fewer dementia diagnoses but also with fewer cases of mild cognitive impairment (MCI), the earliest detectable stage of decline. Shingles vaccination was not only associated with fewer new dementia diagnoses, but also with slower progression and reduced mortality among people who already have dementia.

Across all three studies, a consistent narrative emerges: reducing herpesvirus reactivation may help stabilize the immune environment of the aging brain, especially in people genetically predisposed to microglial dysfunction.

Officially, these remain observational findings, even if they emerge from unusually rigorous quasi-experiments, and the scientific consensus is right to call for randomized trials before establishing any clinical recommendation for dementia prevention. Those trials will tell us whether the observed effects are causal, how large they truly are, and which groups benefit most. But science progresses on two tracks: careful experimentation and real-world decision-making. Millions of older adults—particularly those with APOE4 or strong family histories of Alzheimer’s—are already navigating choices about how to protect their cognitive futures. In that context, individuals and clinicians can make informed, evidence-aware decisions using what is known now about the shingles vaccine’s risks, benefits, and safety profile.

That framing leads naturally to a practical consideration: for someone at higher-than-average risk of dementia, what is the actual downside of receiving a vaccine that is already part of routine preventive care for older adults? The shingles vaccines used today—particularly Shingrix, the preferred non-live recombinant vaccine—have well-established safety records after millions of doses. Side effects such as soreness, fatigue, and fever are common but short-lived. Rare events like Guillain–Barré syndrome occur at only a few excess cases per million doses. For individuals carrying APOE4, whose lifetime risk of Alzheimer’s is several-fold higher, the balance of risks looks different: the probability of cognitive decline is already elevated, shingles itself is debilitating and inflammatory, and the emerging evidence suggests a plausible secondary benefit on dementia.

Current guidelines recommend Shingrix for all adults aged 50 and older, as well as for immunocompromised adults aged 19 and older, given as two doses 2–6 months apart. Unlike the older live vaccine used in the Wales and Australia studies, Shingrix is safe for immunocompromised individuals and is now the dominant global standard. Contraindications are limited—mainly severe allergic reactions to a previous dose or vaccine component, or deferring vaccination during a moderate or severe acute illness. In practical terms, Shingrix is accessible, routinely recommended, and has a safety profile that supports its broad use.

Rather than treating these findings as an endpoint, we should see them as the beginning of more focused research. The next step is to directly investigate how herpesvirus exposure and reactivation influence microglial metabolism, phagocytic capacity, and inflammatory tone in humans. Many questions remain. Does this apply only to the herpes Zoster? What about other viruses or infections? Can preventing reactivation slow or reverse microglial exhaustion markers? AD biomarkers? These epidemiologic findings do not close the case—they sharpen its central question. One new frontier in Alzheimer’s will require understanding how aging, genetics, and viral immunology converge on microglial function. This is why continuing to invest in the science of immunity in Alzheimer’s disease is an important topic to move the needle forward.